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Summary 
Currently in development as anti-cancer drugs, MEK/ERK and FGFR inhibitors have 
induced soft-tissue mineralization and increased plasma Pi and 1,25-dihydroxyvitamin 
D3 (1,25D3) levels in pre-clinical studies. AstraZeneca in-house data reported soft-
tissue mineralization in stomach, kidney and heart of rats administered for >7d with 
MEK (MEKi) or FGFR (FGFRi) inhibitors. In this study, I aimed to unravel the 
mechanisms of soft-tissue mineralization associated with MEK/ERK or FGFR 
inhibition by assessing key processes for mineral homeostasis in rats treated with 
these inhibitors. The main findings of this study are: 
1) Supporting previous studies, MEKi and FGFRi treatment (8d) resulted in soft-
tissue mineralization and increases in plasma Pi and FGF23. Importantly, 
similar effects were observed for the first time in animals treated with an ERK 
inhibitor (ERKi).  
2) Renal CaSR expression remained unchanged following MEKi or FGFRi 
treatment (8d), suggesting that the CaSR is not key for the mineralization 
induced by these inhibitors. Additionally, CaSR expression was detected 
throughout the nephron which supports previously hypothesised roles for this 
receptor in different processes including 1,25D3 production and Pi reabsorption. 
3) Acute dosing (6h) with ERKi or FGFRi resulted in reduced plasma FGF23 and 
altered renal expression of proteins involved in 1,25D3 production (Cyp27b1, 
Cyp24a1) and Pi reabsorption (NaPiIIa), effects indicative of an impared FGF23 
signalling. These results are consistent with MEK/ERK and FGFR inhibition 
promoting soft-tissue mineralization by analogous mechanisms: a blockage of 
FGF23 signalling that results in increased 1,25D3 production and in the 
consequent toxicity. 
4) Repeated dosing (8d) with MEKi and FGFRi resulted in increased renal 
expression of Ca2+-transport (TRPV5, calbindin-D28k, PMCA) and of 
calcification-inducing (alkaline phosphatase) proteins. These increases may 
contribute to mineralization by locally raising Ca2+xPi product and inducing a 
pro-calcifying environment. Since the identified proteins contain VDREs, these 
effects are likely to be induced by increased plasma 1,25D3 levels.  
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1 Introduction 
1.1 Biomineralization 
Biomineralization is the process of mineral production by a biological system (Weiner 
2003). In mammals, biomineralization consists mainly of the deposition of calcium 
phosphate crystals in the form of hydroxyapatite. Under physiological conditions 
biomineralization only occurs in hard tissues such as bone, calcified cartilage and 
teeth (Bonucci 2013), however under pathological conditions this process can also 
occur in soft-tissues (ectopic mineralization), most frequently in kidney, skin, articular 
cartilage and cardiovascular tissue (Kirsch 2006). The consequences of ectopic 
mineralization depend on the affected tissue. For instance, mineralization of articular 
cartilage, associated with osteoarthritis, results in cartilage destruction and joint 
stiffness (Ea et al. 2011) whilst mineralization of blood vessels, associated with 
pathologies such as atherosclerosis and chronic kidney disease, results in the 
stiffening of these vessels and increased risk for myocardial infarction (Wexler et al. 
1996). The mechanism of biomineralization is very complex and appears to be 
regulated by several factors, including levels of free ionized calcium (Ca2+) and 
inorganic phosphate (Pi) (Bethke et al. 1932); formation of matrix vesicles / apoptotic 
bodies (Golub 2009) and presence of proteins and other molecules that regulate 
mineralization (Orimo 2010, Moochhala 2012). These factors are depicted in Figure 
1.1 and will be further described in sections 1.2-1.4. 
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Figure 1.1: Schematic representation of the mechanisms that contribute to the 
occurrence of biomineralization.  The scheme integrates data from different studies 
showing the complexity of biomineralization mechanisms and modulation by diverse 
processes including Ca2+xPi product, matrix vesicles, apoptotic bodies, induction of 
osteogenic phenotype, proteins/ molecules with pro-calcifying and anti-calcifying 
effects. Figure adapted from (Speer and Giachelli 2004). 
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1.2 Calcium and phosphate  
High levels of Ca2+ and/or Pi in blood or body tissues contribute to the occurrence of 
soft-tissue mineralization (Haut et al. 1980, Giachelli et al. 2001). Initially, soft-tissue 
mineralization was thought to be a passive deposition of Ca2+ and Pi, since the 
production of hydroxyapatite is thermodynamically favourable (Johnsson and 
Nancollas 1992, Nancollas 1992). In the last few decades, however, Ca2+ and Pi were 
described to have an active role in this process (Speer and Giachelli 2004). High levels 
of Ca2+ and Pi were reported to promote soft-tissue mineralization by inducing 
changes in cellular phenotype. These effects were first observed in vascular smooth 
muscle cells (VSMCs) cultured in media containing high levels of Ca2+ and Pi, which 
showed the presence of soft-tissue mineralization associated with the suppression of 
smooth muscle cell specific genes such as SM22α and the induction of osteogenic 
genes, such as Runx2 and alkaline phosphatase (Jono et al. 2000, Steitz et al. 2001, 
Yang et al. 2004). Mutations in genes encoding key regulators of Ca2+ and Pi 
homeostasis, such as the calcium sensing receptor (CaSR) and fibroblast growth 
factor 23 (FGF23), have been associated with the occurrence of soft-tissue 
mineralization (Hough et al. 2004, Masi et al. 2009). Moreover, soft-tissue 
mineralization is frequently observed in pathologies that comprise perturbations in 
Ca2+ and/or Pi homeostasis, such as chronic kidney disease  (Evenepoel and Wolf 
2013) and diabetes mellitus (Chen and Moe 2003). 
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1.3 Matrix vesicles / apoptotic bodies 
Matrix vesicles are extracellular particles that originate from the plasma membrane of 
mineralizing cells. These vesicles contribute to mineralization by acting as mineral 
nucleation sites (Anderson 1969, Anderson 2003) and by decreasing the 
pyrophosphate/Pi ratio (Bobryshev et al. 2014). The mineralization functions of matrix 
vesicles involve the expression of pro-calcifying proteins, including alkaline 
phosphatase (Montessuit et al. 1995), annexins (Chen et al. 2008) and phospho-1 
(Roberts et al. 2007). Similarly to matrix vesicles, apoptotic bodies, small particles 
released from cells undergoing apoptosis, contribute to mineralization by acting as 
mineral nucleation sites (Proudfoot et al. 2000, Proudfoot et al. 2001). Nevertheless, 
the mechanisms by which matrix vesicles and apoptotic bodies induce mineralization 
may differ as the latter lack the expression of pro-calcifying proteins such as alkaline 
phosphate and annexins (Kirsch et al. 2003). 
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1.4 Regulators of mineralization 
1.4.1 Pyrophosphate 
Pyrophosphate is a molecule that inhibits mineralization by binding to and preventing 
the growth of hydroxyapatite crystals (Fleisch 1981). Pyrophosphate is formed by 
different processes including the cleavage of adenosine-5’-triphosphate (ATP) or other 
nucleotides by the nucleotide pyrophosphatase phosphodiesterase 1 (NPP1) 
(Terkeltaub 2006). Consistent with the inhibitory role of pyrophosphate in the 
mineralization process, inactivating mutations of the gene that encodes NPP1 have 
been associated with the occurrence of soft-tissue mineralization (Mackenzie et al. 
2012). Pyrophosphate is mainly produced intracellularly in the mitochondria (Johnson 
et al. 2000), however it can also be produced extracellularly by the transmembranous 
and secreted forms of NPP1 (Johnson et al. 1999). Pyrophosphate is extruded from 
the cells to the extracellular space by the progressive ankylosis protein (ANK) (Ho et 
al. 2000). Similarly to NPP1, inactivating mutations of the gene that encodes ANK have 
been associated with the occurrence of soft-tissue mineralization (Morava et al. 2011). 
 
1.4.2 Matrix Gla protein 
Matrix Gla protein (MGP) is a vitamin K-dependent protein expressed in different 
tissues including bone, kidney and heart (Fraser and Price 1988). MGP inhibits 
mineralization by binding to and preventing the growth of hydroxyapatite crystals 
(Price et al. 2002). Besides, MGP may prevent mineralization through other processes 
such as the inhibition of the pro-calcifying protein bone morphogenic protein 2 (BMP2) 
(Sweatt et al. 2003). MGP deficiency has been associated with soft-tissue 
mineralization in MGP knockout mice (Luo et al. 1997, El-Maadawy et al. 2003) and 
in patients with Keutel syndrome (Munroe et al. 1999). Also, MGP polymorphisms 
have been associated with vascular calcification (Herrmann et al. 2000, Crosier et al. 
2009). 
1.4.3 SIBLING 
The small integrin-binding ligand N-linked glycoprotein (SIBLING) family consists in 
five different proteins, bone sialoprotein (BSP), dentin sialophosphoprotein, (DSPP), 
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dentin matrix protein 1 (DMP1), matrix extracellular phosphoglycoprotein (MEPE) and 
osteopontin, which are expressed in different organs including bone (Huang et al. 
2008), kidney (Ogbureke and Fisher 2005) and salivary glands (Ogbureke and Fisher 
2004). The SIBLINGs have both inhibitory and promoter roles in the mineralization 
process, which are conditioned by post-translational modifications such as 
phosphorylation and cleavage (Staines et al. 2012). Nevertheless, BSP (Wang et al. 
2006) and DSPP (Prasad et al. 2010) are generally associated with the promotion and 
DMP1 (Tartaix et al. 2004), MEPE (Gowen et al. 2003) and osteopontin (Steitz et al. 
2002) with the prevention of mineralization. At least partially, the inhibitory effects of 
the SIBLINGs in the mineralization process are associated with the release of a 
peptide containing an acidic serine aspartate-rich MEPE-associated motif (ASARM). 
This peptide is able to bind and prevent the development of hydroxyapatite crystals 
(Addison et al. 2008).  
1.4.4 Alkaline phosphatase 
The alkaline phosphatase protein family is composed by four distinct pro-calcifying 
isozymes. The intestinal, germ cell and placental isozymes show a tissue specific 
expression whilst the tissue nonspecific isozyme is expressed in different tissues 
including kidney, bone and liver (Sharma et al. 2014). The pro-calcifying effects of the 
alkaline phosphatases are mainly associated with the hydrolysis of pyrophosphate 
through a process that generates Pi (Hessle et al. 2002). Also, alkaline phosphatases 
can produce Pi through the breakdown of other molecules such as 
phosphoethanolamine and pyridoxal-5′-phosphate (Sharma et al. 2014). Mice lacking 
tissue nonspecific alkaline phosphatase show skeletal hypomineralization and 
defective growth of hydroxyapatite crystals in the vicinity of matrix vesicles (Anderson 
et al. 2004). These effects are ablated with the knockout of NPP1, the enzyme that 
catalyses the production of pyrophosphate from nucleotides, which suggests that the 
pro-calcifying effects of alkaline phosphatase are associated with the inhibition of 
pyrophosphate, rather than the production of phosphate (Hessle et al. 2002).  
1.4.5 RANK, RANKL and osteoprotegerin 
Receptor activator of NF-kB ligand (RANKL) is a protein from the tumour necrosis 
factor (TNF) superfamily that has key roles in processes that include bone turnover 
and vascular calcification. RANKL is expressed in different tissues including bone and 
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kidney (Kartsogiannis et al. 1999). This protein exerts its biological function by 
activating the receptor activator of NF-kB (RANK), which modulates different signalling 
pathways such as NF-Kb, Src, and MEK/ERK (Wada et al. 2006). In bone, RANK 
activation by RANKL promotes bone resorption by inducing differentiation, maturation 
and activation of osteoclasts (Wada et al. 2006). In the vasculature, RANK activation 
by RANKL induces vascular calcification by a process that is not completely 
understood but appears to include an increased expression of pro-inflammatory 
factors such as interleukin 6 and TNFα and osteogenic markers such as alkaline 
phosphatase and Runx2 (Deuell et al. 2012). RANKL signalling through RANK is 
inhibited by osteoprotegerin, which acts as a decoy receptor for RANKL and prevents 
its binding to RANK. Through the inhibition of RANKL-RANK signalling, 
osteoprotegerin has key roles in the regulation of bone turnover and vascular 
calcification. These roles are evident in the osteoprotegerin knockout mouse, which 
develops osteoporosis and extensive vascular calcification (Bucay et al. 1998). 
1.4.6 Modulators of Wnt signalling 
The Wnt family consists of 19 known glycoproteins that signal through 3 distinct 
pathways, a canonical pathway, which regulates the activation of the transcription co-
activator beta-catenin and two non-canonical pathways. Wnt signalling is modulated 
by various proteins including the inducers leptin and parathyroid hormone (PTH) and 
the inhibitors Dickkopf-1 (DKK1) and sclerostin. Different studies have reported that 
VSMCs cultured in high Pi conditions show activation of the canonical Wnt pathway 
associated with the presence of mineral deposits and increased expression/activity of 
osteogenic markers such as BMP2  and alkaline phosphatase (Martinez-Moreno et al. 
2012, Guerrero et al. 2014). Moreover, these effects were reduced or enhanced 
respectively by adding a Wnt inhibitor (DKK1) or Wnt activators (lithium chloride, 
CHIR98014 or leptin) to the culture media (Zeadin et al. 2012, Guerrero et al. 2014). 
Besides, the addition of magnesium to the culture medium reduced phosphate-
induced calcification and beta-catenin activation in VSMC, suggesting that the process 
by which magnesium prevents the calcification process may involve the modulation of 
Wnt signalling (Montes de Oca et al. 2014). In vivo studies have reported that vascular 
calcification is associated with increased levels of plasma sclerostin (Kuipers et al. 
2015), DKK1 (Kim et al. 2011) and leptin (Reilly et al. 2004). While high levels of 
plasma leptin likely contribute to the occurrence of calcification, the increase in 
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sclerostin and DKK1 levels may be due to an increased expression of these proteins 
in calcified tissue, with the objective of preventing further calcification. To support this 
observation, a different in vivo study has reported that calcified heart valves express 
sclerostin, which is not expressed in non-calcified valves (Brandenburg et al. 2013).  
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1.5 Extracellular free ionised calcium (Ca2+o) and phosphate (Pi) 
homeostasis 
Besides constituting mineral tissue and regulating the mineralization process, Ca2+ 
and Pi are key molecules for different biological processes. Extracellular free ionised 
Ca2+ levels are important to physiological processes such as hormonal secretion 
(Leclercq-Meyer et al. 1981), apoptosis (Lin et al. 1998) and proliferation (Kanatani et 
al. 1991). Additionally, intracellular Ca2+ levels are important for the cellular function 
since Ca2+ is a co-factor for different enzymes and a second messenger in a number 
of signalling pathways (Clapham 2007). Extracellular Pi levels also regulates different 
physiological processes including apoptosis (Mansfield et al. 1999) and cellular 
differentiation (Mozar et al. 2008). The signalling effects of Pi involve the modulation 
of different pathways including RANK (Mozar et al. 2008) and MEK/ERK (Yamazaki 
et al. 2010). In addition to its roles as an extracellular signalling molecule, Pi is a 
component of different nucleotides including ATP, an important energy source for 
different physiological processes (McClare 1975). The levels of extracellular Ca2+ and 
Pi need to be maintained respectively at 1.1-1.4 mmol/L and 0.8-1.4 mmol/L in order 
to preserve mineral homeostasis (Chang et al. 2014). The maintenance of extracellular 
Ca2+ and Pi levels involves the activation of different hormones including 1,25-
dihydroxyvitamin D3 (1,25D3), FGF23, and PTH, which regulate the processes of 
intestinal absorption, bone resorption of these ions (Bergwitz and Juppner 2010). In 
addition to hormonal regulation, extracellular Ca2+ and Pi levels are also maintained 
locally, through the action of different proteins including the CaSR, the transient 
receptor potential cation channel subfamily V members 5 and 6 (TRPV5 and TRPV6) 
and sodium-dependent phosphate transporter 1 (Pit-1) (Zoidis et al. 2004, Civitelli and 
Ziambaras 2011).  
1.5.1 Ca 2+ and Pi reabsorption in kidney 
The kidney is an important homeostatic organ that filters the blood and excretes the 
waste products by producing urine. The functions of the kidney include the excretion 
of toxins, regulation of circulating levels of different ions and control of blood pH 
(Preuss 1993). The kidney contributes to mineral ion homeostasis by tightly regulating 
the reabsorption of Ca2+ and Pi from urine into the plasma. Following glomerular 
filtration, around 70% of the filtered Pi is reabsorbed by transcellular transport in the 
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proximal tubule (PT) in a process mediated by the type IIa (NaPi-IIa) and IIc (NaPi-IIc) 
sodium-phosphate co-transporters (Prasad and Bhadauria 2013). Further Pi 
reabsorption may occur in the distal convoluted tubule (DCT), however the associated 
mechanisms are not completely understood (Lassiter and Colindres 1982). 
Conversely to Pi, the majority of the filtered Ca2+ is reabsorbed paracellularly, 60-70% 
in the PT and 20% in the thick ascending limb of Henle’s loop (TAL) (Blaine et al. 
2015). The paracellular reabsorption of Ca2+ is dependent on the electrochemical 
gradients of sodium and chloride and subject to regulation by tight junction proteins 
such as claudins (Blanchard et al. 2001). A further 10-15% of the filtered Ca2+ is 
actively reabsorbed by transcellular transport in the DCT and connecting tubule (CNT) 
segments in response to the physiological needs for this ion (Boros et al. 2009). Distal 
Ca2+ reabsorption is mediated by the proteins TRPV5, calbindin D28k, Na+/Ca2+ 
exchanger (NCX1) and plasma membrane Ca2+ ATPase (PMCA). TRPV5 promotes 
Ca2+ entry into the cell through the apical membrane; calbindin D28k transports Ca2+ 
through the cytosol to the basolateral membrane and acts as Ca2+ buffer; and NCX1 
and PMCA mediate Ca2+ extrusion through the basolateral membrane (Boros, Bindels 
et al. 2009). The processes associated with renal reabsorption of Ca2+ and Pi are 
represented in Figure 1.2. 
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Figure 1.2: Schematic representation of Ca2+ and Pi reabsorption along the 
nephron.  Proteins directly involved in Ca2+ and Pi transport are represented in red 
and proteins indirectly involved in Ca2+ and Pi transport are represented in blue. 
Abbreviations: NaPi-IIa, type II sodium-phosphate co-transporter; SGLT, sodium-
dependent glucose cotransporter ; NHE3, sodium hydrogen exchanger 3; NBC, 
sodium bicarbonate co-transporter;  NKCC2, sodium potassium 2-chloride co-
transporter;  ROMK, renal outer medullary potassium channel;  CLC-Kb, chloride 
channel Kb; TRPV5, transient receptor potential cation channel subfamily V member 
5; PMCA, plasma membrane Ca2+ ATPase; NCX1, Na+/Ca2+ exchanger; NCC, 
thiazide-sensitive Na+/Cl−cotransporter; NCX1, Na+/Ca2+ exchanger, Kir4.1, Inwardly 
rectifying potassium channel 4.1. Figure adapted from (Riccardi and Kemp 2012). 
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1.6 Parathyroid-Bone-Kidney axis  
The kidney, bone and parathyroid axis and their respectively associated hormones, 
1,25D3, FGF23 and PTH, ensure Ca2+ and Pi homeostasis (Bergwitz and Juppner 
2010, Kuro-o 2010, Haussler et al. 2012). The levels and activity of these hormones 
are altered as a direct response to physiological changes in Ca2+ and / or Pi, and also 
as a consequence of complex feedback mechanisms. The metabolism and roles of 
1,25D3, FGF23 and PTH in Ca2+ and Pi homeostasis are depicted in Figure 1.3 and 
described below.  
 
 
Figure 1.3: Schematic representation of the parathyroid-bone-kidney axis. The 
scheme depicts the effects of Ca2+ and Pi and inter-regulatory mechanisms in the 
production/secretion of PTH, FGF23 and 1,25D3 hormones. Figure adapted from 
(Silver and Naveh-Many 2009). 
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1.7 Vitamin D 
1.7.1 Vitamin D metabolism 
The concept of a vitamin involved in Ca2+ regulation was first suggested in 1922, 
following the discovery that cod liver oil oxidised to destroy vitamin A was able to 
promote Ca2+ deposition in bones of rats suffering from rickets (McCollum et al. 1922). 
In the 1930s, vitamins D2 and D3, the two major forms of vitamin D were identified 
respectively as products of the ultra-violet irradiation of ergosterol (Askew et al. 1930) 
and 7-dehydrocholesterol (Windaus and Bock 1937). Studies carried out in the 
subsequent decades have elucidated the metabolism and physiological roles of 
vitamin D. Vitamin D3, the most important form of vitamin D for mammalian physiology, 
is obtained by exposure to sunlight and dietary intake (Bikle 2014). Then, this vitamin 
is activated in two sequential steps. First, CYP2R1 catalyses the production of 25-
hydroxyvitamin D3 from vitamin D3 in the liver. Subsequently, in the rate limiting step 
of this process, CYP27B1 catalyses the production of 1,25-dihydroxyvitamin D3 
(1,25D3) from 25-hydroxyvitamin D3 mostly in the kidney (Takeyama et al. 1997). To 
a lesser extent than the kidney, 1,25D3 is also produced in other tissues including 
breast, parathyroid gland and placenta, by the action of extra-renal CYP27B1 
(Zehnder et al. 2001, Adams and Hewison 2012). 
The production of  1,25D3 is regulated by different factors including the inducer PTH 
(Armbrecht et al. 2003) and the inhibitors Ca2+, Pi (Fukumoto 2014) and FGF23 
(Perwad et al. 2007). Renal 1,25D3 targets the kidney through autocrine/paracrine 
actions and it is secreted to the circulation and targets other organs by functioning as 
an endocrine factor. Conversely, extra-renal 1,25D3 has mainly local actions by 
functioning as an autocrine/paracrine factor (Zehnder et al. 2002, Morris and Anderson 
2010). Whilst renal 1,25D3 is a key molecule for mineral homeostasis, extra-renal 
1,25D3 seems to have more important roles in other processes including 
immunological response, proliferation and apoptosis (Adams and Hewison 2012, 
Hobaus et al. 2013).  
The effects of 1,25D3 are mainly triggered by its genomic actions, which are mediated 
by the nuclear vitamin D receptor (VDR). Upon the activation by 1,25D3, the nuclear 
VDR functions as a transcription factor and regulates the expression of different genes 
containing vitamin D response elements (VDREs) (Haussler et al. 1997). In addition 
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to the genomic effects, 1,25D3 is able to signal through a membrane VDR that 
modulates different signalling pathways including protein kinase A (PKA) and protein 
kinase C (PKC) (Revelli et al. 1998). The inactivation of vitamin D3 occurs through the 
24-hydroxylation of 1,25D3, a process catalysed by CYP24A1 in different tissues 
including kidney, intestine, bone and skin (Armbrecht et al. 1992). The inactivation of 
vitamin D3 is regulated by different factors including the inducers Ca2+ and Pi, 1,25D3 
and FGF23 and the inhibitor PTH (Shinki et al. 1992, Shimada et al. 2004). 
 
1.7.2 Vitamin D and mineral ion homeostasis 
The production of 1,25D3 is promoted under conditions of hypocalcemia and/or 
hypophosphatemia. In order to restore mineral homeostasis, 1,25D3 increases serum 
levels of Ca2+ and Pi by stimulating the intestinal absorption and renal reabsorption of 
these ions and by enhancing bone resorption (Eisman and Bouillon 2014, Wranicz 
and Szostak-Wegierek 2014). The direct effects of 1,25D3 in intestinal absorption and 
renal reabsorption are associated with the induction of the expression of proteins 
involved in the transport of Ca2+ and Pi including TRPV5/6, calbindin D9K/D28K, PMCA, 
NaPi-IIa/b (Bindels et al. 1991, Hoenderop et al. 2001, van de Graaf et al. 2004, Kido 
et al. 2013). Although the mechanisms have not been fully elucidated so far, the direct 
effects of 1,25D3 in bone resorption appear to be associated with the regulation of the 
expression of RANKL (Kitazawa et al. 2003, Suda et al. 2003). In addition to the direct 
effects in the expression of proteins involved in bone resorption and Ca2+ and Pi 
reabsorption, 1,25D3 also encompasses indirect effects in mineral homeostasis 
including the induction of FGF23 (Barthel et al. 2007) and inhibition of PTH (Naveh-
Many and Silver 1990) hormones. Most of the effects of 1,25D3 in mineral homeostasis 
are associated with the activation of nuclear VDR and regulation of genes that contain 
VDREs (Kumar et al. 2012). 
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1.8 FGF23 and Klotho 
1.8.1 FGF23 structure and metabolism 
Fibroblast growth factor 23 (FGF23), a 251 amino acid protein with key roles in Ca2+ 
and Pi regulation, was identified in mouse brain and thymus in 2000 (Yamashita et al. 
2000). Shortly after the identification, the observation that a missense mutation in the 
FGF23 gene resulted in autosomal dominant hypophosphatemic rickets shed light on 
the importance of FGF23 to mineral homeostasis (White et al. 2000). FGF23 is 
produced mainly by osteocytes in bone (Bonewald and Wacker 2013) and unlike most 
fibroblast growth factors (FGFs), it is secreted to the circulation and functions as an 
endocrine factor (Kuro-o 2008). The production and secretion of FGF23 is regulated 
by different factors, including the inducers Pi (Vervloet et al. 2011), 1,25D3 (Kolek et 
al. 2005) and PTH (Lavi-Moshayoff et al. 2010). The effects of FGF23 encompass 
signalling through the fibroblast growth factor receptors (FGFRs) (Yu et al. 2005). 
There are four FGFRs, namely FGFR1-3, which possess two isoforms (b/c) originated 
by alternative splicing; and FGFR4 which only possesses one isoform (c) (Gong 2014). 
The interaction between FGF23 and the FGFRs has a low affinity, which is greatly 
enhanced by the protein alpha-Klotho (Klotho) (Urakawa et al. 2006). Although most 
of the biological effects of FGF23 require the presence of Klotho, some Klotho-
independent effects were reported including the processes of PTH secretion (Olauson 
et al. 2013) and cardiovascular disease (Faul et al. 2011). FGF23 signalling occurs 
mainly via the fibroblast growth factor receptor substrate 2 (FRS2) and phospholipase 
C (PLC) gamma and involves the activation of different signalling pathways including 
the MEK/ERK pathway (Yamazaki et al. 2010, Brooks et al. 2012).  
1.8.2 Klotho structure and metabolism 
Klotho, the 1014 amino acid transmembrane co-receptor for FGF23, was identified in 
1997 in a study that associated inactivating mutations in its encoding gene with the 
occurrence of a syndrome resembling premature ageing (Kuro-o et al. 1997). 
Nevertheless, the role of Klotho in FGFR signalling was only unravelled in 2006 
(Kurosu et al. 2006), as the result of a study driven by the similarities between Klotho 
and Fgf23 knockout mice (Shimada et al. 2004). Klotho was reported to function as a 
co-receptor for FGF23 by increasing the affinity of the c isoforms of the FGFRs 1, 3 
and 4 for FGF23 (Kurosu et al. 2006). The expression of Klotho is regulated by 
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different factors including the inducer 1,25D3 (Forster et al. 2011), and the inhibitors 
FGF23 (Marsell et al. 2008) and TNF alpha (Moreno et al. 2011). In addition to its 
function as a transmembrane co-receptor for FGF23, a secreted form of Klotho 
regulates different biological processes by acting as an endocrine factor (Huang 
2010). The secretion of Klotho can be induced either by alternative splicing of the 
Klotho gene or by the cleavage of its extracellular domain by the proteases a 
disintegrin and metalloproteinase domain (ADAM) 10 and 17 (Chen et al. 2007).  
1.8.3 FGF23, Klotho and mineral homeostasis 
The production and secretion of FGF23 is promoted in conditions of 
hyperphosphatemia (Gupta et al. 2004). In order to restore mineral ion homeostasis, 
FGF23 inhibits the expression of NaPi-IIa and NaPi-IIc in the kidney, resulting in 
decreased renal Pi reabsorption (Shimada et al. 2004). Additionally, FGF23 induces 
the expression of TRPV5 in the kidney, resulting in increased renal Ca2+ reabsorption 
(Andrukhova et al. 2014). In addition to the direct effects of FGF23 on the expression 
of NaPi-IIa, NaPi-IIc and TRPV5, this hormone indirectly regulates Ca2+ and Pi 
metabolism by inhibiting the expression of PTH in the parathyroid (Ben-Dov et al. 
2007) and the production of 1,25D3 in the kidney (Gattineni et al. 2011). Although the 
associated mechanisms are not completely understood, the secreted form of Klotho 
appears to contribute to mineral ion homeostasis independently of FGF23 by inhibiting 
NaPi-IIa (Hu et al. 2010) and activating TRPV5 (Chang et al. 2005). The importance 
of FGF23 and Klotho in mineral ion homeostasis is evident from the phenotypes of 
mice carrying mutations in these genes, which encompass increased mineralization 
of soft-tissues associated with high serum levels of Pi and 1,25D3 (Tsujikawa et al. 
2003, Shimada et al. 2004). 
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1.9 Parathyroid hormone 
1.9.1 Parathyroid hormone structure and metabolism 
Parathyroid hormone (PTH), an 84 amino acid protein with key roles in Ca2+ and Pi 
homeostasis, was identified in 1925 as the hormone that mediates the actions of the 
parathyroid glands in regulation of blood Ca2+ levels (Collip 1925). PTH is produced 
and stored in the parathyroid glands. The production of active PTH (84 amino acid) 
involves the synthesis of a 115 amino acid precursor (pre-pro-PTH), followed by the 
sequential cleavages of a signal peptide (25 amino acid) and a prosequence (6 amino 
acid) (Habener et al. 1979). Active PTH is then stored in secretory vesicles that are 
released to the circulation under hypocalcemic (Felsenfeld et al. 2007) or 
hyperphosphatemic (Almaden et al. 1996) conditions. Other molecules regulate the 
production and secretion of PTH in addition to Ca2+ and Pi including the inhibitors 
CaSR (Chen and Goodman 2004), 1,25D3 (Cantley et al. 1985) and FGF23 (Ben-Dov 
et al. 2007). The biological effects of PTH involve signalling through the PTH receptors 
type 1   (PTH1R) and 2 (PTH2R), which are G protein-coupled receptors (GPCRs) 
(Mahon 2012). The activation of PTH1R and PTH2R by PTH results in the activation 
of different G proteins and modulation of various signalling pathways including PKC 
(Yang et al. 2006) and MEK/ERK (Lederer et al. 2000). PTH1R can also be activated 
by parathyroid hormone related protein (PTHrP), a hormone that shares some 
structural homology with PTH but exerts different biological roles (Wysolmerski 2012).  
1.9.2 Parathyroid hormone and mineral homeostasis 
The production and secretion of PTH is promoted under conditions of hypocalcemia 
(Felsenfeld et al. 2007) and hyperphosphatemia (Almaden et al. 1996). In order to 
restore mineral ion homeostasis, PTH directly targets the kidney, inhibiting NaPi-IIa in 
order to decrease in Pi reabsorption (Riccardi et al. 2000); and upregulating TRPV5, 
calbindin D28K and NCX1 in order to increase renal Ca2+ reabsorption (van Abel et al. 
2005, de Groot et al. 2009). Besides, PTH also targets the bone, where it induces 
different biological effects according to the length of the exposure. A prolonged 
exposure to PTH promotes bone resorption whilst an intermittent exposure promotes 
bone formation (Kroll 2000). In addition to the direct effects on processes of bone 
resorption and renal Ca2+ and Pi reabsorption, PTH also regulates the metabolism of 
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Ca2+ and Pi indirectly by inducing the expression of FGF23 in the bone (Lavi-
Moshayoff et al. 2010) and the production of 1,25D3 in the kidney (Bajwa et al. 2008).  
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1.10 Calcium sensing receptor 
1.10.1 Structure and metabolism 
The extracellular calcium sensing receptor (CaSR), a 1085 amino acid GPCR with a 
key role in mineral ion homeostasis, was first molecular identified from bovine 
parathyroid glands in 1993 (Brown et al. 1993). In the years that followed its 
identification, the expression and functional roles for the CaSR were reported in 
different tissues, including kidney (Riccardi et al. 1995), bone (Kameda et al. 1998) 
and intestine (Chattopadhyay et al. 1998). The main function of the CaSR is to monitor 
free ionised Ca2+ and magnesium (Mg2+) in order to preserve divalent mineral ion 
homeostasis. In response to any changes in the serum levels of these ions, the CaSR 
regulates local processes such renal Ca2+ reabsorption (Loupy et al. 2012) and 
systemic processes such as PTH secretion (Chen and Goodman 2004) and 1,25D3 
production (Bland et al. 2002). The affinity of the CaSR for Ca2+ can be modified by 
allosteric ligands such as glutathione and amino acids (Cavanaugh et al. 2012). Also, 
the CaSR can be activated by orthosteric ligands other than Ca2+ and Mg2+ including 
trivalent cations, such as gadolinium (Gd3+) and aluminium (Al3+); polyamines such as 
spermine; and aminoglycoside antibiotics such as neomycin (McLarnon et al. 2002, 
Cheng et al. 2004, Geibel 2010). The CaSR is involved in other processes besides 
mineral ion homeostasis, including taste perception (Ohsu et al. 2010), nutrient 
sensing (Conigrave and Brown 2006) and synaptic transmission (Phillips et al. 2008). 
The biological effects of the CaSR involve the induction of different G proteins and the 
modulation of several downstream signalling pathways, including PKC (Godwin and 
Soltoff 2002), cyclic adenosine monophosphate (cAMP) (Conigrave and Avlani 2012) 
and MEK/ERK (Kifor et al. 2001). The biological effects of the CaSR are dependent 
on the ligand activating the receptor since each ligand is able to stabilize a subset of 
receptor conformations that selectively activate downstream signalling pathways 
(ligand-biased signalling) (Leach et al. 2014). Besides, the downstream signalling of 
the CaSR may be influenced by the interaction with binding partners such as filamin-
A, 14-3-3 proteins and caveolin (Awata et al. 2001, Riccardi and Brown 2010). 
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1.10.2 CaSR and mineral homeostasis 
In physiological or hypercalcemic conditions, the CaSR inhibits the production and 
secretion of PTH in the parathyroid gland (Chen and Goodman 2004) and the 
production of 1,25D3 in the kidney (Bland et al. 2002), thus preventing Ca2+ levels from 
increasing. Besides, in hypercalcemic conditions, the CaSR promotes a decrease in 
serum Ca2+ levels by eliciting the secretion of calcitonin from the thyroid (Fox et al. 
1999). Opposite to PTH and 1,25D3, calcitonin inhibits the processes of bone 
resorption and renal Ca2+ reabsorption (Masi and Brandi 2007). In addition to the 
systemic effects associated with the modulation of PTH, 1,25D3 and calcitonin, the 
CaSR also counteracts hypercalcemia by directly preventing bone resorption (Theman 
and Collins 2009) and by inhibiting renal Ca2+ reabsorption. The direct effects of the 
CaSR in renal Ca2+ reabsorption involve the modulation of the transepithelial potential 
in the TAL (Loupy et al. 2012) and the regulation of TRPV5 (Topala et al. 2009) and 
PMCA (Blankenship et al. 2001) in the DCT. Also, the CaSR regulates Pi reabsorption 
in the kidney by preventing the PTH-induced inhibition of NaPi-IIa (Ba et al. 2003). In 
hypocalcemic conditions, the inhibitory effects of the CaSR in the production and 
secretion of PTH and 1,25D3 are removed, thus leading to an increase in the serum 
levels of these hormones and a consequent raise in serum Ca2+ (Bland et al. 2002, 
Chen and Goodman 2004).  
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1.11 Scope and aims 
Mineralization of soft-tissues is frequently observed during preclinical drug safety 
testing. MEK/ERK and FGFR inhibitors are two classes of compounds currently being 
developed to treat cancer (Knights and Cook 2010, McCubrey et al. 2010). In 
toxicology studies with rodents, the administration of these compounds resulted in the 
mineralization of soft-tissues associated with increased serum levels of Pi and 1,25D3 
(Brown et al. 2005, Brown and Gad 2010, Diaz et al. 2012, Yanochko et al. 2013). 
Nevertheless, the molecular mechanisms associated with this toxicity have not been 
fully elucidated. Preliminary studies carried out at AstraZeneca have shown that the 
administration of a MEK 1/2 inhibitor (MEKi) or an FGFR 1-3 (FGFRi) inhibitor for >7d 
to rats results in soft-tissue mineralization in different organs including stomach, kidney 
and heart.  
In this thesis I set out to unravel the mechanisms of soft-tissue mineralization induced 
by the inhibition of the MEK/ERK pathway or FGFRs. The work carried out for this 
thesis is focused on the kidney since the kidney is the organ where 1,25D3 is mainly 
produced and one of the organs displaying mineralization in animals treated with these 
inhibitors. 
I hypothesised that FGFR and MEK/ERK inhibitors prevent FGF23 signalling in the 
kidney and consequently increase the production of 1,25D3. Then, the elevated levels 
of 1,25D3 promote the occurrence of soft-tissue mineralization through different effects 
including the increase in renal Ca2+ and Pi reabsorption and the increase in the 
expression of mineralization inducers such as alkaline phosphatase. Besides, I 
hypothesised that the renal CaSR is involved in this process, since the CaSR was 
previously described to regulate 1,25D3 production (Bland et al. 2002) and Ca2+ (Loupy 
et al. 2012) and Pi (Ba et al. 2003) reabsorption.  
These hypothesis were tested by administering an ERK inhibitor (ERKi), MEKi or 
FGFRi to rats and assessing the effects of these inhibitors in key processes for mineral 
ion homeostasis. 
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The key aims of this work, which are addressed in Chapters 2-4, are described below. 
- Clarification of the intra-renal distribution of the CaSR and assessment of the 
role of this receptor in the soft-tissue mineralization induced by MEKi or FGFRi. 
- Identification of the cell signalling pathways that mediate the effects of ERKi, 
MEKi and FGFRi in mineral ion homeostasis and soft-tissue mineralization in 
the kidney. 
- Evaluation of the role of the hormones 1,25D3, FGF23 and PTH in the process 
of soft-tissue mineralization induced by ERKi, MEKi and FGFRi. 
- Assessment of the effects of ERKi, MEKi and FGFRi in the processes of renal 
reabsorption of Ca2+ and Pi. 
- Assessment of the effects of ERKi, MEKi and FGFRi in the expression of 
circulating and renal calcification modulator proteins. 
- Establishment and use of an ex vivo kidney slice model to further explore the 
findings of the in vivo experiments. 
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2 Intra-renal distribution and role of the CaSR in the 
mineralization induced by inhibition of MEK/ERK 
pathway and FGF receptors  
 
2.1 Introduction 
Mineralization of soft-tissues including kidney, bone and heart has been reported in 
toxicology studies with MEK and FGFR inhibitors (Brown et al. 2005, Brown and Gad 
2010, Diaz et al. 2012, Yanochko et al. 2013). Both classes of compounds are 
currently being developed as drugs to target cancer, since mutations in the FGFRs or 
components of the MEK/ERK signalling pathway are on the origin of several tumours 
including breast, gastric tract, colorectal and thyroid tumours (Knights and Cook 2010, 
McCubrey et al. 2010). In addition to soft-tissue mineralization, the toxicological effects 
of MEK inhibitors (Brown and Gad 2010, Diaz et al. 2012, Yanochko et al. 2013) or 
FGFR inhibitors (Wohrle et al. 2011, Wohrle et al. 2013, Yanochko et al. 2013) in 
rodents include increased production of 1,25D3 and high plasma levels of Pi, 
observable as early as 12-24h after treatment. Similar to the studies mentioned above, 
soft-tissue mineralization in different organs and increased levels of plasma Pi were 
observed following the administration of a MEK 1/2 inhibitor (MEKi) or an FGFR 1-3 
inhibitor (FGFRi) to rats in pre-clinical studies carried out at AstraZeneca. The CaSR 
is a receptor with key roles in mineral ion homeostasis including the regulation of blood 
free ionised Ca2+ and Pi. Activating mutations in the CaSR result in soft-tissue 
mineralization associated with hyperphosphatemia and hypocalcemia in the Nuf 
mouse model (Hough et al. 2004) and in patients with autosomal dominant 
hypocalcemia (Raue et al. 2011). Since the expression of the CaSR is induced by 
1,25D3 (Canaff and Hendy 2002), it is plausible that this receptor is involved in the 
mineral homeostasis perturbations and soft-tissue mineralization observed in rodents 
treated with MEK/ERK or FGF inhibitors. 
Previous studies have reported the involvement of the CaSR in different processes 
associated with mineral homeostasis including the secretion of “calciotropic” 
hormones such as PTH (Conigrave et al. 2004) and 1,25D3 (Bland et al. 2002); bone 
resorption (Kameda et al. 1998); and renal reabsorption of Ca2+ (Topala et al. 2009, 
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Toka et al. 2012) and Pi (Ba et al. 2003). Despite this, the renal localisation, and 
therefore the full physiological role of this receptor in the kidney, remain a matter of 
debate.  Different studies have reported discrepant CaSR expression patterns in the 
kidney (Riccardi et al. 1996, Sands et al. 1997, Yang et al. 1997, Riccardi et al. 1998, 
Loupy et al. 2012), which creates uncertainty regarding some of the renal functions 
described for this receptor. 
Molecular identification of the kidney CaSR was carried out in 1995 (Riccardi et al. 
1995), shortly after the receptor was cloned from bovine parathyroid glands (Brown et 
al. 1993). Initial CaSR messenger ribonucleic acid (mRNA) expression studies in rat 
kidney, carried out by northern blot and in situ hybridization (ISH), detected CaSR 
transcripts predominantly in the outer medulla and medullary rays of the renal cortex. 
This distribution is consistent with the CaSR being primarily expressed in the thick 
ascending limb (TAL) of Henle’s loop (Riccardi et al. 1995). A more detailed analysis 
of transcript distribution in rat kidney using ISH and reverse transcription polymerase 
chain reaction (RT-PCR) in dissected nephron segments showed additional CaSR 
expression in other nephron segments including glomeruli, proximal tubules (PT), 
medullary and cortical TAL, distal tubules (DT) and collecting ducts (CD) (Riccardi et 
al. 1996). Consistent with mRNA expression studies,  CaSR protein distribution in rat 
kidney, examined by immunofluorescence showed receptor expression in PT, 
medullary and cortical TAL, macula densa cells, DT and type A intercalated cells in 
cortical CDs (Riccardi et al. 1998). Along with the observation of such a broad 
distribution, different functional roles were postulated for the CaSR in the different 
segments and a number of functional studies followed the initial characterization 
papers. In mouse, rat and human TAL, CaSR expression was detected basolaterally 
(Riccardi et al. 1998, Loupy et al. 2012) and described to regulate divalent cation 
reabsorption through the PTH-dependent transcellular (Motoyama and Friedman 
2002) and paracellular (Wang et al. 1996, Loupy et al. 2012) pathways. Moreover, the 
effects of the CaSR in the paracellular divalent cation reabsorption were associated 
with the modulation of transepithelial potential difference (Wang et al. 1996) and 
paracellular permeability (Loupy et al. 2012, Gong and Hou 2014). In rat and human 
DT, CaSR expression was found to be present intracellularly/basolaterally (Riccardi et 
al. 1998, Topala et al. 2009) and it was described to regulate urinary Ca2+ reabsorption 
(Topala et al. 2009). In rat CD, the CaSR was detected in the cytoplasm and apical 
25 
 
and basolateral membranes of type A intercalated cells  (Riccardi et al. 1998), where 
its activation was reported to reduce water permeability and to promote urine 
acidification (Renkema et al. 2009). In mouse and rat PT, CaSR expression was found 
at the apical membrane (Riccardi et al. 1998, Ba et al. 2003). Moreover, CaSR 
activation has been associated with 1,25D3 production in a human PT cell line (Bland 
et al. 2002), Pi reabsorption in mouse PT (Ba et al. 2003) and proton secretion and 
fluid reabsorption in mouse and rat PT (Capasso et al. 2013). In the mouse and human 
glomerulus, CaSR expression was detected in podocytes, where the activation of this 
receptor has been linked to pro-survival effects and to a reduction in toxin-induced 
glomerulosclerosis (Oh et al. 2011). In the rat juxtaglomerular apparatus (JGA) CaSR 
was found to be expressed basolaterally and it has been associated with the regulation 
of renin release (Atchison et al. 2010).  
Although the expression and function of the CaSR has been reported in different 
nephron segments, controversies remain regarding the intra-renal CaSR expression 
and cellular polarity, as well as species differences between mouse, rat and human. 
The findings of CaSR mRNA and protein expression in TAL, DT and CD are supported 
by several studies (Riccardi et al. 1996, Sands et al. 1997, Yang et al. 1997, Riccardi 
et al. 1998, Topala et al. 2009, Quinn et al. 2013, Yasuoka et al. 2014). However, 
discrepant expression patterns have been reported within the CD (Riccardi et al. 1998, 
Yasuoka et al. 2014). CaSR expression in glomeruli (Riccardi et al. 1996, Caride et al. 
1998, Oh et al. 2011) and JGA (Ortiz-Capisano et al. 2007, Maillard et al. 2009, Ortiz-
Capisano et al. 2013), has only been reported in a small number of studies and 
expression of the CaSR in PT is still unclear since there are several studies that report 
conflicting data (Yang et al. 1997, Riccardi et al. 1998, Ba et al. 2003, Loupy et al. 
2012, Wu et al. 2013, Yasuoka et al. 2014). A recent study analysed the mRNA and 
protein expression and functionality of the CaSR along the mouse, rat and human 
nephron and concluded that the CaSR is only present in TAL (Loupy et al. 2012).  
The discrepancies in the various reports create some uncertainty in the CaSR 
expression pattern along the nephron, thus proscribing the understanding of CaSR 
renal functions. These discrepancies may be associated with differences between the 
approaches used in the different studies such as the biological material analysed 
(mRNA or protein), processing of the samples (eg. tissue fixation), analysis 
methodologies (eg. immunohistochemistry, Western blotting) and use of different 
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species. The use of such different approaches may result in a lack of sensitivity in 
some cases or non-specific detection of the CaSR in other cases. 
In this chapter, I aimed to assess if the renal CaSR is involved in the process of soft-
tissue mineralization induced by the inhibition of the MEK/ERK pathway or inhibition 
of the FGFRs. Due to the uncertainty about the localization of the CaSR in the kidney, 
I first took a comprehensive approach to assess the intra-renal distribution of this 
receptor. This approach consisted of a sensitive chromogenic branched 
deoxyribonucleic acid (DNA) ISH method, immunohistochemistry using a selection of 
antibodies raised against different epitopes of the CaSR and a highly sensitive and 
specific chromogenic in situ proximity ligation assay. After establishing the intra-renal 
distribution of the CaSR, I analysed the effects of the administration of MEKi for 28d 
or FGFRi for 25d in the renal expression of this receptor using IHC. 
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2.2 Methods 
2.2.1 Origin of mouse, rat and human tissue 
Animal kidney tissue was obtained from adult male CD-1 mice and Han Wistar rats, 
supplied by Harlan (Hillcrest, UK) or Charles River (Harlow, UK). Adult normal human 
kidney cortex tissue used for immunohistochemistry was obtained from the 
AstraZeneca Global Tissue Bank.  The use of this tissue was compliant with the 
Human Tissue Act as well as Global AstraZeneca Policy. Adult human kidney tissue 
used for Western blotting was obtained from ethically-consented human kidneys 
surgically resected at The University Hospital Wales due to renal cell carcinoma 
(Research Ethics Committee approval reference number: 07/WSE04/53) in 
collaboration with the Wales Cancer Bank.  Macroscopically normal kidney cortex 
tissue was taken from a region distant from the carcinoma.  
2.2.2 In situ hybridization  
Mouse, rat and human kidneys were fixed in 10% neutral-buffered formalin for 24 to 
48h and embedded in paraffin. Five µm-thick sections were cut and in situ 
hybridization was performed using QuantiGene ViewRNA ISH tissue assay 
(Affymetrix, Santa Clara, USA) according to manufacturer’s instructions, with the 
following modifications: incubation times were 5 min for pretreatment, 20 min for 
protease digestion, 40 min for PreAmp Hybridization, and 30 min for Amp 
Hybridization and Label Probe incubation. Rat CaSR probes (for mouse and rat 
sections) and human CaSR probes were obtained from Affymetrix (Affymetrix, Santa 
Clara, USA) and used at a concentration of 1:40 in the probe diluents provided by the 
kit. Sections were mounted using Immu-mount (Thermo Scientific, Waltham, USA). 
Negative controls were performed by omission of probes.  
2.2.3 Immunofluorescence 
Method performed by Dr. Martin Schepelmann (Cardiff University) 
The different antibodies used in this study were screened by immunofluorescence 
patterns in human embryonic kidney (HEK) 293 cells stably transfected with the 
human CaSR (CaSR-HEK). Cultures of CaSR-HEK cells were performed as 
previously described (Maldonado-Perez et al. 2003). Cells were fixed in 4% 
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paraformaldehyde in phosphate-buffered saline (PBS), washed and incubated in PBS 
containing 50 mM of NH4Cl. A blocking buffer composed of 1% bovine serum 
albumin/0.05% Triton-X 100 in PBS was used to prevent non-specific antibody 
binding. Primary antibodies (Table 2.1 except N-term6) were incubated overnight at 
4ºC at a dilution of 1:100 in blocking buffer. Alexa Fluor 488 or Alexa Fluor 594 
fluorescence-dye coupled secondary anti IgG antibodies (Life Technologies, 
Carlsbad, USA) were incubated at a dilution of 1:500 in blocking buffer to visualize 
primary antibody binding. Hoechst 34580 (Life Technologies, Carlsbad, USA) was 
used to stain the nuclei.  
 
Table 2.1: Antibodies used to detect the expression of the CaSR 
Antibody Manufacturer Code 
Epitope 
Host Clone 
Concentration 
IHC Species Region 
N-term1 
Abcam / 
Thermo* 
Ab19347 / 
MA1-934* 
Human 
N-term 
(ADD) 
Mouse Monoclonal 1:500 
N-term2 Anaspec 53286 Rat N-term Rabbit Polyclonal 1:500 
N-term3 (W. Chang) 1C12 Human 
N-term 
(ADD) 
Mouse Monoclonal - 
N-term4 (W. Chang) 3A8 Human 
N-term 
(ADD) 
Mouse Monoclonal - 
N-term5 (D. Shoback) - Human 
N-term 
(ADD) 
Rabbit Polyclonal - 
N-term6 Alomone ACR-004 Human 
N-term 
(ADD) 
Rabbit Polyclonal 1:500 
C-term1 (W. Chang) 1C7E4B1 Mouse 
C-term 
(C1) 
Mouse Monoclonal 1:150 
C-term2 LS Bio 
LS-
C117834 
Human C-term Rabbit Polyclonal - 
Full 
length 
Novus Bio 
H00000846
-B01P 
Human 
Full 
length 
Mouse Polyclonal 1:75 
 
2.2.4 Western blotting 
Mouse, rat and human kidney samples were homogenized separately in modified 
radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl, 
1% NP40, 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, 1 mM n-
ethylmaleimide, 1 mM phenylmethanesulfonylfluoride) containing Halt protease and 
phosphatase inhibitors (Pierce, Rockford, USA). Cell lysis was carried out using a 
Polytron (Kinematica, Bohemia, NY, USA) homogenizer. Following lysis, 
homogenates were centrifuged at 10,000 x g for 5 min to remove insoluble debris. 
CaSR-HEK cell extracts prepared by an analogous method were kindly provided by 
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Dr. Sarah Brennan (Cardiff University, UK). Protein extracts were quantified using a 
bicinchoninic acid (BCA) protein assay (Pierce, Rockford, USA). Twenty micrograms 
of each extract were electrophoresed on NuPage® 10% BisTris polyacrylamide gels 
(Invitrogen, Paisley, UK). Gels were transferred to nitrocellulose membranes and 
stained with Ponceau S to confirm even protein loading of wells. Non-specific protein 
binding was blocked using 5% low-fat dried milk in Tris-buffered saline containing 
0.1% Tween (TBST) for 1h at room temperature. Primary antibodies were added at a 
concentration of 1:2000 in 5% milk/TBST overnight at 4ºC. An horseradish peroxidase 
(HRP) conjugated anti-mouse or anti-rabbit secondary antibody (Promega, Madison, 
USA) was added appropriately at a concentration of 1:20,000 or 1:6,000 in 5% 
milk/TBST before detection of immunoreactivity with ECL prime and developing on a 
ChemiDoc MP  (Biorad, Hercules, USA). 
2.2.5 Immunohistochemistry 
Kidneys were fixed for 24 to 48h in 10% neutral-buffered formalin, embedded in 
paraffin, and 4 µm sections were cut. Sections were de-waxed using xylene and 
rehydrated using 100% and 95% ethanol. Immunostainings were performed using a 
Labvision autostainer (Labvision, Fremont, USA). Heat-mediated antigen retrieval was 
performed using a Milestone RHS-2 microwave (Milestone, Sorisole, Italy) at 110°C 
for 2 min in 1 mM ethylenediaminetetraacetic acid (EDTA) buffer, pH 8. Endogenous 
peroxidase activity was blocked with 3% (aq) hydrogen peroxide for 10 min. 
Nonspecific binding of the antibody was prevented by incubating slides with 
background blocker with casein (Menarini, Florence, Italy) for 20 min. Slides were 
incubated with primary antibodies (Table 2.1) for 1h at room temperature. X-Cell Plus 
HRP, Goat HRP (Menarini, Florence, Italy) Ultravision Quanto Mouse on Mouse 
(Thermo Scientific, Waltham, USA) or Envision anti-mouse labelled polymer (DAKO, 
Glostrup, Denmark) was applied to the slides, and peroxidase was then visualized with 
diamino benzidine (DAKO, Glostrup, Denmark). Identification of the nephron 
segments was carried out by double labelling the sections with antibodies against 
aquaporin 2 (1:4000, Sigma, St Louis, USA), Tamm-Horsfall (1:100, Santa Cruz 
Biotechnology, Santa Cruz, USA) or the thiazide-sensitive NaCl cotransporter, NCC 
(1:500, Millipore, Billerica, USA) for 1h at room temperature. Aquaporin 2, Tamm-
Horsfall and NCC were detected by 30 min incubation with goat anti-rabbit antibody 
conjugated with alkaline phosphatase (Invitrogen, Paisley, UK), and visualized using 
30 
 
Quanto Fast Red Permanent (Thermo Scientific, Waltham, USA). Sections were 
counterstained using hematoxylin (Carazzi’s) for 1 min before dehydrating in 95% and 
100% ethanol, clearing in xylene, and mounting using Hystomount (TAAB Labs, 
Aldermaston, UK). Negative controls were performed using isotype controls or 
omission of the primary antibodies. 
Whole slide images were scanned using a Scanscope® scanner (Aperio Technologies 
Incorporated, Vista, USA). Positive Pixel Count Algorithm of the ImageScope software 
(Aperio Technologies Incorporated, Vista, USA) was used to quantify the positive 
signal in whole kidney. Detection thresholds were manually set in order to obtain the 
best signal/noise ratio for the CaSR. The percentage of positive staining (relative 
stained area) was calculated as the sum of all stained pixels divided by the sum of all 
stained and unstained pixels. 
2.2.6 Proximity ligation assay 
Proximity ligation assays (PLA) were performed using the Duolink® assay with 
brightfield detection (Sigma, St Louis, USA) according to the manufacturer’s 
instructions. Briefly, five µm-thick sections were antigen-retrieved and peroxidase 
quenching were carried out as described for immunohistochemistry (IHC).  Sections 
were incubated with primary antibody pairs (N-term1/N-term2, N-term1/N-term6, N-
term2/C-term1, N-term6/C-term1) for 1h at room temperature. Primary antibody pairs 
were detected by secondary antibodies conjugated with oligonucleotide probes (anti-
Rabbit PLA probe Plus and anti-Mouse PLA probe Minus), incubated for 1h at 37º C. 
Ligation of the probes was performed by adding oligonucleotides capable of 
hybridizing to the two probes together with ligase enzyme for 30 min at 37º C. 
Amplification was carried out by adding nucleotides and polymerase enzyme together 
and incubating for 2h at 37 C. Detection was performed by incubation with HRP-
conjugated oligonucleotide probes for 1h at room temperature. Peroxidase was then 
visualized with diamino benzidine (Menarini, Florence, Italy). Sections were 
counterstained with hematoxylin before dehydration in ethanol, clearing in xylene, and 
mounting using Hystomount (TAAB Labs, Aldermaston, UK). Negative controls were 
performed by omission of the primary antibodies, incubation with the corresponding 
immunoglobulin fractions (isotype control), or incubation of C-term1 with Ki-67 (1:200, 
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Novus, Littleton, USA) or N-term6 with smooth muscle actin (1:3000, Sigma. St Louis, 
USA). 
2.2.7 Immunoprecipitation 
Rat kidney samples were homogenized in RIPA buffer (Millipore, Billerica, USA) 
containing Halt protease inhibitors (Pierce, Rockford, USA). Cell lysis was carried out 
using a Polytron homogenizer (Kinematica, Bohemia, USA). Following lysis, 
homogenates were centrifuged at 10,000 x g for 5 min to remove insoluble debris. 
Immunoprecipitation was performed using µMACS Protein G MicroBeads and µ 
Columns (Miltenyi Biotec, Cologne, Germany). Protein extract was pre-cleared by 
incubation with MicroBeads during 45 min at 4º C and passage through the µ Column 
at RT. One mL of the pre-cleared extract was incubated with 3 µg of N-term1 CaSR 
antibody (Thermo Scientific, Waltham, USA), smooth muscle actin (Sigma, St Louis, 
USA) or IgG2a (Abcam, Cambridge, UK) for 45 min at 4º C. Fifty µL of MicroBeads 
were added and the incubated for further 45 min at 4º C. Lysates were loaded into the 
µ Columns at RT and washed with a buffer containing 150 mM NaCl, 50 mM Tris (pH 
7.5) and 1% NP-40. Samples were eluted using 2x NuPage LDS sample buffer and 
reducing agent (Life Technologies, Carlsbad, USA). Twenty microliters of each 
immunoprecipitated sample, the bead flowthrough (negative control) and rat kidney 
extract (positive control) were electrophoresed on NuPage® 4-12% BisTris 
polyacrylamide gels (Invitrogen, Paisley, UK). Western blotting was performed as 
described above for smooth muscle actin (1:2000, Sigma, St Louis, USA) using a 
HRP-conjugated anti-mouse secondary antibody (Promega, Madison, USA). Controls 
for the Western blotting were performed by omission of primary antibody. 
2.2.8 Animal Studies 
The animal studies assessed in this thesis were designed and run by the Safety 
Assessment division at AstraZeneca UK, in compliance with regulations for repeated 
dose toxicity studies issued by European Medicines Agency, Ministry of Health Labour 
and Welfare and Food and Drug Administration. The studies were designed and 
carried out with the aim of assessing the toxicity of the oral administration of a MEK 
1/2 inhibitor (MEKi) and an FGFR 1-3 inhibitor (FGFRi) to Han Wistar rats. These 
studies were planned for 28d dosing periods, to meet specific criteria for regulatory 
purposes. MEKi and FGFRi doses were respectively 300 mg/kg/day with bi-daily 
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administration (BID); 1.4 mg/kg/day; and 20 mg/kg/day, BID. These doses 
corresponded to the maximum tolerated doses, the highest drug concentrations 
administered in prior 7d (MEKi and FGFRi) tolerability studies that did not result in 
unacceptable toxicity. On the last day of each study animals were killed, plasma was 
collected and the major organs were embedded in paraffin. The FGFRi group in the 
28d study had to be terminated earlier, at d25 due to animal welfare reasons. The 
study design, including the earlier terminations is described in Table 2.2. 
 
Table 2.2: Design for the 28d rat in vivo studies using MEKi and FGFRi 
Groups 
Planed 
length 
Effective 
length 
Dose 
(mg/kg/d) 
N Vehicle 
Vehicle 
28d 
 
28d 
0 10 
water containing 
0.5% HPMC 0.1% 
Tween 80 
MEKi 1.4 10 
water containing 
0.5% HPMC 0.1% 
Tween 80 
Vehicle 
25d 
0 (BID) 10 30% PEG in water 
FGFRi 20 (BID) 10 30% PEG in water 
*PEG - Polyethylene glycol 400, HPMC - hydroxypropyl methylcellulose 
2.2.9 Statistics 
All data shown represents mean ± standard error of the mean. Statistical analysis was 
carried out with Microsoft Office Excel (Microsoft, Redmond, USA) using the Real 
Statistics Resource Pack. A two-tailed, Mann Whitney U test was employed and p 
values lower that 0.05 were considered to be significant. 
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2.3 Results  
2.3.1 CaSR mRNA expression 
The CaSR mRNA distribution was analysed using a sensitive chromogenic branched 
DNA ISH in mouse, rat and human kidney. The highest CaSR mRNA expression was 
observed in cortical medullary rays (Figure 2.1 A-C) and outer medulla (Figure 2.1 D-
F) of all species, supporting a predominant expression of the CaSR in the TAL. 
Additionally, lower expression of CaSR mRNA was detected in kidney cortex, with a 
distribution and morphology consistent with DCT and CD (Figure 2.1 A-C). A high 
magnification picture of a CD showing CaSR signal is shown in Figure 2.10 A. In the 
PT and papilla (of mouse and rat only since the human kidney sections did not contain 
this region), CaSR mRNA expression was not distinguishable from the signal observed 
in negative controls performed by incubation with scrambled DNA probes. In these 
controls, the background signal was very low and generally localized in deposits with 
a relatively small size (Figure 2.1 G-I). 
 
By ISH, CaSR mRNA was detected in the TAL, DCT and CD in mouse, rat and human 
kidney. 
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Figure 2.1: Expression of CaSR mRNA in mouse, rat and human kidney.  
Photomicrographs of ISH against CaSR in mouse (A,D), rat (B,E) and human (C,F) 
kidney. CaSR expression was present in kidney cortex (A-C) and medulla (D-F). 
Negative controls were performed in mouse (G), rat (H) and human (I) kidney by 
omission of probe (mouse, human) or use of scrambled probes (rat). CaSR signal 
(red) corresponds to fast red staining. Scale bar = 50 µm. Arrow points to stronger 
signal, consistent with TAL, and arrowhead points to weaker signal, consistent with 
DT and CD. Pictures are representative of at least two experiments. 
  
35 
 
2.3.2 Antibody screening by immunofluorescence 
The discrepancies in CaSR protein distribution reported in the literature could be 
ascribed to the use of different CaSR antibodies, which may differ in specificity or 
detect different forms of the receptor (eg. monomer vs dimer). An initial systematic 
study was undertaken using a panel of eight CaSR antibodies (Table 2.1, except N-
term6) to identify and exclude antibodies that do not specifically detect the CaSR. This 
study was performed by analysing the immunofluorescence pattern of these 
antibodies in HEK293 cells stably transfected with the human CaSR (CaSR-HEK) 
(Figure 2.2), which were previously shown to express the CaSR (Maldonado-Perez et 
al. 2003). All the antibodies with the exception of C-term2 showed immunoreactivity 
mostly in the cytoplasm and plasma membrane, as it would be expected for the CaSR 
(Hjälm et al. 2001). Conversely, C-term2 showed nuclear immunoreactivity and for that 
reason was excluded from further experiments. No signal was observed in the 
negative controls, performed by omission of the primary antibody (not shown). 
 
Seven out of eight tested CaSR antibodies showed a CaSR-like immunoreactivity by 
immunofluorescence. The remaining antibody showed a discrepant immunoreactivity 
pattern and therefore was excluded from further experiments.  
 
 
Figure 2.2: CaSR immunolocalization in CaSR-HEK cells. Immunofluorescence 
pattern of eight different anti-CaSR antibodies, N-term1 (Abcam), N-term2 (Anaspec), 
N-term3 (W. Chang), N-term4 (W. Chang), N-term5 (D. Shoback), C-term1 (W. 
Chang), C-term2 (Lifespan), Full length (Novus). Antibody signal corresponds to red 
staining. Scale bar = 30 µm. 
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2.3.3 Antibody validation by Western blotting 
Since seven antibodies passed the initial immunofluorescence screening, four were 
selected to be used in further studies by considering the recognition of different CaSR 
epitopes. The antibodies N-term1, N-term3, N-term4 and N-term5 were raised against 
the same epitope, a human N-terminal ADD sequence that is conserved in mouse and 
rat. Out of these four antibodies, N-term1 was selected instead of the other ADD 
antibodies because it is commercially available and has been used in a vast number 
of studies (Weston et al. 2005, Heyeraas et al. 2008, Caudrillier et al. 2010, Loupy et 
al. 2012), whilst the remaining ADD antibodies are custom made by two collaborators 
and therefore not as easily accessible to all researchers. In addition to N-term1, the 
antibodies N-term2, Full length and C-term1 were also selected to be used in further 
studies. N-term2 was raised against a different N-terminal epitope from rat CaSR 
(according to the manufacturer), Full length was raised against the full length human 
CaSR protein and C-term1 was raised against a C-terminal epitope of mouse CaSR. 
The specificity of the selected antibodies was confirmed by their ability to detect the 
correct molecular weight species  by Western blotting in samples from mouse, rat and 
human kidneys and CaSR-HEK cell extracts (the latter included as a positive control) 
(Figure 2.3). Western blotting was performed using protein reducing conditions, which 
are consistent with the detection of CaSR-specific immunoreactivity at 130 kDa for the 
CaSR unglycosylated monomer, 140-170 kDa for the glycosylated CaSR monomer 
and 260-300 kDa for the CaSR dimer (Ray et al. 1998, Ward et al. 1998). Figure 7 
shows that all antibodies tested showed CaSR-like immunoreactivity, with bands 
detected at the expected sizes for the glycosylated CaSR monomer and dimer. 
Possibly due to the resolution of the method, it was not possible to detect 
immunoreactivity for the CaSR unglycosylated monomer. Whilst N-term1 and N-term2 
recognized all species, Full length only recognized the human CaSR (in tissue lysates 
and CaSR-HEK extracts) and C-term1 only detected mouse and rat CaSR. These 
observations are consistent with Full length and C-term1 being raised against human 
and mouse antigens, respectively. Besides the differences in species recognition, 
these antibodies showed some differences in the CaSR molecular species detected. 
N-term1 detected stronger immunoreactivity corresponding to the CaSR monomer 
than for the dimeric form of the receptor in mouse and rat samples, while it detected 
comparable immunoreactivity for both forms in human and CaSR-HEK samples. N-
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term2 preferentially detected the dimeric rather than the monomeric form of the 
receptor in all species. Full length detected very weak CaSR immunoreactivity in 
human kidney, but a stronger signal in the CaSR-HEK samples. This antibody 
detected the CaSR monomer and dimer equally well. C-term1, similarly to N-term1, 
predominantly detected the CaSR monomer in mouse and rat samples.  
 
By Western blotting, N-term1, N-term2, Full length and C-term1 specifically detected 
CaSR immunoreactivity. N-term2 preferentially detected the CaSR dimer, whilst the 
remaining antibodies detected comparable levels of both monomer and dimer (human) 
or preferentially the monomeric over the dimeric form of the CaSR protein (mouse and 
rat). 
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Figure 2.3: Western blotting immunoreactivities of the CaSR antibodies used in 
this study.  Western blotting was performed using N-term1 (Thermo, ADD), N-term2 
(Anaspec, N-term), Full length (Novus, fusion protein) and C-term1 (W. Chang, C-
terminal) in mouse (Ms), rat (Rt) and human (Hu) kidney and CaSR-HEK (Hk) extracts. 
Predicted Immunoreactivity corresponding to the glycosylated CaSR monomer and 
dimer are 140-160 kDa and 260-300 kDa, respectively. Negative controls were 
performed by omission of the primary antibodies. MW=Molecular weight. Pictures are 
representative of at least two experiments. 
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2.3.4 CaSR protein expression by immunohistochemistry 
Once the specificity of the four selected antibodies used was ascertained, the CaSR 
intra-renal distribution was investigated. Immunohistochemistry was performed on 
mouse (Figure 2.4) and rat (Figure 2.5) kidney sections using N-term1, N-term2 and 
C-term1 and in human kidney sections (Figure 2.6) using N-term1, N-term2 and Full 
length due to the lack of species cross-reactivity of Full length and C-term1. Similarly 
to the mRNA distribution, in all species, higher immunoreactivity was observed with all 
the antibodies in cortical medullary rays and outer medulla and lower immunoreactivity 
was observed in the kidney cortex. The presence of CaSR immunoreactivity in the 
different nephron segments was assessed by analysing cellular morphology and co-
staining using the CaSR antibodies in combination with established segment-specific 
markers in mouse (Figure 2.7), rat (Figure 2.8), and human (Figure 2.9) sections. In 
the glomeruli and JGA, CaSR immunoreactivity was absent or undistinguishable from 
background. In the PT, identified through the presence of brush border, CaSR 
immunoreactivity was weak and variable between experiments in sections stained with 
N-term1, Full length and C-term1. Conversely, a relatively stronger and consistent 
immunoreactivity was observed in sections stained with N-term2. PT immunoreactivity 
generally increased from S1 to S3, although the staining pattern varied with the 
different antibodies. All antibodies demonstrated cytoplasmic CaSR expression, 
additionally N-term1 and N-term2 showed basolateral staining and N-term2 apical 
membrane staining of certain tubules, which were located mainly in the inner cortex, 
in the vicinity of cortical medullary rays. In TAL, identified by colocalization with Tamm-
Horsfall protein, CaSR immunoreactivity was detected in the basolateral membrane 
and cytoplasm with all the antibodies. In agreement with the ISH results, the TAL was 
the nephron segment that showed higher CaSR immunoreactivity. In the DCT, 
identified by colocalization with NCC, CaSR immunoreactivity was detected in the 
cytoplasm and in the basolateral and apical membranes. In the CNT, identified by the 
analysis of cellular morphology and colocalization with aquaporin 2 (AQP2), CaSR 
was detected at the basolateral membrane and in the cytoplasm. In the CD, identified 
by the analysis of cellular morphology and colocalization with AQP2, CaSR 
immunoreactivity was heterogeneous and some expression differences were obtained 
between species and when different antibodies were used. In mouse and rat cortical 
CDs, all antibodies showed immunoreactivity in the cytoplasm and apical membrane 
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in a population of cells and basolateral immunoreactivity in a different population of 
cells. Conversely, in mouse and rat medullary CDs, only N-term2 showed 
immunoreactivity, which was present in the apical and basolateral membrane. In 
human tissue, all antibodies showed immunoreactivity in the cytoplasm and apical and 
basolateral membranes of most cortical and medullary CD cells, with N-term1 and N-
term2 showing higher immunoreactivity in a population of cells. For all the species, all 
the antibodies showed CaSR CD immunoreactivity both in cells that expressed AQP2 
(CaSR+/AQP2+) and in cells that did not express AQP2 (CaSR+/AQP2-). In cortical 
CDs, N-term2 showed immunoreactivity in all CD cells. Conversely, in medullary CDs 
stained with N-term2 and in cortical and medullary CDs stained with the remaining 
antibodies, some CD cells lacked CaSR immunoreactivity, whilst expressing (CaSR-
/AQP2+) or not (CaSR-/AQP2-) AQP2. High magnification pictures of CaSR 
immunoreactivity in the CD are shown on Figure 2.10 B,D. 
 
IHC with the CaSR antibodies N-term1, N-term2, Full length and C-term1 in mouse, 
rat and human kidney sections showed immunoreactivity in TAL, DCT, CNT and CD. 
Additionally, in the PT, relatively strong immunoreactivity was observed with N-term2 
and weak and variable immunoreactivity was observed with the remaining antibodies 
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Figure 2.4: CaSR immunolocalization in mouse kidney sections. 
Photomicrographs of CaSR immunohistochemistry performed with N-term1 (Thermo, 
ADD, A,D), N-term2 (Anaspec, N-Term, B,E) and C-term1 (W. Chang, C-term, C,F) in 
kidney cortex (A-C) and medulla (D-F). Negative controls performed by omission of 
primary antibody (G-I). Positive signal corresponds to immunoperoxidase staining 
(brown). Arrow indicates stronger immunoreactivity consistent with TAL and 
arrowhead indicates weaker immunoreactivity consistent with DCT and CD. Scale bar 
= 100 µm. Pictures are representative of at least three experiments. 
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Figure 2.5: CaSR immunolocalization in rat kidney sections. Photomicrographs of 
CaSR immunohistochemistry performed with N-term1 (Thermo, ADD, A,D), N-term2 
(Anaspec, N-Term, B,E) and C-term1 (W. Chang, C-term, C,F) in kidney cortex (A-C) 
and medulla (D-F). Negative controls performed by incubation with the Ig fraction 
correspondent to N-term1 (G), N-term2 (H) and C-term1 (I). Positive signal 
corresponds to immunoperoxidase staining (brown). Arrow indicates stronger 
immunoreactivity consistent with TAL and arrowhead indicates weaker 
immunoreactivity consistent with DCT and CD. Scale bar = 100 µm. Pictures are 
representative of at least three experiments. 
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Figure 2.6: CaSR immunolocalization in human kidney sections. 
Photomicrographs of CaSR immunohistochemistry performed with N-term1 (Thermo, 
ADD, A,D), N-term2 (Anaspec, N-Term, B,E) and Full length (Novus, Whole protein 
C,F) in kidney cortex (A-C) and medulla (D-F). Negative controls performed by 
omission of primary antibody (G-I). Positive signal corresponds to immunoperoxidase 
staining (brown). Arrow indicates stronger immunoreactivity consistent with TAL and 
arrowhead indicates weaker immunoreactivity consistent with DCT and CD. Scale bar 
= 100 µm. Pictures are representative of at least three experiments. 
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Figure 2.7: CaSR distribution along the nephron in mouse kidney sections.  
Photomicrographs of CaSR immunohistochemistry performed with N-term1 (Thermo, 
ADD, A,D,G,F), N-term2 (Anaspec, N-Term, B,E,G,H) and C-term1 (W. Chang, C-
term, C,F,I,L) in kidney cortex. CaSR expression was detected in the PT, identified by 
the presence of brush border (A-C); TAL identified by dual staining with Tamm-Horsfall 
protein (D-F); DCT, identified through dual staining with thiazide-sensitive Na-Cl 
cotransporter (NCC, G-I); and CD identified through dual staining with aquaporin-2 
(AQP2, J-L). Nephron segment marker signal corresponds to (red) fast red staining. 
Asterisk indicates PT. Scale bar = 50 µm. Pictures are representative of at least three 
experiments. 
  
45 
 
 
Figure 2.8: CaSR distribution along the nephron in rat kidney sections.  
Photomicrographs of CaSR immunohistochemistry performed with N-term1 (Thermo, 
ADD, A,D,G,F), N-term2 (Anaspec, N-Term, B,E,G,H) and C-term1 (W. Chang, C-
term, C,F,I,L) in kidney cortex. CaSR expression was detected in the PT, identified by 
the presence of brush border (A-C); TAL identified by dual staining with Tamm-Horsfall 
protein (D-F); DCT, identified through dual staining with thiazide-sensitive Na-Cl 
cotransporter (NCC, G-I); and CD identified through dual staining with aquaporin-2 
(AQP2, J-L). Nephron segment marker signal corresponds to (red) fast red staining. 
Asterisk indicates PT. Scale bar = 50 µm. Pictures are representative of at least three 
experiments. 
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Figure 2.9: CaSR distribution along the nephron in human kidney sections.  
Photomicrographs of CaSR immunohistochemistry performed with N-term1 (Thermo, 
ADD, A,D,G,F), N-term2 (Anaspec, N-Term, B,E,G,H) and Full length (Novus, Whole 
protein, C,F,I,L) in kidney cortex. CaSR expression was detected in the PT, identified 
by the presence of brush border (A-C); TAL identified by dual staining with Tamm-
Horsfall protein (D-F); DCT, identified through dual staining with thiazide-sensitive Na-
Cl cotransporter (NCC, G-I); and CD identified through dual staining with aquaporin-2 
(AQP2, J-L). Nephron segment marker signal corresponds to (red) fast red staining. 
Asterisk indicates PT. Scale bar = 50 µm. Pictures are representative of at least three 
experiments. 
  
47 
 
 
Figure 2.10: Expression of the CaSR in rat kidney CD.  Photomicrographs of CaSR 
mRNA expression in CCD detected by ISH (A). CaSR signal (in red) corresponds to 
fast red staining. Photomicrographs of CaSR protein expression in CCD detected by 
IHC with N-term1 (Thermo, ADD, B), N-term2 ( Anaspec, N-term, C), C-term1 (W. 
Chang, C-term, D) or PLA with C-term1 (W. Chang, C-term) and N-term6 (Alomone, 
ADD) (E). Photomicrographs of CaSR protein expression in OMCD, detected by PLA 
with C-term1 (W. Chang, C-term) and N-term6 (Alomone, ADD) (F). Arrows indicate 
CaSR expression. Scale bar = 50µm. Pictures are representative of at least two 
experiments. 
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2.3.5 Proximity ligation assay 
CaSR protein expression was further analysed in rat kidney by chromogenic in situ 
PLA using the C-term1/N-term6 antibody pair in rat kidney sections (Figure 2.11). 
Stronger PLA signal was observed in the outer medulla and cortical medullary rays 
and weaker signal was observed in the cortex. This expression pattern is in agreement 
with the results obtained by ISH and IHC and suggests that the CaSR is strongly 
expressed in TAL and more weakly expressed in DT and cortical CD. In addition to 
these segments, PLA signal was also observed in the glomerulus, where CaSR 
expression was not detected by ISH and IHC and in the PT and medullary CDs (Figure 
2.10 F), where the results ISH and IHC were discrepant. In the glomerulus, PLA signal 
was highly variable, with some glomeruli showing a signal clearly above the 
background levels and other glomeruli, even adjacent glomeruli, completely lacking 
PLA signal. Similar results were obtained when using N-term1/N-term2, N-term1/N-
term6 or N-term2/C-term1 antibody pairs in rat kidney sections (Figure 2.12), C-
term1/N-term6 in mouse kidney sections or Full length/N-term6 in human kidney 
sections (Figure 2.13). The negative controls, performed by incubation with the 
corresponding immunoglobulin fractions (Figure 2.11 B,D) showed a relatively low 
signal, localized to small deposits. Similarly, low signal was observed in sections 
incubated with C-term1 and an antibody against Ki-67, an unrelated protein expressed 
in the nuclei of proliferating cells. A further control was carried out by incubating N-
term6 with smooth muscle actin (SMA), a protein predicted to interact with the CaSR, 
since both proteins interact with filamin (Lebart et al. 1994, Awata et al. 2001) (Figure 
2.14). With the N-term6/SMA antibody pair, the PLA signal was only observed in the 
blood vessels and not along the nephron, consistent with SMA being expressed in the 
blood vessels but not in epithelial cells. The interaction between the CaSR and SMA 
was confirmed by immunoprecipitating rat kidney extracts with N-term1 and analysing 
SMA expression by Western blotting (Figure 2.14 D). 
PLA with different CaSR antibody combinations showed CaSR immunoreactivity in 
different nephron segments including glomerulus, PT, TAL, DCT, CNT and CD.  
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Figure 2.11: Proximity ligation assay to detect the CaSR in rat kidney.  
Photomicrographs from the proximity ligation assay performed using C-term1 
(W.Chang, C-term) and N-term6 (Alomone, ADD): outer cortex (A) and inner cortex 
(C). Negative control performed by incubation with the Igs corresponding to the 
primary antibodies: outer cortex (B) and inner cortex (D). Positive staining corresponds 
to immunoperoxidase staining (brown dots). Arrow points to TAL and asterisk indicates 
PT. Scale bar = 50 µm. Pictures are representative of at least two experiments. 
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Figure 2.12: Proximity ligation assay to detect the CaSR in rat kidney. 
Photomicrographs from the proximity ligation assay performed using different antibody 
combinations: N-term1 (Thermo, ADD) and N-term2 (Anaspec, N-term) - outer cortex 
(A) and inner cortex (B); N-term1 (Thermo, ADD) and N-term6 (Alomone, ADD) - outer 
cortex (C) and inner cortex (D); N-term2 (Anaspec, N-term) and C-term1 (W. Chang, 
C-term) - outer cortex (E) and inner cortex (F). Positive staining corresponds to 
immunoperoxidase staining (brown dots). Arrow indicates TAL, arrowhead indicates 
DCT and CD and asterisk indicates PT. Scale bar = 50µm. Pictures are representative 
of at least two experiments. 
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Figure 2.13: Proximity ligation assay to detect the CaSR in mouse and human 
kidney. Photomicrographs from the proximity ligation assay performed in mouse 
kidney sections using C-term1 (W. Chang, C-term) and N-term6 (Alomone, ADD) - 
outer cortex (A) and inner cortex (C); and in human kidney sections using C-term1 
(Novus, fusion protein) and N-term6 (Alomone, ADD) - outer cortex (E). Negative 
controls for mouse outer cortex (B), inner cortex (D) and human outer cortex (F) were 
performed by omitting the incubation with primary antibodies. Positive staining 
corresponds to immunoperoxidase staining (brown dots). Arrow indicates TAL, 
arrowhead indicates DCT and CD and asterisk indicates PT. Scale bar = 50 µm. 
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Figure 2.14: Controls for CaSR detection by proximity ligation assay in rat 
kidney.  Controls for the proximity ligation assay were performed using C-term1 
(W.Chang, C-term) and anti-Ki-67 antibodies - picture from the outer cortex (A); or N-
term6 (Alomone, ADD) and anti-SMA antibodies - picture from the outer cortex (B) and 
a magnified blood vessel (C). Positive staining corresponds to immunoperoxidase 
staining (brown dots). Arrow indicates the blood vessel. Scale bar = 50 µm for the 
outer cortex pictures and 100 µm for the magnified blood vessel. The interaction 
between SMA and CaSR was confirmed by co-immunoprecipitation: Proteins from rat 
kidney extracts were pulled down with N-term1 (CaSR, Thermo, ADD), anti-SMA 
(SMA) or the corresponding isotype control (Ig, same for N-term1 and SMA). The 
pulled down proteins, together with the buffer used to pre-clear the pull-down assay 
columns (pc) and total protein extracts (Rt) were analysed by Western blotting with an 
anti-SMA antibody (D). Control for the Western blotting was performed by omitting the 
primary antibody (E). SMA MW = 42 kDa. 
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2.3.6 Summary of CaSR distribution 
Table 2.3 shows a summary of the CaSR distribution detected by ISH, IHC and PLA 
in mouse rat and human kidney. 
Table 2.3: Summary of the distribution of the expression of the CaSR observed 
by ISH, IHC and PLA. 
  Glomerulus PT TAL DCT CNT CCD MCD 
ISH - - ++ + + + + 
IHC 
N-term1 - +/- ++ + + + - 
N-term2 - + ++ + + + + 
Full length - +/- ++ + + + - 
C-term1 - +/- ++ + + + - 
PLA 
C-term1+ 
N-term6 
+ + ++ + + + + 
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2.3.7 Effect of MEK and FGFR inhibition on the expression of the CaSR 
In order to investigate the involvement of the renal CaSR in the soft-tissue 
mineralization induced by the inhibition of MEK/ERK pathway or FGFRs in rats, the 
expression of the CaSR was analysed in kidney sections from rats treated for 28d with 
MEKi or 25d with FGFRi. The tissue samples used to perform this assay were obtained 
from retrospective studies in which the administration of MEKi and FGFRi  had 
resulted in soft-tissue mineralization in different organs including kidney, heart and 
stomach, and in increased levels of Pi and Ca2+ (only animals treated with MEKi) in 
plasma (Table 2.4). 
In agreement with the intra-renal distribution described above, the study animals 
evidenced CaSR expression along the nephron, from the PT to the CD with the 
strongest signal detected in the TAL (Figure 2.15 A,D). Treatment with MEKi for 28d 
(Figure 2.15 B,C) or FGFRi for 25d (Figure 2.15 D,F) did not induce any evident 
changes in the expression or cellular distribution of the CaSR. 
 
Expression of the CaSR remained unchanged in animals treated with ERKi, MEKi or 
FGFRi. 
 
Table 2.4: Data from retrospective studies showing plasma levels of Ca2+, Pi and 
presence of soft-tissue mineralization in kidney, stomach and heart of animals 
treated with 1.4 mg/kg/day of MEKi for 28d or 20 mg/kg/day of FGFRi for 25d.   
  Vehicle MEKi Vehicle FGFRi 
Ca2+ d25 2.71 ± 0.01 2.67 ± 0.03 3.01 ± 0.04 3.28 ± 0.06* 
Pi d11/14 2.10 ± 0.06 2.89 ± 0.10* 1.93 ± 0.06 2.69 ± 0.08* 
Pi d25/d28 2.42 ± 0.12 2.70 ± 0.12 1.93 ± 0.10 2.62 ± 0.10* 
Mineral 
deposition 
Kidney - 7/10 - 8/10 
Stomach - 10/10 - 8/10 
Heart - 4/10 - 4/10 
Data representative of N = 10 rats + standard error of the mean (SEM). * p<0.05 vs 
vehicle control (Mann-Whitney). The data presented in this table was generated by the 
Pathology and Clinical Pathology department at AstraZeneca UK. 
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Figure 2.15: Expression of the CaSR in cortical kidney sections from rats treated 
with 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi.  Photomicrograph of CaSR 
immunostaining in sections of rats dosed for 28d with vehicle (A) or MEKi (B); or for 
25d with vehicle (C) or FGFRi (D). Positive signal in immunohistochemistry 
corresponds to the brown staining. Histograms represent the quantification of CaSR 
expression (immunohistochemically stained area) in animals from the studies 1 (C) 
and 2 (F). Data representative of N = 10 rats + standard error of the mean (SEM). * 
p<0.05 vs vehicle control (Mann-Whitney). Scale bar = 100 µm. 
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2.4 Discussion 
Different studies have reported various roles for the CaSR in the kidney, including 
regulation of the reabsorption of Ca2+ (Toka et al. 2012) and Pi (Ba et al. 2003), 
production of 1,25D3 (Bland et al. 2002) and urine acidification (Renkema et al. 2009). 
Since rats treated with MEK/ERK and FGFR inhibitors showed increased levels of 
plasma Ca2+, Pi and 1,25D3 (Brown et al. 2005, Diaz et al. 2012, Yanochko et al. 
2013), I decided to assess if the CaSR was involved in the soft-tissue mineralization 
induced by these inhibitors. In order to accomplish this, it was key to ascertain the 
intra-renal distribution and to develop sensitive methods to detect the CaSR, since the 
lack of consensus over the localization of this receptor in the kidney had generated 
some controversy regarding the its renal functions (Ba et al. 2003, Topala et al. 2009, 
Loupy et al. 2012, Toka et al. 2012). Also, it was important to clarify the intra-renal 
distribution of this receptor in order to allow the full understanding of its renal roles 
since positive CaSR modulators (calcimimetics) are currently in use in the clinic (Block 
et al. 2004) and negative modulators (calcilytics) are being developed for the treatment 
of autosomal dominant hypocalcemia (Nemeth and Shoback 2013).  
In this study, I have established the CaSR expression pattern in mouse, rat and human 
kidney using the most sensitive and specific mRNA and protein detection methods 
currently available. The expression of CaSR mRNA was analysed by a branched DNA 
methodology in which the detection of the CaSR was performed using a probe set 
composed of 20 small oligonucleotide probe pairs. The detection of mRNA sequences 
with a probe set instead of a regular probe pair introduces higher specificity to this 
technique, allowing the distinction between sequences that share a great degree of 
homology (Player et al. 2001). This methodology also contained CaSR signal 
amplification through sequential steps of hybridization with synthetic DNA probes, 
conferring enough sensitivity to detect a single molecule of mRNA (Player et al. 2001). 
Moreover, the simple experimental design of this methodology allowed a faster and 
more reliable detection of mRNA molecules than the traditional radioactive ISH 
methods. The detection of CaSR protein was performed by IHC using automated 
immunostainers and by in situ PLA. The PLA technique was selected because it is 
extremely sensitive, since it comprises an amplification step, and also because it is 
highly specific, since it only produces signal when the epitopes detected by both 
antibodies are closely located (Gustafsdottir et al. 2005). Besides method sensitivity, 
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a factor that may account for discrepancies in protein and mRNA analysis is the use 
of different protocols to process the tissue, since increased exposure to fixatives 
(>48h) can lead to loss of mRNA integrity (Polidoro et al. 2013) and irreversible epitope 
masking which prevents antibody binding (Di Bartolo and Kavurma 2014). Also, mRNA 
fragmentation may be increased when the sections are not freshly cut or when the 
tissue blocks are stored at room temperature for a period longer than one year (von 
Ahlfen et al. 2007). In order to ensure the best RNA preservation, the samples used 
in this study were processed with a protocol that consisted of a strict 24-48h fixation 
in formalin followed by embedding in paraffin, tissue sectioning was carried out up to 
one year after embedding and ISH, IHC or PLA was performed up to 3 days (ISH) or 
2 weeks (IHC and PLA) after sectioning. A significant problem associated with various 
methods of protein detection and analysis is the lack of specificity of some antibodies. 
Particularly, many antibodies that target GPCRs display a significant lack of specificity, 
possibly due to the high structural similarity between the various receptors (Absi and 
Ward 2013). In order to ensure an accurate determination of the CaSR expression, 
eight CaSR antibodies were initially screened by assessing the immunofluorescence 
pattern in CaSR-HEK cells. Out of these antibodies, seven specifically detected the 
CaSR, showing cytoplasmic and membrane immunoreactivity in CaSR-HEK cells; and 
one, C-term2, failed this initial screen by showing nuclear immunoreactivity. These 
data suggest that most CaSR antibodies are specifically detecting the CaSR and 
therefore the cross-detection of other proteins is not the most likely the explanation for 
the discrepancies between studies. Out of the seven antibodies that passed the initial 
screening, four were selected for further studies based on the recognition of different 
epitopes and the specificity of these four antibodies was confirmed by analysing the 
Western blot pattern in mouse, rat and human kidney or CaSR-HEK cell extracts. In 
line with previous reports, all the selected antibodies showed different forms of the 
receptor, consistent with the presence of homodimers/multimers and glycosylated 
forms (Bai et al. 1996, Bai et al. 1998, Ward et al. 1998). Moreover, the antibodies 
show slightly different Western blotting profiles, showing preferential detection of 
monomeric or dimeric forms of the receptor. N-term1, Full length and C-term1 seem 
to detect preferentially monomeric forms of the CaSR in mouse and rat or to detect 
equally the monomeric and dimeric forms in human. Conversely, N-term2 seems to 
preferentially detect the CaSR dimer in all species. By IHC, all antibodies show a 
generally consistent IHC pattern, with CaSR the strongest immunoreactivity observed 
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in TAL and a weaker immunoreactivity observed in CD and DT. In addition, N-term2 
showed a relatively strong immunoreactivity the proximal tubule. Dimerization of the 
CaSR occurs in the endoplasmic reticulum in a process that is independent of agonist 
binding and precedes the trafficking of the receptor to the plasma membrane (Olauson 
et al. 2013), therefore it is plausible that N-term2 preferably detects more mature, 
dimeric forms of the CaSR, which are present in the proximal tubule. Alternatively, the 
signal observed with N-term2 in the PT may be associated with non-specific binding 
to formalin fixed paraffin embedded (FFPE) tissue.  
Thick ascending limb 
The highest CaSR mRNA and protein expression were observed in the TAL, the only 
segment unanimously recognized to express the CaSR. (Wang et al. 1996, Riccardi 
et al. 1998, Motoyama and Friedman 2002, Ba et al. 2003, Loupy et al. 2012, Meister 
et al. 2013). The physiological roles described for the CaSR in this nephron segment 
include the regulation of divalent cation reabsorption through PTH-dependent 
(Motoyama and Friedman 2002) and PTH-independent (Loupy et al. 2012) processes. 
Distal convoluted tubule 
CaSR mRNA and protein expression were also observed in the DCT, in agreement 
with a vast number of studies (Sands et al. 1997, McNeil et al. 1998, Riccardi et al. 
1998, Riccardi et al. 2000, Topala et al. 2009, Quinn et al. 2013, Ronchetti et al. 2013, 
Yasuoka et al. 2014). In this nephron segment, the CaSR was described to regulate 
the expression of the Ca2+ channel TRPV5 (Topala et al. 2009) and the potassium 
channel Kir4.1 (Huang et al. 2007). 
Collecting ducts 
CaSR mRNA and protein expression were detected by all methods in a fraction of the 
cells (roughly 30%) of cortical CDs. Weaker CaSR immunoreactivity was observed in 
the remaining cells by IHC with N-term2 but not with the other methods. Conversely, 
only IHC with N-term2 and PLA showed expression of the CaSR in medullary CDs. 
Although it is possible that IHC with N-term2 shows a higher sensitivity than the other 
methods, it is more likely that this antibody is the only method that detects a specific 
form of the receptor. This hypothesis is supported by the Western blotting results 
showing a preferential detection of the dimer, when compared to the other CaSR 
antibodies. Alternatively, N-term2 may be recognizing non-specific signal in FFPE 
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tissue. Intra-tubular expression of the CaSR in the CD has been a controversial issue. 
In this study, a heterogeneous CaSR distribution was observed within the cytoplasm, 
apical and basolateral membranes of CD in agreement with the initial description of 
CaSR distribution in this segment (Riccardi et al. 1998). The CaSR expression was 
first described in type A intercalated cells, (Riccardi et al. 1998), where the CaSR was 
found to trigger urinary acidification by increasing H+-ATPase activity in response to 
high urinary Ca2+ levels (Renkema et al. 2009). Conversely, a more recent study 
described the CaSR expression as being restricted to type B intercalated cells and 
dependent of the pH (Yasuoka et al. 2014). Other studies supported the expression of 
the CaSR in the apical membrane of principal cells, where the receptor reduced 
arginine vasopressin-elicited osmotic water permeability by inhibiting Aqp2 expression 
(Sands et al. 1997, Bustamante et al. 2008, Procino et al. 2012). In this study CaSR 
expression was observed in a proportion of principal and intercalated cells, since 
populations of CaSR+/Aqp2+, CaSR+/Aqp2-, CaSR-/Aqp2+ and CaSR-/Aqp2- cells 
were observed. Further work will be necessary to understand the heterogeneity and 
polarity of the CaSR in CD and functional roles of the receptor in principal and 
intercalated cells. 
Proximal tubule 
The PT is the nephron segment where the CaSR expression is more controversial 
(Riccardi et al. 1998, Riccardi et al. 2000, Ba et al. 2003, Loupy et al. 2012, Quinn et 
al. 2013, Ronchetti et al. 2013, Wu et al. 2013). In this study, no specific PT CaSR 
expression was observed by ISH. By IHC, whilst N-term2 showed consistent 
immunoreactivity in the PT, all the other antibodies showed a high variation between 
experiments and it was difficult to distinguish CaSR specific signal from the 
background staining obtained in the negative controls. When observed, PT 
immunoreactivity generally increased from the outer cortex to the inner cortex (S1 to 
S3). Using PLA, it was possible to specifically detect a low level of CaSR expression 
in the proximal tubule. Similarly to the distribution observed in some of the IHC 
experiments, CaSR PLA signal increases from S1 to S3. Previous studies reported a 
decrease in CaSR immunoreactivity from the outer cortex to the inner cortex (S1 to 
S3) (Riccardi et al. 1998, Riccardi et al. 2000), the opposite of our findings. These 
discrepancies are possibly associated with differences in the processing of the 
sample, since our studies were performed using FFPE sections and the previous 
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studies were carried out using cryosections of kidneys fixed by perfusion with 
paraformaldehyde. This assumption was confirmed by carrying out IHC with N-term1 
in sections of rat kidneys fixed (data not shown). The observation of the CaSR in the 
PT is in agreement with studies that have observed the expression of the receptor in 
this segment in tissue (Riccardi et al. 1996, Riccardi et al. 1998, Ward et al. 2001, Ba 
et al. 2003) and PT immortalized cell lines (Di Mise et al. 2015) and support functional 
studies that  show a role for the CaSR in 1,25D3 production (Bland et al. 2002), PT 
fluid reabsorption (Capasso et al. 2013) and regulation of PTH inhibition of Pi 
reabsorption (Ba et al. 2003).  
Glomerulus 
A few studies have described the expression of the CaSR in the glomerulus (Caride 
et al. 1998, Oh et al. 2011), while most studies fail to detect the CaSR in this segment 
(Riccardi et al. 1996, Yang et al. 1997, Riccardi et al. 1998, Loupy et al. 2012, Yasuoka 
et al. 2014).  In this study, the CaSR expression was only convincingly observed with 
PLA as the other techniques did not show any expression distinguishable from the 
background levels. By PLA, CaSR expression was highly variable within the glomeruli 
and adjacent glomeruli would frequently show very different CaSR expression levels. 
The observation of the CaSR in the glomerulus supports the functional role reported 
for the receptor in the regulation of apoptosis and cytoskeleton stabilization in the 
podocytes (Oh et al. 2011). Further experiments will be needed to clarify the 
physiological significance of the receptor within the glomeruli. 
Blood vessels 
CaSR expression was also observed in the blood vessels by PLA, where this receptor 
was found to interact with SMA. The interaction was further confirmed by a co-
immunoprecipitation assay in which the SMA expression was observed by Western 
blotting in rat kidney extracts pulled down with the N-term1. The CaSR was previously 
shown to interact with the actin binding protein filamin A, which possibly acts as a 
scaffolding protein, regulating the localization and signalling of the CaSR within the 
cells (Awata et al. 2001, Hjälm et al. 2001). It is plausible that the interaction between 
SMA and CaSR is involved in the localization and signalling of the receptor within 
blood vessels, however further studies will be needed to understand the physiological 
significance of this interaction. 
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The intra-renal distribution of the CaSR observed in this study is consistent with this 
receptor playing roles in different processes associated with the mineralization 
induced by MEK/ERK or FGFR inhibitors including production of 1,25D3 (Bland et al. 
2002) and reabsorption of Ca2+ (Topala et al. 2009) and Pi (Ba et al. 2003). No 
changes in the expression or cellular localization of the CaSR were observed following 
treatment with MEKi or FGFRi. Although these findings may suggest that the CaSR is 
not involved in the process of mineralization induced by MEK/ERK or FGFR inhibitors, 
it is important to acknowledge the possibility of these drugs affecting the activation and 
consequently downstream signalling of the CaSR whilst having no effects in its 
expression levels. Since the FGFRs and the MEK/ERK pathway have a direct role in 
the regulation of 1,25D3 production (Perwad et al. 2007), it is more likely that the 
mineralization induced by MEK/ERK and FGFR inhibitors is the consequence of an 
increased production of 1,25D3 elicited independently of the CaSR. The high levels of 
1,25D3 in the kidney may directly promote the renal reabsorption of Ca2+ and Pi by 
inducing the expression of NaPi-IIa and TRPV5, since these proteins contain vitamin 
D3 responsive elements (Taketani et al. 1998, Weber et al. 2001, Turunen et al. 2007). 
Although these studies did not show any evidence of a role of the CaSR in soft-tissue 
mineralization induced by MEKi or FGFRi, it is possible that the CaSR contributes to 
this process in other organs including parathyroid, where it regulates the expression 
of PTH. Further studies are required to assess a possible role of PTH and parathyroid 
CaSR in the soft-tissue mineralization induced by ERKi, MEKi or FGFRi. 
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2.5 Conclusions 
In summary, this study has shown that the CaSR is expressed throughout the nephron 
with a similar pattern observed in mouse, rat and human kidney. Highest CaSR 
expression is observed in the TAL, however the receptor is also present in other 
segments including glomerulus, PT, DCT, CNT and DT. The expression of the CaSR 
in glomerulus and PT is only convincingly detected by PLA, which displays higher 
sensitivity and specificity than the IHC. These findings clarify the expression pattern 
of the CaSR in mouse, rat and human kidney, thus allowing the full physiological role 
of the receptor to be determined in this organ. The role of the CaSR in the soft-tissue 
mineralization induced by MEK/ERK or FGFR inhibition was analysed by assessing 
the renal expression of the CaSR in animals treated with MEKi or FGFRi. Neither of 
the drugs affected the expression or cellular distribution of the CaSR, which may 
suggest that this receptor is not involved in the soft-tissue mineralization induced by 
inhibition of MEK/ERK pathway or inhibition of the FGFRs.  
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3 Effects of the inhibition of the MEK/ERK pathway or the 
FGF receptors in mineral homeostasis and soft-tissue 
mineralization  
3.1 Introduction 
Soft-tissue mineralization is a relatively frequent finding during preclinical drug safety 
testing. Yet, the study of the mechanisms associated with drug-induced mineralization 
has only emerged over the last decade, following significant advances in the 
understanding of the biomineralization process. Biomineralization is now regarded as 
an active process, regulated by multiple factors including Ca2+, Pi (Haut et al. 1980), 
calcification inducers such as alkaline phosphatase (Orimo 2010) and RANKL (Deuell 
et al. 2012) and calcification inhibitors such as pyrophosphate (Moochhala 2012), 
osteopontin (Staines et al. 2012) and osteoprotegerin (Bucay et al. 1998). 
The administration of MEK (Brown and Gad 2010, Diaz et al. 2012, Yanochko et al. 
2013) or FGFR (Brown et al. 2005, Yanochko et al. 2013) inhibitors to rodents has 
resulted in soft-tissue mineralization associated with altered production or plasma 
levels of 1,25D3, FGF23 and PTH in previous studies. Most of these studies show that 
the renal production and plasma levels of 1,25D3 are increased by MEK or FGFR 
inhibition. 1,25D3 is a hormone mainly produced in the kidney that contributes for 
mineral homeostasis by promoting an increase in Ca2+ and Pi absorption from 
intestine, reabsorption from kidney and resorption from bone (Dusso et al. 2005). Also, 
1,25D3 regulates the mineralization process by inducing the expression of pro-
calcifying proteins such as alkaline phosphatase (Jono et al. 1998), Pit-1 (Tatsumi et 
al. 1998) and RANKL (Cardus et al. 2007, Katsumata et al. 2014). The effects of MEK 
and FGFR inhibition in FGF23 and PTH are more unclear as some studies report that 
both types of inhibitors increase plasma FGF23 (Diaz et al. 2012, Yanochko et al. 
2013) and / or decrease plasma PTH (Brown and Gad 2010, Diaz et al. 2012), while 
other studies report that FGFR inhibitors induce the opposite effects (Wohrle et al. 
2011, Wohrle et al. 2013). FGF23 and PTH are two key hormones in mineral ion 
homeostasis, produced respectively mainly in bone and parathyroid glands. Both 
hormones are able to induce the reabsorption of Ca2+ and inhibit the reabsorption of 
Pi in kidney. In addition, PTH also induces Ca2+ and Pi resorption from bone. The 
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effects of FGF23 are mediated mainly by the FGFRs and require Klotho as a co-
receptor (Jüppner and Wolf 2012).  
The toxicological effects of MEK and FGFR inhibitors resemble the toxicity induced by 
high levels of 1,25D3 (Brown et al. 2005) which include soft-tissue mineralization 
associated with high plasma levels of 1,25D3, FGF23, Ca2+ and Pi and low plasma 
levels of PTH. Mice deficient in FGF23 (Shimada et al. 2004) or Klotho (Kuro-o et al. 
1997) also show the presence of soft-tissue mineralization associated with increased 
levels of 1,25D3 and analogous effects in mineral homeostasis, which can be ablated 
through the knockout of Cyp27b1 (Razzaque et al. 2006, Ohnishi et al. 2009) or VDR 
(Hesse et al. 2007, Anour et al. 2012). Conversely, mice treated with a FGFR1-
activating antibody show increased production of FGF23 and effects opposite to the 
toxicity of MEK inhibitors and FGFR inhibitors, namely hypophosphatemia, 
normocalcemia, downregulation of Cyp27b1 and upregulation of Cyp24a1 (Wu et al. 
2013). Taking together the results from the studies mentioned above, increased 
production / high levels of 1,25D3 appear to be associated and perhaps a triggering 
event for the occurrence of soft-tissue mineralization.  
Despite the comparable pathophysiology, it is not clear if the molecular mechanisms 
leading to increased production of 1,25D3 and occurrence of soft-tissue mineralization 
are similar in animals treated with FGFR inhibitors and animals treated with MEK 
inhibitors. The unravelling of such mechanisms is notoriously difficult due to the high 
complexity of the processes associated with mineral homeostasis. For instance, the 
expression/production of 1,25D3, FGF23 and PTH are regulated not only by plasma 
levels of Ca2+ and Pi, but also by complex cross-regulatory interactions between these 
three hormones (Kuro-o 2010, Haussler et al. 2012), by other ions such as Mg2+ 
(Matsuzaki et al. 2013) and by other hormones such as sclerostin (Ryan et al. 2013).  
Moreover, the expression and effects of 1,25D3, FGF23 and PTH involve signalling 
through different cell signalling pathways such as MEK/ERK, WNT and 
calcineurin/NFAT. Previous studies have shown that FGF23 is able to induce the 
expression of FGF23 in bone (Xiao et al. 2014) and to inhibit the production/expression 
of 1,25D3 in kidney (Ranch et al. 2011, Chanakul et al. 2013) and PTH in the 
parathyroid (Ben-Dov et al. 2007) by signalling through the FGF receptors and the 
MEK/ERK pathway. Taking these observations into account, it is plausible that the 
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dysregulations in 1,25D3, FGF23 and PTH following MEK or FGFR inhibition are the 
consequence of a blockage in the FGF23-induced regulation of these hormones.  
Most likely the kidney has a key role in the mineralization induced by MEK inhibitors 
or FGFR inhibitors since it is the organ where 1,25D3 is mainly produced and one of 
the organs displaying more severe mineralization in animals treated with these 
inhibitors (Brown et al. 2005, Diaz et al. 2012). Also, the renal signalling of FGF23, 
which occurs through the FGFRs and the MEK/ERK pathway, results in the induction 
of TRPV5 and inhibition of NaPi-IIa, two important proteins for renal Ca2+ and Pi 
reabsorption, respectively (Andrukhova et al. 2012, Andrukhova et al. 2014). It is 
plausible that MEK or FGFR inhibitors directly affect renal Ca2+ and Pi reabsorption by 
blocking the FGF23 regulation of TRPV5 and NaPi-IIa. Consistent with these 
observations, NaPi-IIa expression is decreased in mice treated with a FGFR1-
activating antibody (Wu et al. 2013) and increased in rats treated with a FGF23 
inhibitor peptide (Goetz et al. 2010) and in mice lacking FGF23 or Klotho (Memon et 
al. 2008). One aspect proscribing the role of the kidney in the mineralization induced 
by MEK or FGFR inhibitors is the uncertainty about the intra-renal distribution of 
FGFRs and components of the MEK/ERK pathway. Regarding the FGFRs, although 
different studies have reported the expression of mRNA and protein from FGFR 1-4 in 
the kidney (Floege et al. 1999, Fuhrmann et al. 1999, Cancilla et al. 2001, Rossini et 
al. 2005, Liu et al. 2008), these show high discrepancies regarding the distribution of 
the four receptors along the nephron. Regarding the MEK/ERK pathway, whilst 
immunohistochemical studies have described ERK expression to be restricted to distal 
tubules and collecting ducts (Omori et al. 2000, Fujita et al. 2004), functional studies 
carried out in cell cultures suggest that ERK is expressed and attains functional roles 
also in the proximal tubule (Sengul et al. 2003, Su et al. 2006).  
As described above, previous studies have shown that the inhibition of signalling 
through the FGFRs or through the MEK/ERK pathway in rats results in disturbances 
in mineral homeostasis and soft-tissue mineralization. I hypothesise that these effects 
are induced by a mechanism common to both types of inhibitors, which is represented 
in Figure 3.1 and described below: 
- FGFR and MEK/ERK inhibitors may block the FGF23-induced regulation of 
Cyp27b1 and Cyp24a1 expression, thus promoting an increase in the production of 
1,25D3. The elevation in 1,25D3 in turn may promote the following effects:  
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- Elevation in plasma Ca2+ and Pi through the increase of the renal 
reabsorption of these ions.  
- Increase in the expression of mineralization inducers including alkaline 
phosphatase.  
- Compensatory actions for the inhibition of FGFR or the MEK/ERK pathway 
including the negative feedback for 1,25D3 production and the induction of 
FGF23 production 
- FGFR and MEK/ERK inhibitors may also block the FGF23-induced inhibition of 
NaPi-IIa expression, leading to increased Pi reabsorption.  
- Soft-tissue mineralization may occur as a consequence of the increased levels 
of circulating Ca2+ and Pi and the increased expression of mineralization inducers. 
 
The hypothesis described above was tested using an in vivo approach. A 6h (single 
dose) and two 8d (repeated dosing) rat in vivo studies were carried out using inhibitors 
of ERK 1/2 (ERKi), MEK 1/2 (MEKi) or FGFR 1-3 (FGFRi) (Table 3.1: Studies 1-3). 
Additionally, assays were carried out using samples collected in a previous 28d study 
with MEKi and FGFRi (Table 3.1: Study 4). The samples from these four studies were 
analysed for different biological readouts, grouped in 5 topics: 
- Study execution and toxicokinetic analysis of ERKi, MEKi and FGFRi - This 
topic concerns the performance of the in vivo studies and addresses the problems 
encountered during its development, the solutions adopted and the plasma levels of 
the administered drugs during the course of the studies. 
- Effects of ERKi, MEKi and FGFRi in soft-tissue mineralization and mineral 
homeostasis – This topic concerns the effects of the inhibitors in the occurrence of 
soft-tissue mineralization, plasma levels of Pi, Ca2+ and Mg2+ and production and 
plasma levels of the hormones 1,25D3, FGF23 and PTH. 
- Effects of ERKi, MEKi and FGFRi on the activation of cell signalling pathways 
in the kidney - This topic addresses: a) The susceptibility of the different nephron 
segments to be directly targeted by the inhibitors through the analysis of the 
distribution of ERK, MEK, Klotho and FGFR1-4; b) The efficacy of the inhibitors in 
preventing the activation of the ERK pathway; c) The identification of downstream 
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signalling pathways affected by the inhibitors, which may be involved in the soft-tissue 
calcification process. 
- Effects of ERKi, MEKi and FGFRi in renal reabsorption of Pi and Ca2+ – This 
topic addresses the effects of the inhibitors in the expression of proteins involved in 
the renal transport of Pi (NaPi-IIa), renal transport of Ca2+ (TRPV5, calbindin-D28k 
and PMCA) and key proteins for the regulation of these processes (Klotho). 
- Effects of ERKi, MEKi and FGFRi in the expression of calcification modulator 
proteins – This topic addresses the effect of the inhibitors in a) the expression of 
alkaline phosphatase and Pit-1, two pro-calcifying proteins susceptible induction by 
1,25D3; b) the expression of calcification inhibitors osteopontin, osteoprotegerin, 
DKK1, sclerostin, which were previously found to be upregulated in calcifying tissue. 
It is important to mention that, at the start of this project, in 2011, soft-tissue 
mineralization and perturbations of mineral homeostasis had been reported with MEK 
(Brown and Gad 2010) and FGFR (Brown et al. 2005) inhibitors, however very little 
information was available regarding the mechanisms responsible for these effects. 
The mechanistic studies presented in the introduction were carried out and published 
during the course of this work (Wohrle et al. 2011, Diaz et al. 2012, Wohrle et al. 2013, 
Yanochko et al. 2013). Moreover, for some mechanistic aspects such as the effect of 
the MEK and FGFR inhibition in the alteration of vitamin D3 metabolism and NaPi-IIa 
activation, I had obtained analogous findings at the time of the publication of these 
studies (Wohrle et al. 2011, Diaz et al. 2012). 
 
Figure 3.1: Hypothetical model for the mechanism of soft-tissue mineralization 
induced by inhibition of the FGFRs or MEK/ERK pathway.  ALP, alkaline 
phosphatase. 
 
68 
 
3.2 Methods 
3.2.1 Animal Studies 
The animal studies assessed in this thesis were designed and run by the Safety 
Assessment division at AstraZeneca UK, in compliance with the regulations for 
repeated dose toxicity studies issued by European Medicines Agency, Ministry of 
Health Labour and Welfare and Food and Drug Administration. The studies were 
designed and carried out with the aim of assessing the toxicity of the oral 
administration of a MEK 1/2 inhibitor (MEKi) and a FGFR 1-3 inhibitor (FGFRi) to Han 
Wistar rats. These studies were planned for 8d (2 studies) and 28d dosing periods, to 
meet specific criteria for regulatory purposes. Additionally, a 6h, single dose study was 
designed to assess the effects of acute dosing with the inhibitors. Due to problems 
with the licensing of the MEKi, this compound had to be substituted with an ERK 1/2 
inhibitor (ERKi) in two of the studies (6h and 8d). ERKi, MEKi and FGFRi dosages 
were respectively 300 mg/kg/day with bidaily administration (BID); 1.4 mg/kg/day; and 
20 mg/kg/day, BID. These dosages corresponded to the maximum tolerated doses, 
the highest drug concentrations administered in prior 4d (ERKi) or 7d (MEKi and 
FGFRi) tolerability studies that did not result in unacceptable toxicity. In the last day of 
each study animals were killed, plasma was collected and the major organs were 
embedded in paraffin and/or flash frozen. In the 8d studies, the killing of the animals 
was carried out 2h after the last dosing, a time when the drugs were expected to reach 
the maximum concentrations in blood. The ERKi group in the 8d study and the FGFRi 
group in the 28d study had to be killed earlier due to animal welfare reasons, 
respectively at d3 and d25. The study design, including the earlier terminations is 
described in Table 3.1.  
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Table 3.1: Rat in vivo studies using ERKi, MEKi and FGFRi 
 Groups 
Planed 
length 
Effective 
length 
Dose 
(mg/kg/d) 
N Vehicle 
Study 
1 
Vehicle 
8d 8d 
0 3 30% PEG in water 
MEKi 1.4 
6 (4 for 
IHC) 
water containing 
0.5% HPMC 0.1% 
Tween 80 
FGFRi 20 (BID) 
6 (5 for 
WB) 
30% PEG in water 
Study 
2 
Vehicle 
8d 
 
8d 0 6 
10% PEG, 40.5% 
HP-b-CD 
ERKi 3d 300 (BID) 
6 (4 for 
IHC) 
10% PEG, 40.5% 
HP-b-CD 
FGFRi 8d 20 (BID) 
6 (4 for 
IHC) 
30% PEG in water 
Study 
3 
Vehicle 
6h 6h 
0 6 
10% PEG, 40.5% 
HP-b-CD 
ERKi 150 6 
10% PEG, 40.5% 
HP-b-CD 
FGFRi 20 6 30% PEG in water 
Study 
4 
Vehicle 
28d 
 
28d 
0 10 
water containing 
0.5% HPMC 0.1% 
Tween 80 
MEKi 1.4 10 
water containing 
0.5% HPMC 0.1% 
Tween 80 
Vehicle 
25d 
0 (BID) 10 30% PEG in water 
FGFRi 20 (BID) 10 30% PEG in water 
*PEG - Polyethylene glycol 400, HPMC - hydroxypropyl methylcellulose 
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3.2.2 Toxicokinetic analysis 
Toxicokinetic analysis was carried out by the Drug Metabolism and Pharmacokinetics 
department at AstraZeneca UK. 
ERKi, MEKi and FGFRi were analysed using liquid chromatography-tandem mass 
spectrometry in samples extracted from plasma with acetonitrile. 
3.2.3 Ca2+, Mg2+ and Pi determination 
Plasma Ca2+, Mg2+ and Pi were quantified by the Clinical Pathology department at 
AstraZeneca UK. 
Plasma Ca2+, Mg2+ and Pi were measured using a Roche Modular P analyser (Roche 
Diagnostics, West Surrey, UK). Pi and Mg2+ were quantified using assay kits supplied 
by Roche (Roche Diagnostics, West Surrey, UK). Ca2+ was quantified using a 
colorimetric end point method (Instrumentation Laboratory, Warrington, UK).  
3.2.4 Mineralization assay 
Kidneys were fixed for 24 to 48h in 10% neutral-buffered formalin, embedded in 
paraffin, and 4 µm sections were cut. Sections were de-waxed using xylene and 
rehydrated using 100% and 95% ethanol. Mineralization was assessed by staining the 
sections with Von Kossa’s stain. Briefly, sections were incubated with a 2.5% silver 
nitrate solution for 20 min under an ultraviolet light. Sections were rinsed with water 
and the excess silver was removed by incubating with 5% sodium thiosulphate for 5 
min. Sections were counterstained with nuclear fast red for 1 min before dehydrating 
in 95% and 100% ethanol, clearing in xylene, and mounting using Hystomount (TAAB 
Labs, Aldermaston, UK).  
3.2.5 In situ hybridization  
Rat kidneys were fixed in 10% neutral-buffered formalin for 24 to 48h and embedded 
in paraffin. Five µm-thick sections were cut and in situ hybridization was performed 
using QuantiGene ViewRNA ISH tissue assay (Affymetrix, Santa Clara, USA) 
according to manufacturer’s instructions, with the following modifications: incubation 
times were 5 min for pretreatment, 20 min for protease digestion, 40 min for PreAmp 
Hybridization, and 30 min for Amp Hybridization and Label Probe incubation. Rat 
FGFR1-4 probes were obtained from Affymetrix (Affymetrix, Santa Clara, USA) and 
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used in concentration of 1:40 in the probe diluents provided by the kit. Sections were 
mounted using Immu-mount (Thermo Scientific, Waltham, USA). Negative controls 
were performed by omission of probes.  
3.2.6 Immunohistochemistry 
Kidneys were fixed for 24 to 48h in 10% neutral-buffered formalin, embedded in 
paraffin, and 4 µm sections were cut. Sections were de-waxed using xylene and 
rehydrated using 100% and 95% ethanol. Immunostainings were performed using a 
Labvision autostainer (Labvision, Fremont, USA) or a Ventana XT autostainer 
(Ventana, Tucson, USA). The sections stained with the Labvision autostainer had a 
previous heat-mediated antigen retrieval step performed in a Milestone RHS-2 
microwave (Milestone, Sorisole, Italy) at 110°C for 2 min in 1 mM EDTA buffer, pH 8 
or 10 mM Citrate buffer, pH 6. Endogenous peroxidase activity was blocked with 3% 
(aq) hydrogen peroxide for 10 min. Nonspecific binding of the antibody was prevented 
by incubating slides with background blocker with casein (Menarini, Florence, Italy) for 
20 min. Slides were incubated with primary antibodies (Table 3.2) for 1h at room 
temperature. X-Cell Plus HRP, Goat HRP (Menarini, Florence, Italy), Ultravision 
Quanto Mouse on Mouse (Thermo Scientific, Waltham, USA) or Envision anti-mouse 
labelled polymer (DAKO, Glostrup, Denmark) was applied to the slides, and 
peroxidase was then visualized with diamino benzidine (DAKO, Glostrup, Denmark). 
Immunostainings with the Ventana XT autostainer were carried out using Ventana 
reagents (Ventana, Tucson, USA) and a pre-set immunostaining protocol that included 
antigen-retrieval and had antibody incubation times similar to the Labvision protocol. 
Sections were counterstained using hematoxylin (Carazzi’s) for 1 min before 
dehydrating in 95% and 100% ethanol, clearing in xylene, and mounting using 
Hystomount (TAAB Labs, Aldermaston, UK). Negative controls were performed using 
isotype controls or omission of the primary antibodies. 
Whole slide images were scanned in a Scanscope® scanner (Aperio Technologies 
Incorporated, Vista, USA). Positive Pixel Count Algorithm of the ImageScope software 
(Aperio Technologies Incorporated, Vista, USA)), was used to quantify the positive 
signal in whole kidney. Detection thresholds were manually set in order to obtain the 
best signal/noise ratio for each protein. The percentage of positive staining (relative 
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stained area) was calculated as the sum of all stained pixels divided by the sum of all 
stained and unstained pixels. 
 
Table 3.2: Antibodies used for immunohistochemistry  
Protein Supplier/Code 
Raised 
in 
Dilution 
Antigen 
retrieval 
ALP 1 Abcam / ab65834 Rabbit 1:200 CC1 
Calbindin-
D28k 
Sigma / c9848 Mouse 1:3000 CC2 / Citrate 
EGR1 CST2 / CST4153 Rabbit 1:50 CC1 
ERK CST / CST4695 Rabbit 1:200 CC2 / Citrate 
FGFR1 Abcam / ab31324* Goat 1:500 Citrate 
FGFR2 Abcam / ab10648* Rabbit 1:2000 Proteinase K 
FGFR3 Abcam / ab10651* Rabbit 1:2000 Proteinase K 
FGFR4 Abcam / ab41948 Rabbit 1:500 EDTA 
Klotho ADI3 / KL11-A Rabbit 1:200 CC1 / EDTA 
MEK CST / CST 9122 Rabbit 1:100 CC1 / EDTA 
NaPi-IIa ADI / NPT27-A Rabbit 1:200 CC1 / EDTA 
Osteopontin IBL / 18628 Rabbit 1:100 CC1 / EDTA 
Phopho-ERK CST / CST4376 Rabbit 1:100 CC1 / EDTA 
Phospho-MEK CST / CST 9121 Rabbit 1:100 CC1 / EDTA 
Phospho-RSK Abcam / ab32413 Rabbit 1:75 CC1 / EDTA 
Pit-1 Abcam / ab177147 Rabbit 1:800 CC2 / Citrate 
PMCA Santa Cruz / sc-20028 Mouse 1:300 / 1:100 CC2 / Citrate 
RSK BD / 610226 Mouse 1:150 CC2 / Citrate 
TRPV5 Alomone / ACC-035 Rabbit 1:400 / 1:100 CC2 / Citrate 
VDR Santa Cruz / sc-13133 Mouse 1:100 / 1:500 CC1 / EDTA 
1 - Alkaline phosphatase; 2 – Cell Signaling Technology; 3 – Alpha Diagnostics International 
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3.2.7 Quantitative reverse transcription polymerase chain reaction 
Ribonucleic acid (RNA) was extracted from rat kidneys using an RNeasy Plus Mini Kit 
(QIAGEN, Venlo, Netherlands), according to the manufacturer’s instructions. RNA 
was quantified using NanoDrop 2000 (Thermo Scientific, Waltham, USA) and RNA 
integrity was assessed using an Agilent 2100 Bioanalyzer with an Agilent RNA 6000 
Nano Kit (Agilent, Stockport, UK). Reverse transcription was carried out using 800 ng 
of RNA into a final volume of  20 µl with SuperScript® III First-Strand Synthesis 
SuperMix for qRT-PCR (Life Technologies, Carlsbad, USA). Two µl from each sample 
were pooled and used to create a standard curve. The remaining 18 µl of each sample 
were diluted 10-fold with water. Real time polymerase chain reaction (qPCR) was 
performed in a MX3000P qPCR system (Agilent, Stockport, UK) using RT² SYBR® 
Green with ROX (QIAGEN, Venlo, Netherlands). The primers for Cyp24a1 (RT² qPCR 
Primer Assay for Rat Cyp24a1) were obtained from QIAGEN (QIAGEN, Venlo, 
Netherlands) and the primers for beta-actin, (Fw-GAGGCCCCTCTGAACCCTAA, Rv-
ACCAGAGGCATACAGGGACAA), Cyp27b1 (Fw-TGGTGAAGAATGGCAGAG, Rv-
GTCCAGAGTTCCAGCATA), and VDR (Fw-CAGTCTGAGGCCCAAGCTA, Rv-
TCCCTGAAGTCAGCGTAGGT) were obtained from Sigma (Sigma, St Louis, USA). 
Relative mRNA expression of Cyp27b1, Cyp24a1 and VDR was calculated by 
interpolating the Ct values in the standard curves and normalizing the results to beta-
actin expression. Negative controls were performed by omission of template and by 
omission of the reverse transcriptase during the complementary DNA synthesis step. 
3.2.8 Plasma analysis 
Analysis of plasma 1,25D3, Klotho, FGF23, PTH, DKK1, sclerostin and 
osteoprotegerin were carried out by the Clinical Pathology department at AstraZeneca 
UK. 
Plasma 1,25D3 was analysed using 1,25-dihydroxyvitamin D3 radioimmunoassay 
(Immunodiagnostics systems, Boldon, UK), according to the manufacturer’s 
instructions. 
Plasma Klotho was analysed using Rat Klotho ELISA Kit (Cusabio, Wuhan, China), 
according to the manufacturer’s instructions. 
Plasma FGF23 was analysed using a FGF23 ELISA Kit (Kainos laboratories, Tokyo, 
Japan), according to the manufacturer’s instructions. 
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Plasma PTH, DKK1, sclerostin and osteoprotegerin were analysed using a multiplex 
assay, Rat Bone Magnetic Bead Panel 1 (Millipore, Billerica, USA), according to the 
manufacturer’s instructions. Data collection was performed using a BioPlex 200 
instrument (Biorad, Hercules, USA). 
3.2.9 Western blotting 
Rat kidney samples were homogenized in T-PER buffer (Pierce, Rockford, USA) 
containing Halt protease and phosphatase inhibitors (Pierce, Rockford, USA). Cell 
lysis was carried out using a Polytron (Kinematica, Bohemia, NY, USA) homogenizer. 
Following lysis, homogenates were centrifuged at 10,000 x g for 5 min to remove 
insoluble debris. Protein extracts were quantified using a BCA protein assay (Pierce, 
Rockford, USA). Twenty micrograms of each extract were electrophoresed on 
NuPage® 4-12% BisTris polyacrylamide gels (Invitrogen, Paisley, UK). Gels were 
transferred to nitrocellulose membranes and stained with Ponceau S to confirm even 
protein loading of wells. Non-specific protein binding was blocked using 5% low-fat 
dried milk in Tris-buffered saline containing 0.1%Tween (TBST) for 1h at room 
temperature. Primary antibodies were added at a concentration of 1:2000 in 5% 
milk/TBST overnight at 4ºC. An horseradish peroxidase conjugated anti-mouse or anti-
rabbit secondary antibody (Promega, Madison, USA) was added appropriately at a 
concentration of 1:20,000 or 1:6,000 in 5% milk/TBST before detection of 
immunoreactivity with ECL prime and development and development on HyperfilmTM 
ECL (GE Healthcare, Little Chalfont, UK). 
3.2.10 Reverse Phase Protein Array  
Reverse phase protein array (RPPA) was carried out at the Edinburgh Cancer 
Research Centre using a ZeptoMARK platform (Bayer, Leverkussen, Germany). The 
samples used for the RPPA were snap frozen kidneys from study 3 (6h dosing with 
ERKi, FGFRi or vehicle).  
3.2.11 Statistics 
All data shown represent mean ± standard error of the mean. Statistical analysis was 
carried out with Microsoft Office Excel (Microsoft, Redmond, USA) using the Real 
Statistics Resource Pack. A two-tailed, Mann Whitney U test was employed and p 
values lower that 0.05 were considered to be significant.  
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3.3 Results - Study execution and toxicokinetic analysis of ERKi, 
MEKi and FGFRi 
 
3.3.1 Study execution 
All studies lasted for the designed duration, with the exception of the ERKi group in 
the 8d study, which had to be killed at d3 due to animal welfare reasons. Also, in the 
previous 28d study, the FGFRi group had been killed at d25 for the same reasons. 
The clinical signs that lead to the earlier termination of these studies include weight 
loss, staining around the uro/ano-genital region, piloerection, hunched posture and 
decreased motor activity. 
3.3.2 Toxicokinetic analysis 
Plasma drug concentrations were analysed during the 12h period following the 
administration of ERKi, MEKi or FGFRi at d1 (single dose) and d7 (repeated dose) of 
the 8d study. Due to the earlier termination of the study, the d7 plasma drug 
concentrations were not analysed for ERKi. A graphical representation of this analysis 
is shown in Figure 3.2 and the estimated toxicokinetic parameters of maximum drug 
concentration (Cmax), drug concentration at 12h post-dose (C12h) and drug half-life (t1/2) 
are shown in Table 3.3.  
ERKi – At d1, ERKi showed a Cmax of 155±15 μmol/L, which was detected 2h after 
dosing. Also, ERKi evidenced a t1/2 of 9.5h and the C12h of 52±7 μmol/L, around 35% 
of the Cmax. Considering that ERKi was administered twice daily, these results suggest 
that plasma concentrations of this compound remained high during the whole study. 
MEKi – At d1, MEKi showed a Cmax of 1.27±0.22 μmol/L, which was detected 2h after 
dosing. Also, MEKi evidenced a t1/2 of 3.4h and the C12h of 0.11±0.01 μmol/L, around 
9% of the Cmax. At d7, MEKi showed values of Cmax (1.77±0.37 μmol/L), t1/2 (3.7h) and 
C12h (0.11±0.03) comparable to d1. The low t1/2 and C12h values, together with the fact 
that MEKi was only dosed once a day, suggest that the plasma concentrations of this 
drug decreased to very low levels between dosing intervals. 
FGFRi – At d1, FGFRi showed a Cmax of 2.94±0.27 μmol/L, which was detected 2h 
after dosing. Also, FGFRi evidenced a t1/2 of 4.7h and the C12h of 0.07±0.03 μmol/L, 
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around 2% of the Cmax. Conversely, at d7, FGFRi showed a Cmax of 2.00±0.38 μmol/L, 
a t1/2 of 8.2h and the C12h of 0.39±0.11 μmol/L, around 20% of the Cmax. The increase 
in the values of t1/2 and C12h from d1 to d7 may be associated with the accumulation of 
FGFRi in the different tissues. The t1/2 and C12h values observed during the repeated 
dose phase, together with the fact that FGRi was dosed twice a day suggest that the 
plasma concentration of this compound remained high during most of the study.  
 
ERKi, MEKi and FGFRi showed the highest plasma drug concentrations 2h after 
dosing. 
t1/2 and C12h suggest that the concentrations of ERKi and FGFRi remained high during 
most of the study, while the concentrations of MEKi decreased to extremely low levels 
between dosing intervals. 
Cmax and t1/2 suggest that the timing for the last dosing (2h before termination for 8d 
studies / 6h before termination for 6h study) was consistent the presence of high drug 
concentrations of ERKi, MEKi (only at 2h) and FGFRi in plasma. 
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Figure 3.2: Plasma drug concentrations during a 12h period following the 
administration of 150 mg/kg of ERKi, 1.4 mg/kg of MEKi or 10 mg/kg of FGFRi to 
rats by oral gavage.  Plasma drug concentrations of ERKi (A), MEKi (B) or FGFRi 
(C) were evaluated following a single dose (d1) and at d7 of a repeated dosing period 
(d7) with these inhibitors. Data representative of N = 3-6 rats + SEM. Plasma drug 
concentrations were analysed by the Drug Metabolism and Pharmacokinetics 
department at AstraZeneca UK. 
 
Table 3.3: Maximum drug concentration (Cmax), drug concentration at 12h (C12h) 
and drug half-life (t1/2) following the oral administration of ERKi, MEKi and 
FGFRi to rats, respectively at 150 mg/kg, 1.4 mg/kg or 10 mg/kg concentrations.   
 Day Cmax (μmol/L) 
C12h 
(μmol/L) 
t1/2 
(h) 
ERKi d1 155±15 52±7 9.5 
MEKi 
d1 1.27±0.22 0.11±0.01 3.4 
d7 1.77±0.37 0.11±0.03 3.7 
FGFRi 
d1 2.94±0.27 0.07±0.03 4.7 
d7 2.00±0.38 0.39±0.11 8.2 
Data representative of N = 3-6 rats + SEM. Toxicokinetic parameters were estimated 
by the Drug Metabolism and Pharmacokinetics department at AstraZeneca UK. 
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3.4 Results - Effects of ERKi, MEKi and FGFRi in soft-tissue 
mineralization and mineral homeostasis 
3.4.1 Effect of ERK, MEK and FGFR inhibition on soft-tissue mineralization 
Kidney, stomach and heart were analysed for the presence of mineralization using a 
von Kossa stain on sections of tissue obtained from animals treated with ERKi, MEKi 
and FGFRi. These analysis aimed not only to confirm that MEKi and FGFRi are able 
to induce the mineralization effects previously reported with other inhibitors of the 
same classes but also to assess if ERK inhibition also resulted in similar effects. 
Mineralization of soft-tissues was observed in animals treated with ERKi for 3d or with 
MEKi or FGFRi for 8d or 25/28d (Table 3.4). For all the inhibitors, the stomach was 
the most affected organ, with mineralization detected in nearly all animals. In the heart, 
mineralization was observed in animals from all the MEKi and FGFRi treatment 
groups. In the kidney, mineralization was detected in the cortex the majority of the 
animals treated with MEKi for 28d or FGFRi for 8d or 25d. Kidney mineralization 
appeared to be mainly present in connective tissue adjacent to distal tubules. 
Conversely, mineralization was not detected in kidneys of animals treated with ERKi 
for 3d or MEKi for 7d. Figure 3.3 shows representative pictures of mineral deposition 
in kidney sections from rats treated with MEKi or FGRi, observed by von Kossa and 
hematoxylin and eosin (H&E) stainings.  
 
Treatment with ERKi for 3d or MEKi or FGFRi for >8d resulted in soft-tissue 
mineralization in different organs including stomach, heart and kidney. 
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Table 3.4: Number of animals showing the presence of mineralization by von 
Kossa staining.  
 Groups Stomach Kidney Heart 
Study 1 (8d) 
MEKi 6/6 0/4 1 /6 
FGFRi 5/6 0/6 3 /6 
Study 2 (3/8d) 
ERKi 3/6 0/4 0 /6 
FGFRi 6/6 3/4 5 /6 
Study 4 (25/28d) 
MEKi 10/10 7/10 4 /10 
FGFRi 8/10 8/10 4 /10 
 
 
 
Figure 3.3: Mineralization in the kidney cortex of rats dosed with 1.4 mg/kg/day 
of MEKi for 28 days or 20 mg/kg/day of FGFRi for 25 days.  Lower magnification 
photomicrographs of von Kossa staining in cortical kidney sections of rats dosed with 
MEKi (A) or FGFRi (B). Higher magnification photomicrographs of von Kossa (C) or 
H&E staining (D) in cortical kidney sections of rats treated with MEKi. Arrows illustrate 
focal deposits of angular crystals in the renal tubules. Scale bar = 100 µm. 
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3.4.2 Effect of ERK, MEK and FGFR inhibition on mineral homeostasis  
Plasma levels of calcium (Ca2+), phosphate (Pi) and magnesium (Mg2+) were analysed 
at different time points in animals dosed for 6h or 3/8d with ERKi, MEKi and FGRi 
(Figure 3.4).  
Treatment with ERKi, MEKi and FGFRi did not induce any increase in plasma Pi at 2h 
or 6h post-dose. In fact, a slight, but significant decrease in plasma Pi was even 
observed 2h after dosing with ERKi (-31%) or FGFRi (-21%) in one of the studies. 
Increased plasma Pi levels were first detected 12h post dosing with MEKi (+21%) or 
FGFRi (+14%) and 24h post dosing with ERKi (+50%). Plasma Pi levels were further 
increased at d3 of ERKi (+104%) treatment and at d4 and d7 of MEKi (+55-63%) or 
FGFRi (+55-114%) treatments. 
Plasma Ca2+ levels remained mostly unchanged during the course of the studies. 
Nevertheless, plasma Ca2+ levels showed slight, but significant decreases following 
the administration of ERKi (-8%) or FGFRi (-9%) for 2h and increases following the 
administration of ERKi for 3d (+11%) or FGFRi for 24h (+5%) or 4d (+5%). 
Plasma levels of Mg2+ remained mostly unchanged during the course of the studies. 
However, plasma Mg2+ levels showed a slight, but significant decrease in animals 
treated with FGFRi for 2h (-7%) and increase in animals treated with FGFRi for 12h 
(+11%). 
 
Plasma levels of Pi were increased from 12h post-dosing with MEKi or 24h post-dosing 
with ERKi or FGFRi until the end of the study period (d7). 
Plasma levels of Ca2+ and Mg2+ remained mostly unchanged during the course of the 
treatments with ERKi, MEKi or FGFRi. 
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Figure 3.4: Plasma concentrations of Ca2+, Pi and Mg2+ in animals treated with 
150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day FGFRi.  Plasma 
Ca2+ (A-C), Pi (D-F) and Mg2+ (G-I) concentrations in animals from Study 1 (A,D,G), 
Study 2 (B,E,H) and Study 3 (C,F,I). Data representative of N = 3-6 rats + SEM. * # 
p<0.05 vs vehicle (Mann-Whitney, * vehicle vs MEKi/ERKi, # vehicle vs FGFRi).  
Plasma concentrations of Ca2+, Pi and Mg2+ were analysed by the Clinical Pathology 
department at AstraZeneca UK. 
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3.4.3 Effect of ERK, MEK and FGFR inhibition on the production of 1,25-
dihydroxyvitamin D3 
In the previous 28d study with MEKi, the plasma levels of 1,25D3 had been analysed 
at different time points using a commercial radioimmunoassay (Figure 3.5). In that 
study, MEKi did not induce any significant changes in plasma levels of 1,25D3. 
Nevertheless, the levels of 1,25D3 showed a high variability likely associated with the 
low sensitivity of the assay. This variability may have contributed to the lack of 
statistical significance in the analysis of those samples (N = 5 animals per group). In 
fact, a power analysis estimated that an N = 22 would be required to obtain statistical 
significance for the quantification of 1,25D3 using this assay. The 1,25D3 
radioimmunoassay required a large sample volume, which, due to the strict home 
office license regulations of plasma collection, would have precluded the analysis of 
1,25D3 and other analytes such as Pi, Ca2+ and FGF 23 in the same samples. In the 
light of the sample limitations and the high variability of the assay, the quantification of 
1,25D3 was not performed in animals from the remaining dosing groups. Recently, 
mass spectroscopy methods have been reported to yield more sensitive results in the 
quantification of 1,25D3 than radioimmunoassays (Strathmann et al. 2011). For this 
reason, a collaborator at Astrazeneca tried to develop an in house assay to quantify 
1,25D3 by mass spectroscopy, however this attempt was not successful. 
As an alternative to the detection of plasma 1,25D3, the expression of the enzymes 
responsible for its production, Cyp27b1, and degradation, Cyp24a1, were analysed. 
Also, the activity of 1,25D3 was indirectly analysed through the assessment of the 
expression of its receptor, VDR, which is susceptible to regulation by 1,25D3 (Healy et 
al. 2003). The expression of Cyp27b1, Cyp24a1 and VDR was analysed in the kidney, 
since the kidney is the organ where 1,25D3 is primarily produced and one of the organs 
where 1,25D3 signalling contributes to mineral ion homeostasis. The expression of 
Cyp27b1 and Cyp24a1 mRNA was assessed by qPCR and the expression of VDR 
mRNA and protein was quantified by qPCR, IHC and Western blotting.   
By qPCR, Cyp27b1 mRNA expression was increased in animals treated with ERKi 
(25-fold) or FGFRi (10-fold) for 6h (Figure 3.6 A) or ERKi (103-fold) for 3d (Figure 3.6 
C). Conversely, no significant increases in Cyp27b1 mRNA expression were observed 
in animals treated with FGFRi for 8d (Figure 3.6 C).  
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Cyp24a1 mRNA expression was decreased in animals treated with ERKi (31-fold) or 
FGFRi (18-fold) for 6h (Figure 3.6 B) or with ERKi (23-fold) for 3d (Figure 3.6 D). 
Conversely, no significant decreases in Cyp24a1 mRNA expression were observed in 
animals treated with FGFRi for 8d (Figure 3.6 D). 
By IHC, VDR protein was detected in glomerular podocytes, PT, DT and CD in and 
cytoplasm of DT (Figure 3.7 D,G). By qPCR, IHC and Western blotting, decreases in 
both VDR mRNA and protein expression were observed in animals treated with ERKi 
(-35% mRNA, -50% protein) or FGFRi (-40% mRNA, -50% protein) for 6h (Figure 3.7 
An mRNA; Figure 3.7 C,E-F protein) or with ERKi (-40% mRNA, -65% protein) for 3d 
(Figure 3.7 B mRNA; Table 7.10 protein). Animals treated with FGFRi for 8d showed 
a small decrease in mRNA (-19%, Figure 3.7 B), but not in protein expression (Table 
7.10). By IHC, no changes in VDR protein expression were observed in animals dosed 
MEKi for 8d (Table 7.10). Conversely, increases in VDR protein expression were 
observed in animals treated with MEKi (150%) or FGFRi (43%) for 25/28d (Figure 3.7 
H-I). 
 
No changes in 1,25D3 were detected following MEKi treatment – However it was 
observed that the 1,25D3 radioimmunoassay displayed a high variability. 
Treatment with ERKi for 6h or 3d or FGFRi for 3d resulted in the increase of Cyp27b1 
and decrease of Cyp24a1 mRNA expression, consistent with the increased production 
of 1,25D3 – these effects were not observed following the 8d treatment with FGFRi 
Treatment with ERKi for 6h or 3d or FGFRi for 3d resulted in a decrease in VDR 
expression. Conversely, VDR expression remained unchanged following 8d with MEKi 
or FGFRi and increased following 28d treatment with these inhibitors.  
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Figure 3.5: Plasma concentrations of 1,25D3 in animals treated for 5, 14 or 28 
days with 1.4 mg/kg/day of MEKi.  Plasma 1,25D3 concentrations in animals from 
study 1. Data representative of N = 5 rats + SEM. Plasma concentrations of Ca2+, Pi 
and Mg2+ were analysed by the Clinical Pathology department at AstraZeneca UK 
 
 
 
Figure 3.6: Expression of Cyp27b1 and Cyp24a1 mRNA in kidneys from rats 
treated with 150 mg/kg/day of ERKi or 20 mg/kg/day of FGFRi.  Cyp27b1 (A, C) 
and Cyp24a1 (B,D) mRNA quantified by qPCR in kidney extracts of rats from the 
studies 3 (A,B) and 2 (C,D), dosed with vehicle, ERKi or FGFRi for respectively 3/8d 
or 6h. Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle control 
(Mann-Whitney). 
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Figure 3.7: Expression of VDR mRNA and protein in kidneys from rats treated 
with 150 mg/kg/day of ERKi or 20 mg/kg/day of FGFRi.  VDR mRNA was quantified 
by qPCR in kidney extracts of rats from the studies 3 (A) and 2 (B), dosed with vehicle, 
ERKi or FGFRi for respectively 6h or 3/8d. VDR protein analysed by Western blotting 
in animals from Study 3 (C). Photomicrographs of VDR immunostaining in sections of 
rats from study 3, dosed with vehicle (D) and FGFRi (E) for 6h; and study 4, dosed 
with vehicle (G) or FGFRi (H) for 25d. Positive signal in immunohistochemistry 
corresponds to the brown staining. Histograms represent the quantification of VDR 
expression (immunohistochemically stained area) in animals from the studies 3 (F) 
and 4 (I). Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle control 
(Mann-Whitney). Scale bar = 100 μm. 
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3.4.4 Effect of ERK, MEK and FGFR inhibition on the plasma levels of FGF23 
and PTH 
Plasma levels of FGF23 were analysed at different time points in animals treated with 
ERKi for 6h or 3d, MEKi for 8d or FGFRi for 6h or 8d (Figure 3.8) using an enzyme-
linked immunosorbent (ELISA) assay. All the compounds caused an initial decrease 
in FGF23, reaching a 3-fold decrease around 6h after dosing. FGF23 levels remained 
decreased after 3d dosing with ERKi. Conversely, longer dosing periods with MEKi 
(7d) and FGFRi (4/7d) induced a 4-10 fold increase in FGF23 levels. 
Plasma levels of PTH were analysed in terminal samples from animals dosed for 8d 
with MEKi or FGFRi (Figure 3.9) using a multiplex assay. No changes in PTH were 
observed following treatment with either of the inhibitors. Nevertheless, it was 
observed that the results showed high variability within each group, which suggests 
that the assay may have a low sensitivity or samples were not adequately processed. 
For these reasons, the assay was not performed in samples from animals treated with 
ERKi (samples from animals treated with ERKi were processed using a similar 
protocol as samples from animals treated with MEKi or FGFRi).  
 
Plasma FGF23 levels initially decrease (2-6h) following the administration of ERKi, 
MEKi or FGFRi. Conversely, following repeated dosing (>4d) with MEKi or FGFRi, 
FGF23 levels increase. 
PTH remained unchanged in animals treated with MEKi or FGFRi 
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Figure 3.8: Plasma concentrations of FGF23 in animals treated with 150 
mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day FGFRi.  Plasma 
FGF23 concentrations in animals from the Studies 1 (A), 2 (B) and 3 (C). Data 
representative of N = 3-6 rats + SEM. * # p<0.05 (Mann Whitney - * vehicle vs 
MEKi/ERKi, # vehicle vs FGFRi). Plasma concentrations of FGF23 were analysed by 
the Clinical Pathology department at AstraZeneca UK. 
 
 
Figure 3.9: Plasma concentrations of PTH in animals treated for 8 days with 1.4 
mg/kg/day of MEKi or 20 mg/kg/day FGFRi.  Plasma PTH concentrations in animals 
from study 1. Data representative of N = 3-6 rats + SEM. Plasma concentrations of 
PTH were analysed by the Clinical Pathology department at AstraZeneca UK. 
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3.4.5 Summary 
Treatment with ERKi, MEKi and FGFRi resulted in soft-tissue mineralization in rats. In 
addition, these inhibitors induced an increase in plasma levels of Pi and affected the 
production/expression of the hormones 1,25D3 and FGF23. The effects of ERKi, MEKi 
and FGFRi in mineral homeostasis were dependent upon the duration of the 
treatment, as evidenced by the differences in the expression of Pi, 1,25D3 and FGF23 
following the first dose (>6h) and during the repeated-dosing phase (>3d) of the 
studies. At 6h post-dosing, ERKi, MEKi and FGFRi induced a decrease in plasma 
levels of FGF23 and an increase in the production of 1,25D3 (estimated in animals 
treated with ERKi and FGFRi through the assessment of the expression of Cyp27b1 
and Cyp24a1). These effects preceded the increase in Pi, which was only observed 
at 12h/24h post-dosing. Opposite to the effects observed at 6-12h post-dosing, the 
administration of MEKi or FGFRi for >4d induced an increase in the plasma levels of 
FGF23 and in no changes in the expression of Cyp27b1 and Cyp24a1.  
Table 3.5 shows the common effects of ERKi, MEKi and FGFRi in plasma levels of Pi 
and FGF23 and the effects of ERKi or FGFRi in the renal expression of Cyp27b1 and 
Cyp24a1 at 6h, 12/24h, 3d/4d and 7d/8d of the treatment period. 
Table 3.6 summarizes the effects of ERKi, MEKi and FGFRi in the mineralization of 
soft-tissues, plasma levels of the ions Ca2+, Pi, Mg2+, plasma levels of the hormones 
1,25D3, FGF23 and PTH and renal expression of the genes/proteins Cyp27b1, 
Cyp24a1 and VDR. 
 
Table 3.5: Summary of the effects of ERKi, MEKi and FGFRi on Pi, FGF23, 
Cyp27b1 and Cyp24a1 following different treatment periods with the inhibitors. 
 Drug 6h 12h/24h 3d/4d 7d/8d 
Pi ERKi, MEKi 
or FGFRi 
= + + + 
FGF23 - - +1 + 
Cyp27b1 ERKi or 
FGFRi 
+ NA + (ERKi) + (FGFRi) 
Cyp24a1 - NA -  (ERKi) - (FGFRi) 
1 – FGF23 levels were remained unchanged in animals treated with ERKi for 24h 
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Table 3.6: Summary of the effects of ERKi, MEKi and FGFRi in the occurrence 
of soft-tissue mineralization and mineral homeostasis. 
 Method Dosing ERKi MEKi FGFRi 
Mineralization von Kossa 
6h - - - 
d3/81 + + + 
Calcium 
Roche P 
analyser 
6h = = = 
d3/8 = = = 
Phosphate 
Roche P 
analyser 
6h = = = 
d3/8 + + + 
Magnesium 
Roche P 
analyser 
6h = = = 
d3/8 = = = 
1,25D3 RIA 
6h NA NA NA 
d3/8 NA =2 NA 
Cyp27b1 qPCR 
6h + NA + 
d3/8 + NA = 
Cyp24a1 qPCR 
6h - NA - 
d3/8 - NA = 
VDR 
qPCR / IHC / 
Western 
6h - NA - 
d3/8 - = = 
FGF23 ELISA 
6h - - - 
d3/8 = + + 
PTH Luminex 
6h NA NA NA 
d3/8 NA = = 
1 – At this time point, mineralization is observed in other organs than kidney in animals 
treated with ERKi and MEKi. 
2 – 1,25D3 values showed high variability between animals of the same group, 
suggesting a low sensitivity of the method 
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3.5 Results - Effects of ERKi, MEKi and FGFRi in the activation of 
cell signalling pathways in the kidney 
3.5.1 Expression of Fibroblast Growth Factor Receptors 
As described in the introduction, the kidney likely has a key role in the mineralization 
induced by MEK/ERK or FGFR inhibition, since it is the organ where 1,25D3 is mainly 
produced and where Ca2+ and Pi are reabsorbed from urine. Moreover, these 
processes are susceptible of regulation by FGF23 signalling through the FGFRs and 
MEK/ERK pathway (Andrukhova et al. 2012, Andrukhova et al. 2014). Hence, it is 
possible that MEK/ERK or FGFR inhibition affect the production of 1,25D3 and 
reabsorption of Ca2+ and Pi by preventing the regulatory effects of FGF23 in these 
processes.  
The intra-renal distributions of ERK, MEK, FGFR1-4 and Klotho are currently unclear 
as the reports of the localization of these proteins available in the literature are 
inconsistent. In order to identify which parts of the nephron could be directly affected 
by ERKi, MEKi or FGFRi, the distribution patterns of ERK, FGFR 1-4 and Klotho 
mRNA and protein and MEK protein were analysed in rat kidney by in situ hybridization 
and immunohistochemistry.  
Generally, a comparable expression pattern was detected with both techniques. FGFR 
1 (Figure 3.10 A-B) was detected throughout the nephron, showing strong apical 
membrane expression in PT, DT and CD and weak staining in the glomerulus. FGFR 
2 (Figure 3.10 C-D) and FGFR 3 (Figure 3.10 E-F) were detected in the basolateral 
membrane of DT and CD and to a lower extent in the apical membrane of PT and in 
the glomerulus. FGFR4 (Figure 3.10 G-H) was detected in the PT and DT, displaying 
a punctuate pattern in the cytoplasm. Klotho was detected in the cytoplasm, 
basolateral and apical membrane of PT, DT and CD, with the stronger expression 
observed in a population of DT cells (Figure 3.11). ERK (Figure 3.12 A,C) and MEK 
(Figure 3.12 E) were detected throughout the nephron, showing a cytoplasmic and 
nuclear (ERK) staining pattern. Conversely, phospho-ERK (Figure 3.12 D) and 
phospho-MEK (Figure 3.12 F) were detected predominantly in nuclei from DT and 
CDs, and, in very low levels in the PT. These results show a broad distribution of FGFR 
1-4, Klotho, ERK and MEK in the kidney. A summary of the mRNA and protein 
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distribution of FGFR1-4, ERK, phospho-ERK, MEK and phospho-MEK is shown on 
Table 3.7. 
The FGF receptors, Klotho, MEK and ERK are expressed throughout the nephron.  
Some expression differences are evident between the different FGFRs such as the 
polarity and intensity of the immunoreactivity in the different nephron segments. 
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Figure 3.10: Expression of FGFRs 1-4 in the kidney cortex of control rats 
detected by in situ hybridization and immunohistochemistry.  mRNA (A,C,E,G) 
and protein (B,D,F,H) expression patterns of FGFR 1 (A,B), FGFR 2 (C,D), FGFR 3 
(E,F) and FGFR4 (G,H). Positive signal is indicated by the purple (FGFRs) staining in 
in situ hybridization and by the brown staining in immunohistochemistry. The square 
in the bottom left corner of each image shows the negative control. Scale bar = 100 
μm. 
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Figure 3.11: Expression of Klotho in the kidney cortex of control rats detected 
by in situ hybridization and immunohistochemistry. Positive signal is indicated by 
the purple staining by in situ hybridization (A) and by the brown staining in 
immunohistochemistry (B). The square in the bottom left corner shows the negative 
control. Scale bar = 100 μm. 
 
 
Figure 3.12: Expression of phospho- and total ERK and MEK in the kidney cortex 
of control rats detected by in situ hybridization and immunohistochemistry. 
mRNA (A,B) and protein (C,D,E,F) expression patterns of total ERK (A,C), control (B), 
phospho-ERK (p-ERK, D), total MEK (E) and phospho-MEK (p-MEK, F). Positive 
signal is indicated by the purple (FGFRs) staining in in situ hybridization and by the 
brown staining in immunohistochemistry. Scale bar = 100 μm. 
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Table 3.7: Summary of the distribution of FGFR1-4, Klotho, ERK, phospho-ERK, 
MEK and phospho-MEK mRNA and/or protein. 
  Glomerulus PT TAL DT CD 
FGFR1 
ISH + ++ ++ ++ ++ 
IHC + ++ / a  ++ / a ++ / a ++ / a 
FGFR2 
ISH + + ++ ++ ++ 
IHC + + / a ++ / b ++ / b ++ / b 
FGFR3 
ISH - + ++ ++ ++ 
IHC - + / a ++ / b ++ / b ++ / b 
FGFR4 
ISH - + ++ ++ - 
IHC - + / c ++ / c ++ / c - 
Klotho 
ISH - + ++ ++ + 
IHC - +/ a,b,c ++ / a,b,c ++ / a,b,c + / a,b,c 
ERK 
ISH ++ ++ ++ ++ ++ 
IHC ++ ++ / c, n ++ / c, n ++ / c, n ++ / c, n 
phospho
-ERK 
IHC - + / n ++ / n ++ / n ++ / n 
MEK IHC ++ ++ / c, n ++ / c, n ++ / c, n ++ / c, n 
phospho
-MEK 
IHC - + / n ++ / n ++ / n ++ / n 
Apical (a), basolateral (b), cytoplasmic (c) or nuclear (n) immunoreactivity. 
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3.5.2 Effect of ERK, MEK and FGFR inhibition on the activation of the MEK/ERK 
signalling pathway 
The activation of the ERK pathway was analysed in animals treated with ERKi and 
MEKi in order to confirm that both compounds effectively target the kidney. In addition, 
ERK activation was also analysed in animals treated with FGFRi in order to assess if 
this compound also inhibited the MEK/ERK pathway in the kidney. Phopho-ERK was 
not a suitable biomarker to assess ERK activation in animals treated with ERKi, since 
this compound does not prevent ERK from becoming phosphorylated. For this reason, 
in addition to phospho-ERK, the downstream proteins in the MEK/ERK pathway p90 
ribosomal S6 kinase (RSK) and early growth response protein 1 (EGR1) were used 
as biomarkers to assess ERK activation. 
By IHC and Western blotting, ERK phosphorylation was increased in animals dosed 
with ERKi for 6h (+15-fold, Table 7.13) or 3d (+15-fold, Figure 3.13 E-F,L), decreased 
in animals dosed with MEKi for 8d (-92%, Figure 3.13 B-C,K) or 28d (-61%, Table 
7.13) and remained unchanged in animals treated with FGFRi for 6h (Table 7.13), 8d 
(Figure 3.13 C,F,K-L) or 25d (Table 7.13).  
By IHC and Western blotting, total ERK levels were reduced in animals treated with 
ERKi for 3d (-87%, Figure 3.13 H,J,L). Also, by IHC total ERK levels were reduced in 
animals treated with FGFRi for 8d (-72%, Figure 3.13 I,J) in Study 2, however this 
effect was not evident by Western blotting (Figure 3.13 L). By IHC and Western blotting 
total ERK levels remained unchanged in animals treated with ERKi for 6h or MEKi or 
FGFRi for 6h, 8d (Study 1) or 25/28d (Figure 3.13 K, Table 7.14). 
By IHC, phospho and total RSK were detected in glomeruli, TAL, DT, blood vessels 
smooth muscle and to less extent PT. Phospho-RSK (Figure 3.14 A) was expressed 
predominantly in the nucleus, with some cells also showing membrane and 
cytoplasmic expression. Total RSK (Figure 3.14 D) was detected mainly in the 
cytoplasm. The expression of both phospho- (Figure 3.14 A-C, Table 7.15) and total 
RSK (Figure 3.14 D-F, Table 7.16) was highly variable from animal to animal and 
although it appears to be generally decreased in animals treated with ERKi, MERKi or 
FGFRi, due to the high variability between samples it was not possible to obtain any 
meaningful conclusions. These data suggests that phospho-RSK is not a sensitive 
biomarker for ERK activation.  
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By IHC, EGR1 was detected in the nuclei of cells from glomeruli, distal nephron and 
blood vessels (Figure 3.15 A,D). Expression of EGR1 was strongly decreased in 
animals treated with ERKi for 6h (-84%, Table 7.17) or 3d (-74%, Figure 3.15 E-F) or 
MEKi for 8d (-70%, Figure 3.15 B-C). Conversely, EGR1 expression remained 
unchanged in animals treated with FGFRi for 6h (Table 7.17) and it was increased in 
animals treated for 8d with FGFRi (+84%, Figure 3.15 F). 
The results obtained for the expression/activation of ERK, RSK and EGR1 suggest 
that FGFRi treatment does not result in the inhibition of the MEK/ERK pathway in the 
kidney. As FGFR inhibition has been previously described to reduce the 
phosphorylation of ERK in the kidney (Yanochko et al. 2013), I aimed to assess if the 
administration of FGFRi was able to effectively inhibit FGFR signalling in the kidney. 
Previous studies carried out at AstraZeneca UK have shown that the FGFRi treatment 
is able to prevent the phosphorylation of the FGFRs and the phosphorylation of the 
downstream signalling protein FRS2 in to tumour cell models (AstraZeneca UK 
unpublished data). Since no methods to detect phospho-FGFR and phospho-FRS2 in 
rat kidney were previously reported, I evaluated the suitability of three antibodies 
against phospho-FGFR (pan), phospho-FGFR3 and phospho-FRS2 alpha using IHC 
and Western blotting techniques in control rat kidney tissue. No immunoreactivity was 
detected for the phospho-FGFR (pan) and phospho-FRS2 alpha antibodies with either 
of the methods and for the phospho-FGFR3 antibody with Western blotting (not 
shown). Conversely, weak immunoreactivity was detected mainly in the DT by IHC 
with the phospho-FGFR3 antibody (Figure 3.16). Unfortunately, this method showed 
high variability between samples and high background signal, which resulted in a low 
signal/background ratio. The low sensitivity of the IHC and the inability to confirm the 
identity of the detected proteins by Western blotting deemed this method unsuitable 
to assess the activation of FGFRs. Due to the lack of a suitable method to detect the 
expression of phospho-FGFR or phospho-FRS2 in rat kidney, it was not possible to 
confirm the inhibition of the FGFRs by FGFRi.  
 
ERK pathway signalling is inhibited by ERKi and MEKi, but not FGFRi. 
Total ERK expression is reduced by ERKi, but not MEKi or FGFRi. 
It was not possible to obtain a method to assess FGFR activation. 
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Figure 3.13: Expression of phospho-ERK and ERK protein in kidneys from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of 
FGFRi. Photomicrographs of phospho-ERK (p-ERK) immunostaining in sections of 
rats from study 1 dosed with vehicle (A) or MEKi (B) for 8d; and study 2, dosed with 
vehicle (D) for 8d or ERKi (E) for 3d. Photomicrographs of total ERK immunostaining 
in sections of rats from study 2 dosed with vehicle (G) for 8d, ERKi (H) for 3d or FGFRi 
for 8d (I). Positive signal in immunohistochemistry is visible as brown staining. 
Histograms represent the quantification of phospho-ERK expression 
(immunohistochemically stained area) in animals from the studies 1 (C) and 2 (F) and 
the expression of total ERK in the study 2 (J). Phospho-ERK and ERK analysed by 
Western blotting in animals from the studies 2 (K) and 3 (L). Data representative of N 
= 3-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar = 
100 μm. 
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Figure 3.14: Expression of phospho-RSK and RSK protein in kidneys from rats 
treated with 150 mg/kg/day of ERKi or 20 mg/kg/day of FGFRi.  Photomicrographs 
of phospho-RSK (p-RSK) immunostaining in sections of rats from study 1 dosed with 
vehicle (A) or MEKi (B) for 8d. Photomicrographs of total RSK immunostaining in 
sections of rats from study 1 dosed with vehicle (D) or MEKi (E) for 8d. Positive signal 
in immunohistochemistry corresponds to the brown staining. Histograms represent the 
quantification of phospho-RSK (C) and total RSK (F) expression 
(immunohistochemically stained area) in animals from study 1. Data representative of 
N = 3-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar = 
100 µm. 
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Figure 3.15: Expression of EGR1 in cortical kidney sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi. 
Photomicrograph of EGR1 immunostaining in sections of rats from study 1 dosed with 
vehicle (A) or FGFRi (B) for 8d; and from study 2 dosed with vehicle (D) for 8d or ERKi 
(E) for 3d. Positive signal in immunohistochemistry corresponds to the brown staining. 
Histograms represent the quantification of EGR1 expression (immunohistochemically 
stained area) in animals from the studies 1 (C) and 2 (F). Data representative of N = 
3-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar = 100 
µm. 
 
 
Figure 3.16: Expression of phospho-FGFR3 in control rat kidney. 
Photomicrographs of phospho-FGFR3 (p-FGFR3) immunostaining in cortical (A) and 
medullary (B) rat kidney sections. Positive signal in immunohistochemistry 
corresponds to the brown staining. Scale bar = 100 µm. 
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3.5.3 Effects of ERK and FGFR inhibition on cell signalling in the kidney. 
Although treatment with FGFRi did not result in the inhibition of ERK signalling, it 
resulted in similar effects in mineral homeostasis as treatments with ERKi and MEKi. 
It is plausible that the three inhibitors induce these effects through the activation or 
inhibition of common downstream cell signalling pathways. In order to identify 
signalling pathways affected by ERKi and FGFRi that may contribute to the process 
of soft-tissue mineralization, the expression of 60 cell signalling pathway proteins was 
analysed by RPPA using kidneys of animals treated for 6h with these inhibitors (Table 
3.8).  
By RPPA, phospho-ERK expression was increased in animals treated with ERKi 
(+331%) and remained unchanged in animals treated with FGFRi, whilst total ERK 
expression remained unchanged in animals treated with either of the inhibitors. These 
results are consistent with the expression of phospho-ERK and ERK observed by IHC 
and Western blotting. Besides the mentioned increase in phospho-ERK, all the 
alterations in protein expression and/or activation were small (<40% expression 
change), which suggests that this assay may have failed to identify the key pathways 
contributing to process of ERKi and FGFRi induced mineralization. Nevertheless, the 
noteworthy findings of this assay are described below. In order to ensure that the 
common effects of ERKi and FGFRi on cell signalling are identified by this assay 
despite their small nature, two different thresholds were considered in the statistical 
analysis, p<0.05 and p<0.10.  
- The downstream MEK/ERK pathway proteins MNK1 and cAMP response 
element-binding protein (CREB) show decreased activation following treatment 
with ERKi (p<0.1) and FGFRi (p<0.05). 
- The downstream FGFR signalling protein PLC gamma shows decreased 
activation following treatment with ERKi (p<0.1) and FGFRi (p<0.05). 
- FGFRi increased the expression (p<0.05) and both inhibitors increased inhibitory 
phosphorylations (p<0.05) of beta-catenin – a downstream component of the WNT 
signalling pathway previously described to be involved in soft-tissue mineralization 
processes. 
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- FGFRi increased the expression of poly ADP ribose polymerase (PARP) (p<0.05) 
and both inhibitors increased the expression of B-cell lymphoma-x (Bcl-x) 
(p<0.05). These two proteins are key regulators of the apoptotic process. 
- FGFRi, but not ERKi prevents the activation of a number of downstream proteins 
in FGFR signalling including Src (p<0.05) (Li et al. 2004) and mitogen-activated 
protein kinase-activated protein kinase 2 (MAPKAPK-2) (p<0.05) (Tan et al. 1996). 
Neither of the inhibitors affected the activation of a number cell signalling proteins 
including c-Jun N-terminal kinase (JNK), AKT, nuclear factor kappa-light-chain-
enhancer of activated B cells (NFkB) and p38 – most likely these proteins are not 
involved in the process of mineralization induced by ERKi and FGFRi. 
 
RPPA showed similar results as IHC and Western blotting for the expression and 
phosphorylation of ERK in animals treated with ERKi and FGFRi 
With the exception of phospho-ERK, the proteins analysed by RPPA showed small 
expression changes (<40% expression) in animals treated with ERKi and FGFRi, 
which suggests that the key pathways leading to soft-tissue mineralization were not 
identified by this assay. 
By RPPA, ERKi and FGFRi were found to induce similar effects in the expression 
and/or phosphorylation of a number of proteins involved in different pathways including 
MEK/ERK, PLC and WNT.  
By RPPA, FGFRi but not ERKi was found to decrease the activation of a number of 
downstream proteins in FGFR signalling 
  
102 
 
Table 3.8: RPPA performed in total kidney homogenate samples from rats 
treated for 6h with 150 mg/kg of ERKi or 20 mg/kg FGFRi.   
 Akt p-Akt Bcl-x β-Cat 
p-β-
Cat 
Calpain2 CC3 p-Chk1 c-Jun p-c-Jun CREB p-CREB p-EGFR EGFR 
GSK-
3β 
ERKi 117* 100 112* 106 108* 103 104 102 95 101 88 88# 101 95 103 
FGFRi 114 92# 125* 112* 126* 109 100 96 110 103 70* 86* 102 88* 107 
 
p-
GSK-
3β 
p-
IGF-
1Rβ 
p-IKK 
α/β 
IRS-1 
p-
IRS-1 
JAK1 
MAPKAPK-
2 
p-MAPKA 
PK-2 
MEK1/2 
p-
MEK1/2 
p-
MNK1 
p-MSK1 mTOR 
p-
NFkB 
p-p21 
ERKi 111* 105 112# 101 100 104 92 95 91 105 91# 89 99 99 112 
FGFRi 111# 114 105 106 98 119* 99 89* 91 91 91* 82# 100 98 119# 
 p38 p-p38 ERK 
p-
ERK 
PARP 
p-
PDGFR 
p-PDK-1 PI3 K α PKA PKC- α p-PKC 
p-
VEGFR 
PLC-γ1 
p-
PLC- 
γ 1 
PTEN 
ERKi 100 99 90# 431* 113 98 98 99 97 100 91 98 94 92# 99 
FGFRi 105 81 96 90 123* 103 105 96 88# 94 89* 95 95 82* 99 
 
p-Raf 
259 
p-Raf 
338 
Raf1 Rap1 
p-S6 
Rib 
JNK p-JNK p-Smad1/5 Src P-Src P-Tyk2 Ubiquitin - - - 
ERKi 92 113* 105 100 66 103 105 101 94 94 93 93 - - - 
FGFRi 86* 110* 116* 95 61 113* 108 90 95 85* 98 95 - - - 
Array results are presented as relative protein expression (%) versus the vehicle 
group, after normalization to beta actin expression. Data representative of N = 6 rats 
+ SEM. * p<0.05 vs the vehicle control; # p<0.10 vs the vehicle control (Mann-Whitney 
test, expression increase in green and decrease in red). RPPA was performed at the 
Edinburgh Cancer Research Centre. 
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3.5.4 Effects of ERK, MEK and FGFR inhibition on WNT signalling. 
The modest protein expression effects of ERKi and FGFRi detected by RPPA may 
develop into more pronounced effects at later timepoints and/or in the activation of 
downstream signalling proteins. Nevertheless, it is important to ensure that the effects 
observed are consistent and evident by other methods such as IHC and Western 
blotting. With the aim of validating the RPPA assay, IHC was carried out to analyse 
the expression of beta-catenin in samples from animals treated with ERKi or FGFRi. 
Beta-catenin was selected to perform this assay since in addition to showing increased 
expression by RPPA following treatment with  FGFRi, this protein has been previously 
associated with the process of soft-tissue calcification (Gu et al. 2014).  
By IHC, beta-catenin expression was observed with stronger intensity in TAL, DT and 
CD and with weaker intensity in PT and glomeruli (Figure 3.17 A,D). In all segments 
beta-catenin expression was detected mainly in the basolateral membrane and / or 
cytoplasm, but not in the nucleus. Treatment with ERKi, MEKi or FGFRi during 6h 
(Figure 3.17 A-C), 3/8d (Figure 3.17 D-F, Table 7.20) or 25/28d (Table 7.20) did not 
induce any evident changes in the expression or localization of beta-catenin. 
Nevertheless, the intensity of the immunoreactivity showed great differences between 
animals of the same groups, which may have prevented the detection of subtle protein 
expression changes. 
 
By IHC, animals treated with ERKi, MEKi or FGFRi showed no evident alterations of 
the expression or cellular localization of beta catenin.  
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Figure 3.17: Expression of beta-catenin in cortical kidney sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of 
FGFRi.  Photomicrographs of beta-catenin immunostaining in sections of rats from 
studies 3 dosed with vehicle (A) or FGFRi (B) for 6h; and from study 3 dosed with 
vehicle (D) or FGFRi (E) for 8d. Positive signal in immunohistochemistry corresponds 
to the brown staining. Histograms represent the quantification of beta-catenin 
expression (immunohistochemically stained area) in animals from the studies 3 (C) 
and 2 (F). Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle control 
(Mann-Whitney test). Scale bar = 100 µm. 
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3.5.5 Summary  
The targets of ERKi, MEKi and FGFRi, respectively ERK, MEK and the FGFRs, 
showed a broad intra-renal distribution, thus suggesting that these drugs may be able 
to directly affect different parts of the nephron. Analysis of ERK phosphorylation and 
EGR1 expression showed that the activation of the ERK pathway is effectively 
prevented by ERKi and MEKi but not by FGFRi. A RPPA used to identify downstream 
pathways that may contribute in soft-tissue mineralization showed small expression 
changes (<40% expression) in proteins involved in different signalling pathways 
including MEK/ERK, PLC and WNT. The effects of ERKi, MEKi and FGFRi in the 
activation of cell signalling pathways described in this subchapter are summarized in 
Table 3.9. 
 
Table 3.9: Summary of the effects of ERKi, MEKi and FGFRi in the expression of 
phospho-ERK, ERK, phospho-RSK, RSK, EGR1, beta catenin. 
 Method Dosing ERKi MEKi FGFRi 
phospho-ERK 
IHC / 
Western 
6h + NA = 
d3/8 + - = 
ERK 
IHC / 
Western 
6h = NA = 
d3/8 - = = 
phospho-RSK1 IHC 
6h = NA = 
d3/8 = = = 
RSK1 IHC 
6h = NA = 
d3/8 = = - 
EGR1 IHC 
6h - NA = 
d3/8 - - = 
Beta-catenin IHC 
6h = = = 
d3/8 = = = 
1The expression of phospho-RSK and RSK displayed a high variability.  
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3.6 Results - Effects of ERKi, MEKi and FGFRi on the expression of 
proteins involved in renal Ca2+ and Pi reabsorption  
3.6.1 Effect of ERK, MEK and FGFR inhibition on the expression of proteins 
involved in renal Pi reabsorption 
The expression of NaPi-IIa, the transporter that accounts for 60-70% of the renal Pi 
reabsorption (Wagner et al. 2008), was analysed by immunohistochemistry in rat 
kidney sections of animals treated with ERKi, MEKi or FGFRi in order to assess if the 
increase in plasma Pi induced by the administration of these inhibitors is associated 
with alterations in renal Pi reabsorption. 
NaPi-IIa was detected in cytoplasmic vesicles and in the brush border of PT, with a 
comparable expression observed in the outer and inner cortical regions ( A,D). ERKi, 
MEKi or FGFRi induced distinct effects in the expression pattern of NaPi-IIa, 
depending in the length of the treatment. Treatment with ERKi (Figure 3.18 B) or 
FGFRi (Figure 3.18 C) for 6h induced an increase a shift in NaPi-IIa expression from 
cytoplasmic vesicles to the brush border membrane. These effects correspond to 
changes in the protein expression pattern rather than pronounced changes in protein 
expression levels. Hence, although evident by observation of the immunostainings, 
these effects were not easily detected by image analysis. A slight decrease in NaPi-
IIa expression was observed in rats treated with ERKi for 3d (Figure 3.18 G) or with 
FGFRi for 8d in Study 2 (Figure 3.18 E,G) or 25d (Figure 3.18 H). In these treatment 
groups, the expression decrease was detected in the outer cortex, with inner cortical 
immunoreactivity remaining unchanged or even slightly increased. Conversely, NaPi-
IIa expression remained unchanged in animals treated with MEKi or FGFRi for 8d in 
Study 1 (Table 7.21) and was increased in the inner cortex of animals treated with 
MEKi for 8d (Figure 3.18 H). Nevertheless, animals from the vehicle group of the 28d 
study with MEKi showed a significantly lower outer cortical expression of NaPi-IIa 
when compared to the 8d study, which may have contributed for the discrepancies 
between the treatment groups. 
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Treatment with ERKi and FGFRi for 6h results in shift of NaPi-IIa expression from the 
cytoplasmic vesicles to the brush border membrane, consistent with increased 
reabsorption of Pi 
Treatment with ERKi, MEKi and FGFR for >3d results in no changes or slight 
alterations of NaPiIIa expression pattern (decreased outer cortical expression and/or 
increased inner cortical expression), depending on the studies.  
 
 
Figure 3.18: Expression of NaPi-IIa in cortical kidney sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi. 
Higher magnification photomicrographs of NaPi-IIa immunostaining in sections of rats 
from study 3 dosed with vehicle (A), ERKi (B) or FGFRi (C) for 6h. Lower magnification 
photomicrographs of NaPi-IIa immunostaining in animals from study 2 dosed with 
vehicle (D) or FGFRi (E) for 8d. Positive signal in immunohistochemistry corresponds 
to the brown staining. Histograms represent the quantification of NaPi-IIa expression 
(immunohistochemically stained area) in animals from the studies 3 (F), 2 (G) and 4 
(H). Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-
Whitney test). Scale bar = 100 µm. 
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3.6.2 Effect of ERK, MEK and FGFR inhibition on the expression of proteins 
involved in renal Ca2+ reabsorption 
 
Renal Ca2+ reabsorption is induced by 1,25D3 (Johnson and Kumar 1994) and FGF23 
(Andrukhova et al. 2014). In this study, despite the effects of ERKi, MEKi and FGFRi 
in the production of these hormones, plasma levels of Ca2+ remained mostly 
unaffected during the course of the treatments. Plasma Ca2+ levels are strictly 
regulated at a systemic level by different hormones including PTH and calcitonin 
(Felsenfeld et al. 2013) and by local actions of the CaSR in different organs such as 
such as bone (Theman and Collins 2009) and intestine (Garg 2013). For this reason, 
it is possible that 1,25D3 and/or FGF23 induce an increase in renal reabsorption and 
local Ca2+ levels whilst having little effects on the plasma Ca2+ levels. In order to assess 
if the inhibition of MEK/ERK pathway or FGFR signalling affects Ca2+ reabsorption, 
the expression of three proteins involved in the process (TRPV5, calbindin-D28k and 
PMCA) were analysed by IHC in animals treated with ERKi, MEKi or FGFRi. 
By IHC, TRPV5 was detected in the apical membrane of DT (Figure 3.19 A,D,F). A 
decrease in TRPV5 expression was observed in animals dosed with ERKi (-51%, 
Figure 3.19 C) or FGFRi (-75%, Figure 3.19 B,C) for 6h or animals dosed with ERKi 
(60%,Figure 3.19 I) for 3d. Conversely, an increase in TRPV5 expression was 
observed in animals treated with MEKi (+10-fold, Figure 3.19 E-F) or FGFRi (+3-fold/4-
fold, Figure 3.19 F,H-I) for 8d or animals treated with MEKi (+42%,Table 7.22) or 
FGFRi (+73%,Table 7.22) for 25/28d. 
By IHC, calbindin-D28k was detected in the cytoplasm of DT (Figure 3.20 A,D). No 
changes in calbindin-D28k expression were found in animals treated with ERKi or 
FGFRi for 6h or ERKi for 3d (Table 7.23). Conversely, an increase in calbindin-D28k 
expression was observed in animals treated with MEKi (+182%, Figure 3.20 B,C) or 
FGFRi (+184%, Figure 3.20 E,F) for 8d or with MEKi (+89%, Table 7.23) or FGFRi 
(+57%, Table 7.23) for 25/28d. 
By IHC, PMCA was detected in the basolateral membrane of DT (Figure 3.21 A). 
Expression of PMCA was unchanged in animals treated with ERKi or FGFRi for 6h, 
ERKi for 3d or FGFRi for 25d (Table 7.24) Conversely, expression of PMCA was 
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increased in animals treated with MEKi (+7.5-fold, Figure 3.21 B,C) or FGFRi (+3.5-
fold, Figure 3.21 C) for 8d or with MEKi for 28d (+68%, Table 7.24) 
Treatment with MEKi and FGFRi for >8d resulted in increased expression of the 
proteins involved in Ca2+ reabsorption TRPV5, calbindin-D28k and PMCA. 
Treatment with ERKi for 6h or 3d or with FGFR for 6h resulted in a decrease in the 
expression of TRPV5. 
 
 
Figure 3.19: Expression of TRPV5 in cortical kidney sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi.  
Photomicrographs of TRPV5 immunostaining in sections of rats from Study 3 dosed 
with vehicle (A) or FGFRi (B) for 6h; Study 1 dosed with vehicle (D) or MEKi (E) for 
8d; and Study 2 dosed with vehicle (G) or FGFRi (H) for 8d. Positive signal in 
immunohistochemistry corresponds to the brown staining. Histograms represent the 
quantification of TRPV5 expression (immunohistochemically stained area) in animals 
from the studies S3 (C), S1 (F) and S2 (I). Data representative of N = 3-6 rats + SEM. 
* p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar = 100 µm. 
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Figure 3.20: Expression of calbindin-D28k in cortical kidney sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of 
FGFRi.  Photomicrographs of calbindin-D28k immunostaining in sections of rats from 
Study 1 dosed with vehicle (A) or MEKi (B) for 8d; and Study 2 dosed with vehicle (D) 
or FGFRi (E) for 8d. Positive signal in immunohistochemistry corresponds to the brown 
staining. Histograms represent the quantification of calbindin-D28k expression 
(immunohistochemically stained area) in animals from the studies 1 (C) and S2 (F). 
Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-
Whitney test). Scale bar = 100 µm. 
 
 
Figure 3.21: Expression of PMCA in cortical kidney sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi.  
Photomicrographs of PMCA immunostaining in sections of rats from the study S1 
dosed with vehicle (A), MEKi (B) or FGFRi (C) for 8d. Positive signal in 
immunohistochemistry corresponds to the brown staining. Histograms represent the 
quantification of PMCA expression (immunohistochemically stained area) in animals 
from the studies S1 (D), S2 (E) and S4 (F). Data representative of N = 3-6 rats + SEM. 
* p<0.05 vs the vehicle control (Mann-Whitney test).  Scale bar = 100 µm. 
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3.6.3 Effect of ERK, MEK and FGFR inhibition on the expression of Klotho 
Another key protein for the renal reabsorption of Ca2+ and Pi is Klotho. Klotho regulates 
the expression of NaPi-IIa and TRPV5, not only by acting as a co-receptor for FGF23 
but also through FGF-23 independent effects, which are mediated by its secreted form 
(Huang 2010). Given that the expression of Klotho can be induced by 1,25D3 (Wang 
et al. 2005) and inhibited by FGF23 (Dai et al. 2012), it is plausible that perturbations 
in the expression of Klotho may contribute to the altered expression of NaPi-IIa or 
TRPV5. In order to investigate if the expression of the Klotho is affected by treatment 
with ERKi, MEKi or FGFRi, renal expression and plasma levels of Klotho were 
analysed by IHC and ELISA, respectively, in samples from animals treated with these 
inhibitors.  
By IHC, no changes in renal Klotho expression were detected in animals treated with 
ERKi or FGFRi for 6h (Table 7.25); ERKi, MEKi or FGFRi for 3/8d (Figure 3.22 B-C, 
Table 7.25); or MEKi or FGFRi for 25/28d (Table 7.25). Plasma levels of Klotho were 
analysed in terminal samples from animals dosed with MEKi or FGFRi for 8d (Figure 
3.23). Plasma Klotho levels were increased (+12%) in animals treated with MEKi and 
decreased (-14%) in animals treated with FGFRi.  
 
Kidney expression of Klotho remained unchanged. 
Plasma Klotho was increased in animals treated with MEKi and decreased in animals 
treated with FGFRi. 
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Figure 3.22: Expression of Klotho in cortical kidney sections from rats treated 
with 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi. Photomicrographs of Klotho 
immunostaining in sections of rats from Study 1 dosed with vehicle (A) or FGFRi (C) 
for 8d. Positive signal in immunohistochemistry corresponds to the brown staining. 
Histograms represent the quantification of Klotho expression (immunohistochemically 
stained area) in animals from Study 1 (D). Data representative of N = 3-6 rats + SEM. 
* p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar = 100 µm. 
 
 
Figure 3.23: Plasma concentrations of Klotho in animals treated for 8 days with 
1.4 mg/kg/day of MEKi or 20 mg/kg/day FGFRi. Plasma levels of Klotho in animals 
from Study 1. Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle 
control (Mann-Whitney test). Plasma concentrations of Klotho were analysed by the 
Clinical Pathology department at AstraZeneca UK. 
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3.6.4 Summary  
The effects of ERKi, MEKi and FGFRi in Ca2+ and Pi reabsorption were conditioned 
by the type/length of the treatment. Acute (6h) dosing with ERKi and FGFRi induced 
an increase in brush border membrane expression of NaPi-IIa, consistent with 
increased Pi reabsorption. Additionally, it induced a decrease in TRPV5, consistent 
with decreased distal Ca2+ reabsorption. Conversely, repeated dosing with ERKi, 
MEKi or FGFRi for >3d induced change in NaPi-IIa expression pattern in some of the 
treatment groups. These consisted in a decrease in NaPi-IIa expression in the outer 
cortex and/or an increase in the inner cortex. Also, repeated dosing with MEKi or 
FGFRi for >8d induced an increase in the expression of TRPV5, calbindin-D28k and 
PMCA, consistent with an increase in distal Ca2+ reabsorption. Table 3.10 summarizes 
the effects of ERKi, MEKi and FGFRi in the renal expression of NaPi-IIa, TRPV5, 
calbindin-D28k, PMCA and Klotho and plasma levels of Klotho. 
 
Table 3.10: Summary of the effects of ERKi, MEKi and FGFRi in the expression 
of key proteins involved in the reabsorption of Ca2* and Pi or in the regulation of 
this process. 
 Method Dosing ERKi MEKi FGFRi 
NaPi-IIa1 IHC 
6h = NA + 
d3/8 - =/+ =/- 
TRPV5 IHC 
6h = NA - 
d3/8 - + + 
Calbindin-D28k IHC 
6h = NA = 
d3/8 = + + 
PMCA IHC 
6h = NA = 
d3/8 = + + 
Klotho (plasma) ELISA 
6h NA NA NA 
d3/8 NA - + 
Klotho (kidney) IHC 
6h = NA = 
d3/8 = = = 
1 – In NaPi-IIa, there was a shift in the localization of the immunoreactivity. Shorter 
treatments (6h) with ERKi or FGFRi induced a shift of the immunoreactivity from 
cytoplasmic vesicles to the brush border membrane that could not be easily quantified 
by image analysis. Conversely longer treatments (>3d) resulted in expression pattern 
changes in some of the treatment groups.  
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3.7 Results - Effects of ERKi, MEKi and FGFRi in the expression of 
calcification modulator proteins 
3.7.1 Effect of ERK, MEK and FGFR inhibition on the expression of alkaline 
phosphatase and Pit-1 
As an active and regulated process, soft-tissue mineralization is modulated by multiple 
factors including the expression of proteins that promote or inhibit calcification. 
Alkaline phosphatase and Pit-1 are two pro-calcifying proteins susceptible to 
regulation by 1,25D3 (Jono et al. 1998, Tatsumi et al. 1998). It is plausible that besides 
affecting Pi and Ca2+ reabsorption, 1,25D3 contributes to the occurrence of soft-tissue 
mineralization in rats treated with ERKi, MEKi or FGFRi by promoting the expression 
of alkaline phosphatase and Pit-1. In order to investigate if the expression of alkaline 
phosphatase and Pit-1 is affected by ERKi, MEKi and FGFRi treatment, IHC was 
carried out on kidney sections from animals treated with these inhibitors. 
By IHC, alkaline phosphatase was detected at extremely low levels in the distal tubule, 
where it displayed a vesicular pattern (Figure 3.24 A,D). No differences in alkaline 
phosphatase expression were observed in animals treated with ERKi or FGFRi for 6h 
(Table 7.27). Conversely, alkaline phosphatase expression was increased at in 
animals treated with ERKi (+2-fold, Figure 3.24 D) for 3d or with FGFRi for 8d (+2-fold, 
Study 2). An increase in alkaline phosphatase expression was also evident by 
microscopic observation of the slides of animals treated with MEKi (Figure 3.24 B) or 
FGFRi (not shown) for 8d in Study 1. However, these changes were not deemed 
significant by image analysis (MEKi, p=0.077; FGFRi, p=0.070), likely due to the fact 
that the alkaline phosphatase immunostainings from Study 1 showed a low IHC 
signal/background ratio which prevented a specific detection of the positive IHC signal 
by the image analysis software.  
By IHC, Pit-1 was broadly detected in the kidney, with the strongest expression 
observed in glomeruli and blood vessels and a weaker and variable expression 
observed in the PT and CD (Figure 3.25 A-D). Treatment with ERKi, or FGFRi for 6h 
(Figure 3.25 B-C) or ERKi, MEKi and FGFRi for 3/8d (Figure 3.25 E-F, Table 7.28) did 
not induce any evident changes in the expression of Pit-1. 
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Expression of alkaline phosphatase was increased in animals treated for longer 
periods (>3d) with ERKi, MEKi or FGFRi. 
No changes in the expression pattern of Pit-1 were observed following treatment with 
ERKi, MEKi or FGFRi 
 
 
Figure 3.24: Expression of the alkaline phosphatase in cortical kidney sections 
from rats treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 
mg/kg/day of FGFRi. Photomicrographs of alkaline phosphatase (ALP) 
immunostaining in sections of rats from study 1 dosed with vehicle (A) or MEKi (B) for 
8d; and study 2 dosed with vehicle (D) or FGFRi (E) for 3d. Positive signal in 
immunohistochemistry corresponds to the brown staining. Histograms represent the 
quantification of alkaline phosphatase expression (immunohistochemically stained 
area) in animals from the studies 1 (C) and 2 (F). Data representative of N = 3-6 rats 
+ SEM. * p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar = 100 µm. 
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Figure 3.25: Expression of Pit-1 in cortical kidney sections from rats treated with 
150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi or 20 mg/kg/day of FGFRi. 
Photomicrographs of Pit-1 immunostaining in sections of rats from Study 3 dosed with 
vehicle (A) or FGFRi (B) for 6h and in animals from Study 1 dosed with vehicle (D) or 
FGFRi (E) for 8d. Positive signal in immunohistochemistry corresponds to the brown 
staining. Histograms represent the quantification of Pit-1 expression 
(immunohistochemically stained area) in animals from Study 3 (C) and Study 1 (F). 
Data representative of N = 3-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-
Whitney test). Scale bar = 100 µm. 
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3.7.2 Effect of ERK, MEK and FGFR inhibition on the expression of osteopontin, 
osteoprotegerin, sclerostin and DKK1 
 
Different studies have shown that soft-tissue mineralization is accompanied by an 
increase in local and/or plasma expression of various calcification inhibitors including 
osteopontin (Kwon et al. 2000, Yu et al. 2009), osteoprotegerin (Schoppet et al. 2004, 
Abedin et al. 2007), sclerostin (Koos et al. 2013, Kuipers et al. 2015) and DKK1 
(Ueland et al. 2009, Kim et al. 2011). Although the mechanisms are not completely 
clear, the expression of such proteins may be induced by calcifying cells with the aim 
of preventing the occurrence of further calcification. In order to investigate if the soft-
tissue mineralization induced by ERKi, MEKi and FGFRi is associated with the 
upregulation of calcification inhibitor proteins, renal expression of osteopontin was 
analysed by IHC and plasma expression of osteoprotegerin, DKK1 and sclerostin was 
analysed by a multiplex assay using samples from rats treated with these inhibitors. 
By IHC, the expression of osteopontin was detected in the thin limbs of the renal 
medulla and not in the cortex of vehicle-treated animals (Figure 3.26 A). Some of the 
animals treated with FGFRi for 8d (Figure 3.26 B-C) or 25d or with MEKi for 28d (not 
shown) showed cortical expression of osteopontin in distal tubules, blood vessels and 
glomeruli. Moreover, the animals that displayed cortical immunoreactivity of ostepontin 
also evidenced calcium deposition by von Kossa (Figure 3.3). Conversely, no kidney 
cortical osteopontin expression was observed in animals from the remaining groups, 
which also did not show evidence of soft-tissue mineralization in the kidney (not 
shown). 
By multiplex assay, ERKi or FGFRi dosing for 6h did not induce any changes in the 
plasma levels of osteoprotegerin (Figure 3.27 A), DKK1 (Figure 3.27 B) and sclerostin 
(Figure 3.27 C). Conversely, ERKi dosing for 3d induced and increase in plasma levels 
of osteoprotegerin (+58%, Figure 3.27 A) and DKK1 (+68%, Figure 3.27 B), but not 
sclerostin (Figure 3.27 C) whilst FGFRi dosing for 8d induced an increase in plasma 
levels of osteoprotegerin (+39%, Figure 3.27 A), DKK1 (+60%, Figure 3.27 B) and 
sclerostin (+200%, Figure 3.27 C). Due to limited availability of plasma samples, it was 
not possible to perform this assay using animals treated with MEKi. 
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Cortical expression of osteopontin was induced in animals treated for 8d with FGFRi 
or 28d with MEKi or FGFRi (consistent with the presence of mineralization).  
Treatment for with ERKi for 3d or FGFRi for 8d induced an increase in DKK1 and 
osteoprotegerin. 
Treatment with FGFRi for 8d induced an increase in sclerostin. 
 
 
Figure 3.26: Expression of the osteopontin in cortical kidney sections from rats 
treated with 150 mg/kg/day of ERKi or 20 mg/kg/day of FGFRi.  Photomicrograhs 
of osteopontin immunostaining in sections of rats from study 2 dosed with vehicle (A) 
or FGFRi (B) for 8d. Positive signal in immunohistochemistry corresponds to the brown 
staining. Histogram represents the quantification of osteopontin expression 
(immunohistochemically stained area) in animals from study 2 (C). Data representative 
of N = 4-6 rats + SEM. * p<0.05 vs the vehicle control (Mann-Whitney test). Scale bar 
= 100 µm. 
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Figure 3.27: Plasma concentrations of osteoprotegerin, DKK1 and sclerostin in 
animals treated for 6h or 3/8d with 150 mg/kg/day of ERKi or 20 mg/kg/day 
FGFRi.  Plasma osteoprotegerin (A), DKK1 (B), and sclerostin (C) levels in animals 
from the studies 2 and 3. Data representative of N = 4-6 rats + SEM. * p<0.05 vs the 
vehicle control (Mann-Whitney test). The quantification of the plasma concentrations 
of osteoprotegerin, DKK1 and sclerostin was carried out by the Clinical Pathology 
department at AstraZeneca UK. 
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3.7.3 Summary table 
Animals treated with ERKi, MEKi or FGFRi for >3d showed increased expression of 
the calcification inducer alkaline phosphatase. Associated with the presence of kidney 
mineralization, renal cortical expression of ostepontin was observed in animals treated 
with MEK for 28d or FGFRi for >8d. Besides, plasma levels of DKK1 and 
osteoprotegerin were increased in animals treated with ERKi for 3d or FGFRi for 8d 
and plasma levels of sclerostin were increased in animals treated with FGFRi for 8d 
(DKK1, osteoprotegerin and sclerostin were not assessed in animals treated with 
MEKi). The increases in renal expression of osteopontin and plasma levels of DKK1, 
osteoprotegerin and sclerostin are consistent with previous studies that show 
increased expression of these calcification inhibitors in calcifying tissue (Kwon et al. 
2000, Schoppet et al. 2004, Abedin et al. 2007, Ueland et al. 2009, Yu et al. 2009, Kim 
et al. 2011, Koos et al. 2013, Kuipers et al. 2015). Table 3.11 summarizes the effects 
of ERKi, MEKi and FGFRi in the renal expression of alkaline phosphatase, Pit-1 and 
osteopontin and plasma levels of osteoprotegerin, DKK1 and sclerostin. 
 
Table 3.11: Summary of the effects of ERKi, MEKi and FGFRi in the expression 
of calcification modulators 
 Method Dosing ERKi MEKi FGFRi 
Alkaline 
phosphatase 
IHC 
6h = NA = 
d3/8 + + + 
Pit-1 IHC 
6h = NA = 
d3/8 = = = 
Osteopontin1 IHC 
6h = NA = 
d3/8 = + + 
Osteoprotegerin Luminex 
6h = NA = 
d3/8 + NA + 
DKK1 Luminex 
6h = NA = 
d3/8 + NA + 
Sclerostin Luminex 
6h = NA = 
d3/8 = NA + 
1 – Osteopontin immunoreactivity in the cortex – no change in osteopontin 
immunoreactivity was observed in the medulla.  
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3.8 Discussion 
 
Study execution 
This study assessed the mechanisms of soft-tissue mineralization following the 
administration of an ERK 1/2 inhibitor (ERKi), a MEK 1/2 inhibitor (MEKi) or an FGFR 
1-3 inhibitor (FGFRi) to rats. The effects of these inhibitors in mineral homeostasis and 
soft-tissue mineralization were analysed following a single dose (6h post-dose) or 
following a 3/8d repeated dosing period. Also, the effects of MEKi and FGFRi were 
analysed in samples available from a previous 25/28d study carried out at 
AstraZeneca. ERKi, MEKi and FGFRi were administrated at the maximum tolerated 
dose (MTD), with a dosing regimen designed to keep effective plasma drug 
concentrations during the whole study. Moreover, the animals were terminated 2h after 
the last dosing, a time where these inhibitors were expected to reach maximal 
concentrations in blood (Cmax). The drug dosages, dosing regimens and length of the 
treatments used in this study aimed to prevent and/or address differences in drug 
exposure, which may have contributed to the discrepant biological effects previously 
observed in animals treated with MEK and FGFR inhibitors (Brown et al. 2005, Wohrle 
et al. 2011, Diaz et al. 2012, Wohrle et al. 2013, Yanochko et al. 2013).  
 
Toxicokinetic analysis 
The toxicokinetic analysis has shown that plasma ERKi and FGFRi concentrations 
remained high during the course of the study, as planned. Conversely, MEKi 
concentrations may have dropped to low levels between dosing intervals since this 
compound was only administered once a day due to its toxicity and its C12h 
corresponded to 9% of its Cmax. Nevertheless, the toxicokinetic analysis also confirmed 
that ERKi, MEKi and FGFRi reached the Cmax at 2h post dosing, suggesting that the 
animals were terminated and the biological tissues were collected at the a period when 
the effects of the inhibitors should be detectable. 
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Effects of ERKi, MEKi and FGFRi in soft-tissue mineralization and mineral 
homeostasis 
 
Soft-tissue mineralization 
In this study, the administration of ERKi, MEKi or FGFRi to rats resulted in soft-tissue 
mineralization in different organs including stomach, heart and kidney (the latter not 
observed with ERKi) and increased plasma Pi. Analogous findings were reported in 
rats treated with the MEK inhibitors PD352901 and GEN-A (Brown and Gad 2010, 
Diaz et al. 2012, Yanochko et al. 2013) and the FGFR inhibitors PD176067 or 
PD0330361 (Brown et al. 2005, Yanochko et al. 2013). The observation that soft-
tissue mineralization is induced by treatment with different MEK and FGFR inhibitors 
strongly suggests that this effect is a consequence of the primary pharmacology (class 
effect) of these compounds, rather than an off-target effect. Moreover, the observation 
for the first time that an ERK inhibitor treatment is also able to induce soft-tissue 
calcification further supports a role for the MEK/ERK pathway in this process. 
 
Bone, kidney and parathyroid axis 
I aimed to analyse the expression of FGF23, 1,25D3 and PTH in animals treated with 
ERKi, MEKi and FGFRi since these molecules are key hormones for mineral 
homeostasis, susceptible to regulation by FGFR and MEK/ERK signalling (Ben-Dov 
et al. 2007, Chanakul et al. 2013, Xiao et al. 2014).  
 
1,25D3 
Since it was not possible to find a sensitive assay to quantify plasma levels of 1,25D3, 
I analysed the expression of the genes that encode the proteins responsible for its 
production, Cyp27b1, and degradation, Cyp24a1, in the kidney. The expression of 
Cyp27b1 was increased and the expression of Cyp24a1 was decreased in animals 
treated with ERKi or FGFRi for 6h or ERKi for 3d, consistent with an increase in 1,25D3 
production. These changes precede the increase in plasma Pi, which is only observed 
at 12h/24h post-dosing. Since 1,25D3 is able to induce renal reabsorption and 
intestinal absorption of Pi, most likely the increase in 1,25D3 production contributes to 
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the increase in plasma Pi levels (Dusso et al. 2005, Kido et al. 2013). The increase in 
Cyp27b1 and decrease in Cyp24a1 was not statistically significant in animals treated 
with FGFRi for 8d. This may be the result of a negative feedback mechanism in which 
1,25D3 induces a downregulation of Cyp27b1 (Murayama et al. 1998) and an 
upregulation of Cyp24a1 (Vaisanen et al. 2005) to prevent a further increase in its 
levels. In addition to the renal effects in 1,25D3 production, it is possible that inhibitors 
of ERK, MEK and FGFR induce increased production of 1,25D3 in extra-renal tissues 
since extra-renal Cyp27b1 is normally inhibited by FGF23 signalling through the FGF 
receptors and the MEK/ERK pathway (Chanakul et al. 2013). The effects of ERKi, 
MEKi and FGFRi in 1,25D3 production support previous studies that report that MEK 
(Brown and Gad 2010, Diaz et al. 2012, Yanochko et al. 2013) or FGFR (Wohrle et al. 
2011, Yanochko et al. 2013) inhibitors induce an upregulation of Cyp27b1, a 
downregulation of Cyp24a1 and/or an increase in 1,25D3 detectable from 4h-12h post 
dosing. In addition to the effects on the production of 1,25D3, ERKi, MEKi and FGFRi 
also affected the expression of its receptor, VDR. VDR expression was markedly 
decreased in animals treated with ERKi or FGFRi for 6h or ERKi for 3d. Conversely, 
this effect was reversed in animals treated with MEKi or FGFRi for 8d and an increase 
in VDR expression was observed in the 25d/28d studies. VDR mediates the genomic 
actions of 1,25D3 (Haussler et al. 1998). Consequently the presence and expression 
levels of VDR condition the susceptibility of different tissues to 1,25D3- induced gene 
regulation. The expression of VDR can be regulated by different factors including the 
inducers 1,25D3 (Healy et al. 2003) and FGF23 (Canalejo et al. 2010) and the inhibitor 
PTH (Reinhardt and Horst 1990). It is plausible that the inhibition of signalling through 
the FGFRs or through the MEK/ERK pathway blocks FGF23-induced VDR expression, 
leading to an initial decrease in VDR levels. Conversely, following longer treatment 
periods, the increased levels of 1,25D3 may signal through the VDR molecules and 
gradually increase the expression of this receptor. This way, shorter dosing periods 
with ERKi, MEKi and FGFRi may result in increased production of 1,25D3 but also in 
some limitations in the genomic actions of this hormone. Conversely, following longer 
treatment periods, VDR levels are normalized and 1,25D3 is able to carry out its 
genomic actions to the full extent.  
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FGF23 
FGF23 was measured in different time points following the administration of ERKi, 
MEKi or FGFRi. All compounds induced an initial decrease (2-12h post dose) in 
plasma FGF23. This decrease is observed at the same time as the alterations in the 
expression of Cyp27b1 and Cyp24b1 mRNA, and precedes the increase in Pi. 
Considering that the expression of FGF23 can be induced by activated FGF receptors 
signalling through the MEK/ERK or PLC gamma pathways (Xiao et al. 2014), it is 
probable that this initial decrease in FGF23 is the consequence of a blockage in the 
FGFR-induced FGF23 expression in bone, either at the FGFR or MEK/ERK pathway 
level. Animals treated with MEKi or FGFRi for >4 days showed increased plasma 
levels of FGF23. This increase may be the consequence of an enhanced induction of 
FGF23 gene expression by the high levels of 1,25D3 (Prie and Friedlander 2010) or Pi 
(Arai-Nunota et al. 2014). The observation that the effects of ERKi and MEKi in plasma 
levels of FGF23 differ with the duration of the treatment explains some of the 
discrepancies previously reported. To be exact, in previous studies mice treated with 
a FGFR inhibitor for <7h showed a decrease in the production and plasma levels of 
FGF23 (Wohrle et al. 2011) whilst rats treated with a MEK or an FGFR inhibitor for 
>24h showed increased plasma levels of FGF23 (Diaz et al. 2012, Yanochko et al. 
2013).  
 
PTH 
No changes in PTH were observed following treatment with MEKi or FGFRi for 8d. 
Nevertheless, the variability of the results was very high, possibly due to a low 
sensitivity of the method. PTH is not an easy analyte to detect due to the existence of 
different fragments of this hormone (Martin and González 2007). Previously, some 
studies have successfully detected intact PTH in rodents treated with MEKi or FGFRi 
using ELISA methods (Brown and Gad 2010, Wohrle et al. 2011, Diaz et al. 2012), 
while others have failed to detect this analyte using similar methods (Yanochko et al. 
2013). In the studies where PTH was detected successfully, this analyte was assessed 
using an N = 4-6 animals per group, a number comparable to what was used in this 
study. Nevertheless, the values of PTH measured in these studies were associated 
with high values for the standard error of the mean, thus suggesting that the methods 
125 
 
employed also attain low sensitivities. For instance, some of the treatments shown in 
these studies evidenced PTH values with a 2-3 fold difference in comparison to the 
vehicle, which was not deemed significant. A factor that may contribute to the 
variability of the PTH results is the processing of the sample. Previous studies indicate 
that freeze-thawing the samples may decrease the stability of PTH, therefore leading 
to an increased variability in PTH results (Brinc et al. 2012). Accordingly, PTH 
variability is decreased when samples are collected in EDTA, stored at 4ºC and 
analysed within 48h (Hanon et al. 2013). Due to the low sensitivity of the available 
assays and to also due the nature (frozen) and limited availability of the plasma 
samples, the detection of PTH by ELISA was not carried out in animals treated with 
ERKi, MEKi or FGFRi. Since 1,25D3 (Kugai et al. 1984) and FGF23 (Ben-Dov et al. 
2007) are able to inhibit the production and secretion of PTH in the parathyroid, it is 
plausible that the altered levels of FGF23 and 1,25D3 associated with ERKi, MEKi or 
FGFRi treatment affect the expression of PTH. In fact, the previous studies have 
shown that the plasma levels of PTH were increased in mice treated with an FGF 
receptor inhibitor for <7h (Wohrle et al. 2011) and decreased in rats treated with MEK 
inhibitor for >24h (Brown and Gad 2010, Diaz et al. 2012).  
The involvement of PTH in the mechanism of soft-tissue mineralization induced by the 
inhibition of the FGFRs or the inhibition of the MEK/ERK pathway should be addressed 
when more sensitive PTH detection methods become available or by using the PTH 
ELISA methods currently available with an optimized sample processing and a larger 
number of animals in each treatment group. 
 
Effects of ERKi, MEKi and FGFRi in the activation of cell signalling pathways in 
the kidney 
 
MEK/ERK inhibitors and FGFR inhibitors induce analogous perturbations in mineral 
ion homeostasis, however there is no direct evidence to support that these 
perturbations are induced by similar molecular mechanisms. It is plausible that these 
perturbations are induced by analogous mechanisms involving the kidney since 
FGF23 signalling through FGFRs via the MEK/ERK pathway was previously described 
to regulate different processes involved in mineral homeostasis including the 
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production of 1,25D3 (Chanakul et al. 2013) and the expression of NaPi-IIa 
(Andrukhova et al. 2012) and TRPV5 (Andrukhova et al. 2014). Nevertheless, the 
uncertainty of the distribution of the FGFRs 1-4, Klotho, MEK and ERK along the 
nephron generated some controversy regarding the role of FGF23 in these processes. 
In order to clarify the intra-renal distribution of FGFRs 1-4, Klotho, MEK and ERK these 
proteins and assess which nephron segments could be directly affected by ERKi, 
MEKi and FGFRi, the expression these proteins was analysed in the kidney using ISH 
and IHC. 
 
FGFRs and Klotho 
Whilst the FGFRs, MEK and ERK are direct targets of FGFRi, MEKi and ERKi, Klotho 
is a co-receptor required for the interaction between endocrine FGFs such as FGF23 
and the FGFRs (Urakawa et al. 2006). FGFRs 1-4 were detected throughout the 
nephron including the PT, DT and CD (not FGFR4) segments. The results shown in 
this study are partially in agreement with a study performed by Cancilla and coworkers, 
which reported a similar expression pattern for FGFR1, FGFR2 and for FGFR3, with 
the exception of CD in FGFR3 and PT in FGFR3 (Cancilla et al. 2001). Klotho was 
observed with stronger intensity in DT and CD and weaker intensity in PT, in 
agreement with recent reports (Hu et al. 2010, Andrukhova et al. 2012). The detection 
of the FGFRs and Klotho in the PT strongly support that FGF23 regulates the 
production of 1,25D3 (Chanakul et al. 2013) and expression of NaPi-IIa (Andrukhova 
et al. 2012) by directly targeting this nephron segment. The direct targeting of the PT 
by FGF23 is a more plausible explanation for the effects of FGF23 in this nephron 
segment than a paracrine regulation elicited by the DCT, which was suggested in 
previous studies that detected the expression of Klotho in the DCT but not in the PT 
(Farrow et al. 2009). 
 
ERK and MEK 
ERK and MEK were also detected throughout the nephron including the PT, DT and 
CD segments. The phosphorylated forms of these proteins were mainly observed in 
DT and only to a smaller extent in the PT. Previous studies had reported expression 
of ERK by IHC in the DT and CD, but not in PT (Omori et al. 2000, Fujita et al. 2004). 
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Conversely, functional studies carried out in cell cultures suggest the expression and 
functional roles for ERK in the proximal tubule including cytokine production and 
angiotensin signalling (Sengul et al. 2003, Su et al. 2006). The observation of the 
expression of MEK and ERK in the PT supports these functional studies.  
The discrepancies in the IHC patterns of the FGFRs between this study and previous 
studies may be explained by the use of antibodies that recognize different isoforms of 
the same FGFR. On the other hand, the differences in the IHC patterns of Klotho, MEK 
and ERK detected in this study and the patterns reported in previous studies may be 
ascribed to the sensitivity of the IHC methods or to deficient tissue processing that 
may have prevented antigen recognition in the previous studies.  
The co-localization of the FGF receptors, Klotho, MEK and ERK in the PT and DT 
support previous studies that described that FGF23 regulates the expression of NaPi-
IIa (Andrukhova et al. 2012), Cyp27b1 (Chanakul et al. 2013) and TRPV5 (Andrukhova 
et al. 2014) by signalling through the FGFRs and through the MEK/ERK pathway in 
these nephron segments. These observations are consistent with FGFRi, MEKi and 
ERKi inducing the production of 1,25D3 and Pi reabsorption in the kidney by a common 
mechanism involving in the inhibition of FGF23 signalling, either at the level of the 
FGFRs or at the level of the MEK/ERK pathway. 
 
MEK/ERK signalling pathway activation 
The inhibition of MEK/ERK signalling by ERKi or MEKi was confirmed through the 
analysis of the phosphorylation of ERK and expression of its downstream target 
EGR1. ERKi induced an increase in the phospho-ERK, consistent with the drug mode 
of action, which prevents the binding of phospho-ERK to its targets, but not its 
phosphorylation, thus leading to an accumulation of phospho-ERK (AstraZeneca 
unpublished data). Conversely, MEKi induced a decrease in phospho-ERK and both 
compounds induced a decrease in the expression of the transcription factor EGR1, 
consistent with the inhibition of the MEK/ERK pathway. ERK phosphorylation and 
EGR1 expression remained mostly unchanged in animals treated with FGFRi. 
Previous studies have shown that the MEK/ERK pathway is a downstream component 
of the renal FGFR signalling, involved in the FGF23-induced regulation of the proteins 
NaPi-IIa (Andrukhova et al. 2012), Cyp27b1 (Chanakul et al. 2013) and TRPV5 
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(Andrukhova et al. 2014). Moreover, FGF23 administration was found to induce ERK 
activation in mouse kidney (Farrow et al. 2009) and FGFRi treatment was found to 
decrease ERK phosphorylation in tumour cell models displaying high FGF receptor 
signalling (Astrazeneca unpublished work). The observation that FGFRi had no effects 
in ERK phosphorylation and EGR1 expression suggests that this compound is not able 
to prevent the activation of the MEK/ERK pathway and therefore may induce soft-
tissue mineralization by a different mechanism than ERKi and MEKi. Nevertheless, 
the MEK/ERK pathway can be activated by different receptors including vascular 
endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) 
and CaSR (Kifor et al. 2001, Adams et al. 2004, Narasimhan et al. 2009). Since the 
activation of ERK by FGF23 is low under basal conditions (Farrow et al. 2010), it is 
possible that FGFRi effectively prevents the FGFR-mediated activation of MEK/ERK 
signalling whilst having little changes in the overall activation of this pathway. This 
assumption is supported by the observation that ERK phosphorylation was not 
increased following treatment with FGFRi for >8d, despite the presence of increased 
levels of phosphate and FGF23, which were previously found to induce ERK activation 
by signalling through the FGFRs (Yamazaki et al. 2010). Conversely to FGFRi, the 
administration of the pan-FGFR inhibitor PD-0330361 to rats resulted in a significant 
decrease in ERK phosphorylation in the kidney in a previous study (Yanochko et al. 
2013). Due to the high degree of homology between the different tyrosine kinases, 
FGFR inhibitors may inhibit to a lower degree other kinases (Broekman et al. 2011). 
This way, it is possible that inhibition of ERK by PD-0330361 in that study is a result 
of the drug hitting other kinases that signal through the MEK/ERK pathway. This is 
supported by the observation that PD-0330361 was administered in a very high dose, 
which led to marked toxicity effects and earlier termination of the study. Another 
explanation is that FGFRi is does not reach the kidney in effective concentrations and 
the mineral homeostasis perturbations are induced by the effects of FGFRi in other 
organs. Nevertheless, this hypothesis would not explain why the ERK phosphorylation 
levels are not increased by the high FGF23 levels observed in animals treated with 
FGFRi for >8d.  
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FGFR signalling activation 
I aimed to confirm the inhibition of the FGFRs by analysing the expression of phospho-
FGFR and/or phospho-FRS2 (target of FGFR) in kidney sections from animals treated 
with FGFRi. Unfortunately, it was not possible to carry out this analysis since none of 
the three antibodies assessed for this purpose was able to specifically detect is 
corresponding target in rat kidney. Other targets of the FGFRs include PLC-gamma 
(Rhee 2001) and different signalling pathways such as Src (Sandilands et al. 2007) 
and Janus kinase (JAK) / signal transducer and activator of transcription (STAT) 
(Dudka et al. 2010). Nevertheless, PLC-gamma and the components of these 
signalling pathways are likely not good biomarkers for FGFR activation, since these 
proteins are also targets of other receptors (Rhee 2001, Parsons and Parsons 2004, 
Johnston and Grandis 2011). 
 
RPPA evaluation of the effects of ERKi and FGFRi on cell signalling 
An RPPA assay was carried out in rats treated for 6h with ERKi or FGFRi with the aim 
of identifying the pathways that are affected within hours of the administration of these 
inhibitors and may contribute to the occurrence of soft-tissue mineralization. This 
method showed similar results as IHC and Western blotting for the expression of 
phospho and total ERK, which were included in the analysis as controls. Besides 
phospho-ERK, all the effects of ERKi and FGFRi in protein expression detected by 
RPPA were small (<40% expression change). This observation suggests that RPPA 
failed to identify the key proteins contributing to soft-tissue mineralization, however it 
may not be the case as some of the small expression changes identified may increase 
following longer treatment periods with the inhibitors. The expression changes induced 
by ERKi include slight decreases in the activation of MNK1 and CREB, downstream 
proteins of MEK/ERK signalling. These effects were also observed in animals treated 
with FGFRi, which additionally attained slight decreases in the activation of 
MAPKAPK-2, Src and PLC gamma, downstream proteins in FGFR signalling. These 
observations support that FGFRi effectively inhibits the FGFRs and the FGFR-
mediated ERK activation in the kidney. Other proteins that showed small expression 
changes following treatment with ERKi and FGFRi include beta-catenin and GSK3-
beta, components of the WNT pathway; and PARP1 (only FGFRi) and Bcl-x, two 
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proteins involved in regulation of the apoptotic process. Although the expression 
changes observed by RPPA are too small to indicate a clear role for these processes 
in mineralization induced by ERKi or FGFRi, activation of WNT signalling (Zeadin et 
al. 2012, Guerrero et al. 2014, Yao et al. 2015) and apoptosis (You et al. 2009) were 
previously associated with the induction of soft-tissue mineralization. As validation for 
the RPPA assay, beta-catenin expression was also analysed by IHC. Beta-catenin 
showed a variable expression between animals and the treatment with ERKi or FGFRi 
did not induce any evident changes in the expression or localization of this protein. 
The discrepancy between both methods suggests that the small expression changes 
observed by RPPA may not be real. Nevertheless, this may not hold true since RPPA 
may be more sensitive than IHC to detect beta-catenin. In fact, consistent with a 
dysregulation of the WNT pathway, animals treated with ERKi for 3d or FGFRi for 8d 
showed an increase in the plasma levels of the WNT pathway inhibitors DKK1 and 
sclerostin (only FGFRi). 
 
Effects of ERKi, MEKi and FGFRi on the expression of proteins involved in renal 
Ca2+ and Pi reabsorption  
 
Pi reabsorption in the PT 
The contribution of the renal Pi reabsorption to the increased plasma Pi levels was 
investigated. Due to the strict home office license regulations it was not possible to 
conciliate the experimental design used in this study with the collection of urine using 
metabolic cages. As an alternative, the expression of NaPi-IIa, the transporter that 
accounts for 70% of the renal Pi reabsorption (Wagner et al. 2008), was analysed. 
Treatment with ERKi or FGFRi for 6h promoted a shift of NaPi-IIa expression from 
cytoplasmic vesicles to the brush border membrane. Conversely, longer (>3d/8d) 
treatment with ERKi or FGFRi the inhibitors resulted in a slight decrease in NaPi-IIa 
expression in the outer cortex, and no changes or even a slight increase in NaPi-IIa 
expression in the inner cortex. Besides, treatment with MEKi for 8d did not affect NaPi-
IIa expression, whilst treatment with this inhibitor for 28d resulted in a slight increase 
in NaPi-IIa expression in the inner cortex. These results suggest that NaPi-IIa may 
contribute to the initial increase in plasma Pi levels, but not to the sustained high Pi 
131 
 
levels following longer treatments with ERKi, MEKi or FGFRi. Previous studies have 
shown that FGF23 promotes the internalization of NaPi-IIa mainly through Klotho-
dependent processes (Andrukhova et al. 2012) involving signalling through FGFR1 
and ERK (Yan et al. 2005, Gattineni et al. 2009). To a lesser extent, FGF23 also 
promotes the internalization of NaPi-IIa by Klotho-independent processes 
(Andrukhova et al. 2012) and signalling through FGFR4 (Gattineni et al. 2009). Most 
likely, the regulation of NaPi-IIa by FGF23 can also occur independently of ERK, since 
the Klotho-independent actions of FGF23 were previously shown to involve other 
pathways than ERK (Faul et al. 2011, Olauson et al. 2013). Opposite to FGF23, 1,25D3 
induces the of expression of NaPi-IIa in the inner cortex, whilst having no effects in the 
outer cortical expression of this protein (Taketani et al. 1998). The increase in the 
brush border expression of NaPi-IIa observed 6h post dosing with ERKi or FGFRi is 
likely the effect of a decrease in the internalization of this protein promoted by the low 
levels of FGF23. Conversely, the slight alterations in the expression pattern of NaPi-
IIa observed following longer treatment periods with ERKi, MEKi and FGFRi may be 
the outcome of opposite regulatory signals of FGF23 and 1,25D3. Whilst 1,25D3 
induces the expression of NaPi-IIa in the inner cortex of the kidney, FGF23, possibly 
by signalling through FGFR4 and pathways other than ERK, inhibits NaPi-IIa 
expression throughout the kidney cortex. In three different studies with rodents, 
treatment with a FGFR or a MEK inhibitor for <12h did not affect NaPi-IIa mRNA or 
protein expression (Wohrle et al. 2011, Diaz et al. 2012, Wohrle et al. 2013). 
Conversely, one study showed that NaPi-IIa expression decreased in rats treated 
during 4d with an FGFR inhibitor and remained unchanged in rats treated during 6d 
with a MEK inhibitor (Yanochko et al. 2013). A different study showed that NaPi-IIa 
expression decreased in rats treated for 3d treatment with a MEK inhibitor (Diaz et al. 
2012). The discrepancies in NaPi-IIa expression between the various studies may be 
associated with different drug exposures. Whilst in this study plasma drug 
concentrations were high at the time that the animals were killed, this may have not 
occurred in the other studies. For instance, a low exposure to the drug would explain 
the decrease in NaPi-IIa expression observed in rats treated for 4d with a FGFR 
inhibitor or for 3d with a MEK inhibitor, since these effects are consistent with the 
compensatory response of the organism to the high levels of Pi or FGF23. Renal 
reabsorption of Pi can also be mediated by other transporters than NaPi-IIa, including 
NaPi-IIc and sodium-dependent phosphate transporter 2 (Pit-2). The expression of 
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these two receptors is regulated by plasma Pi levels (Ohkido et al. 2003, Villa-Bellosta 
et al. 2009). Also, similarly to NaPi-IIa, the expression of NaPi-IIc can be induced by 
1,25D3 (Masuda et al. 2010) and inhibited by FGF23 (Gattineni et al. 2009). Further 
studies should clarify if NaPi-IIc and Pit-2 are involved in the increase in Pi induced by 
ERKi, MEKi and FGFRi. 
Besides the increase in renal Pi reabsorption, a factor that may contribute to the 
elevated plasma Pi levels is a decrease in renal function (McMillan 2013). Although 
renal function could not be accurately analysed in this study due to the lack of urinary 
data, it was observed that treatment with ERKi for 3d or FGFRi for 8d or 28d induced 
an increase plasma creatinine levels (Table 7.33), which is consistent with a decrease 
in renal function. Further studies should accurately assess if the administration of 
ERKi, MEKi and FGFRi to rats decreases the renal function and evaluate how this 
impairment contributes to the elevated levels of Pi. 
 
Ca2+ reabsorption in the DCT 
Treatment with ERKi or FGFRi for 6h or ERKi for 3d resulted in the decreased 
expression of TRPV5. Conversely, treatment with MEKi or FGFRi for >8d resulted in 
the increased expression of TRPV5, calbindin-D28k and PMCA in the kidney, 
consistent with an increased reabsorption of Ca2+ in the DCT. FGF23 is able to induce 
the expression of TRPV5 by signalling through the FGFRs and through the MEK/ERK 
pathway (Andrukhova et al. 2014). Also, 1,25D3 is able to induce the expression of 
TRPV5, calbindin-D28k and PMCA (Huang and Christakos 1988, Hoenderop et al. 
2001, Kip and Strehler 2004). Most likely, the initial decrease in TRPV5 following the 
administration of ERKi or FGFRi is induced by the low FGF23 levels and/or inhibition 
of FGF23 signalling. Conversely, the increased expression of TRPV5, PMCA and 
calbindin-D28k following longer treatments (>8d) with MEKi or FGFRi is likely induced 
by the high levels of 1,25D3. These results suggest that long term treatment with MEKi 
or FGFRi results in increased Ca2+ reabsorption in the kidney, despite the lack of 
changes in plasma Ca2+. Nevertheless, these two situations are not incompatible since 
the Ca2+ is strictly regulated at a systemic level through the activation of processes 
such as resorption from bone or absorption from intestine. Even without affecting 
plasma Ca2+ levels, an increase in renal Ca2+ reabsorption could promote kidney 
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mineralization by increasing the Ca2+ x Pi product locally. Consistent with this 
hypothesis, kidney mineralization was mainly detected in connective tissue contiguous 
to distal tubules in animals treated with MEKi or FGFRi. 
 
Effects of ERKi, MEKi and FGFRi in the expression of calcification modulator 
proteins 
 
Calcification inducers 
Soft-tissue mineralization is not the simple deposition of Ca2+ and Pi but rather an 
active and regulated process (Giachelli 2004). This way, in addition to the high Ca2+ x 
Pi product, the induction of soft-tissue mineralization is generally associated with an 
increased expression of calcification inducers and / or a decreased expression of 
calcification inhibitors (Giachelli 2004).  
 
Alkaline phosphatase 
Treatment with ERKi for 3d or MEKi or FGFRi for 8d induced an increase in kidney 
expression of the calcification inducer protein alkaline phosphatase, mainly in the 
DCT. The observation of high alkaline phosphatase expression in treatment groups 
where kidney mineralization was not observed (eg. animals treated with ERKi for 3d 
or MEKi for 8d) suggests that the increase in alkaline phosphatase expression 
precedes the occurrence of soft-tissue mineralization. Likely, alkaline phosphatase 
contributes to the initiation of the mineralization process following treatment with ERKi, 
MEKi or FGFRi, as this protein is able to hydrolyse the calcification inhibitor 
pyrophosphate, generating Pi and creating suitable conditions to the occurrence of 
mineralization (Schoppet and Shanahan 2008).  Alkaline phosphatase expression can 
be induced by 1,25D3 (Jono et al. 1998) and Pi (Orimo and Shimada 2008) and 
inhibited by FGF23 (Shalhoub et al. 2011). Moreover, regulation of alkaline 
phosphatase by Pi and FGF23 involves at least partially signalling through the 
MEK/ERK (Shalhoub et al. 2011) pathways, respectively. This way, the increase in 
alkaline phosphatase expression following treatment with ERKi, MEKi or FGFRi may 
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be induced by the high levels 1,25D3 and/or Pi or by the blockage in the FGF23-
mediated inhibition of alkaline phosphatase.  
 
Pit-1 
Pit-1, a transporter with a key role in the induction of soft-tissue calcification (Chavkin 
et al. 2015) and possibly involved in renal Pi reabsorption (Tenenhouse et al. 1998) 
was also analysed. Strong Pit-1 expression was observed in kidney blood vessels and 
glomeruli and weaker expression was observed throughout the nephron including the 
PT, DCT and CD segments. To my knowledge, this is the first description of the 
expression pattern of Pit-1 in rat kidney. This description is consistent with the 
expression pattern previously reported for Pit-1 mRNA in mouse kidney (Tenenhouse 
et al. 1998). Treatment with ERKi, MEKi or FGFRi did not affect the expression or 
distribution of Pit-1, which suggests that this transporter is not involved in the 
mineralization or increased plasma Pi levels observed in animals treated with these 
inhibitors.  
 
Calcification inhibitors 
Soft-tissue mineralization is generally accompanied by a phenotype transition and 
induction of different calcification inhibitors (Kwon et al. 2000, Schoppet et al. 2004, 
Abedin et al. 2007, Ueland et al. 2009, Yu et al. 2009, Kim et al. 2011, Koos et al. 
2013, Kuipers et al. 2015), possibly elicited to prevent the occurrence of further 
calcification.  
 
Osteopontin 
Osteopontin, a calcification inhibitor normally detected in the renal medulla, was also 
expressed in the cortex of the animals treated with MEKi and FGFRi that displayed 
kidney mineralization. The expression of osteopontin in these animals showed a 
similar pattern as the mineral deposition detected by von Kossa, which suggests that 
this protein is expressed in calcifying tissue.  
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Osteoprotegerin, DKK1 and sclerostin 
Also, the plasma levels of the calcification inhibitors osteoprotegerin, DKK1 and 
sclerostin were increased by treatment with ERKi for 3d (only osteoprotegerin and 
DDK1) and FGFRi for 8d. Conversely, no changes in the expression of 
osteoprotegerin, DKK1 and sclerostin were observed in animals treated with these 
inhibitors for 6h. These observations suggest that the increase in osteopontin, 
osteoprotegerin, DKK1 and sclerostin succeed the settling of mineralization. 
Consistent with these observations, the expression of osteopontin (Mohler et al. 1997), 
osteoprotegerin (Schoppet et al. 2004), DKK1 (Kim et al. 2011) and sclerostin (Kuipers 
et al. 2015) was previously found to be upregulated in calcifying tissue. Also, the 
plasma levels of these proteins were found to be increased in patients showing 
evidences of vascular calcification (Abedin et al. 2007, Ueland et al. 2009, Abdel-
Azeez and Al-Zaky 2010, Brandenburg et al. 2013).  
Osteopontin, osteoprotegerin, DKK1 and sclerostin inhibit soft-mineralization through 
distinct processes. Osteopontin inhibits mineralization by releasing a peptide that 
binds to hydroxyapatite and prevents the development of the crystals (Addison et al. 
2010); DKK1 and sclerostin inhibit mineralization by preventing the activation of the 
WNT signalling pathway, which regulates the expression of pro-calcifying proteins 
such as BMP2 and alkaline phosphatase (Martinez-Moreno et al. 2012, Guerrero et 
al. 2014); Osteoprotegerin inhibits mineralization by acting as a decoy-receptor for the 
pro-calcifying protein RANK (Boyce and Xing 2007) and the pro-apoptotic protein TNF-
related apoptosis-inducing ligand (TRAIL) (Sandra et al. 2006). The activation of such 
diverse processes illustrates the complexity of the mechanism of mineralization 
induced by ERKi, MEKi and FGFRi. 
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3.9 Conclusion 
 
In summary, administration of ERKi, MEKi and FGFRi to rats resulted in soft-tissue 
mineralization of different organs including kidney, stomach and heart. Associated with 
soft-tissue mineralization, the three inhibitors induced similar perturbations in mineral 
homeostasis including increased plasma levels of Pi and altered production of 1,25D3 
and FGF23. The kidney appears to have a key role in the process of soft-tissue 
mineralization induced by ERKi, MEKi and FGFRi since the treatment with these 
inhibitors affected the renal expression of genes/proteins involved in the production of 
1,25D3, reabsorption of Ca2+ and Pi and modulation of mineralization. In addition, bone 
is also expected to have an important role in this process since ERKi, MEKi and FGFRi 
induced alterations in the plasma levels of FGF23, which is mainly produced in this 
organ.   
Most likely, the process of soft-tissue mineralization is initially triggered by the 
inhibition of FGF23 signalling, either at the FGFR or at the MEK/ERK pathway levels. 
Supporting this conjecture, the perturbations in mineral homeostasis observed 6h 
post-dosing with these inhibitors are direct effects of FGF23 inhibition. These include 
increased expression of Cyp27b1 and NaPi-IIa and decreased expression of 
Cyp24a1, TRPV5, VDR and decreased plasma levels of FGF23. Furthermore, 
following longer treatment periods, the altered expression of Cyp27b1 and Cyp24a1 
likely promotes an increased production of 1,25D3, which may be the driving factor for 
soft-tissue mineralization. Supporting with this view, the biological effects observed 
following MEKi and FGFRi treatment for >8d are consistent with 1,25D3 toxicity. These 
effects include increased plasma levels of FGF23 and Pi and increased expression of 
proteins involved in Ca2+ reabsorption in the DCT and pro-calcifying proteins such as 
alkaline phosphatase. Finally, the tissues undergoing soft-tissue mineralization 
resulting from the high Ca2+xPi product and increased expression of pro-calcifying 
proteins promote the expression calcification inhibitors such as sclerostin, DKK1, 
osteoprotegerin and osteopontin in order to prevent the occurrence of further 
calcification. The model of soft-tissue mineralization induced by treatment with ERKi, 
MEKi or FGFRi that I hypothesized is represented in Figure 3.28. 
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Figure 3.28: Model of the soft-tissue mineralization induced by administration 
of ERKi, MEKi or FGFR to rats. The model hypothesises the effects of ERKi, MEKi 
and FGFRi 6h after dosing (left) and following >3d/8d treatment with these inhibitors 
(right). ALP, alkaline phosphatase; OPG, osteoprotegerin. 
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4 Evaluation of an ex vivo kidney tissue slice model 
 
4.1 Introduction 
In the previous chapters I have addressed the renal mechanisms by which ERK 1/2 
(ERKi), MEK 1/2 (MEKi) or FGFR 1-3 (FGFRi) induce soft-tissue mineralization by 
carrying out in vivo studies with rats. Rats treated with these inhibitors evidenced soft-
tissue mineralization associated with alterations in the renal expression of key 
genes/proteins for mineral homeostasis including Cyp27b1, TRPV5 and alkaline 
phosphatase. In addition, these animals evidenced alterations in plasma levels of 
different hormones including FGF23, osteoprotegerin and DKK1. Moreover, these 
biological effects were different in animals dosed acutely (6h) or repeatedly (>3d) with 
ERKi, MEKi or FGFRi. Due to the systemic character, such complex mechanisms are 
difficult to unravel using only in vivo studies. In vitro or ex vivo models allow the 
assessment of drug effects in specific organs, tissues or cell types and therefore these 
models are often used as alternatives or complements to in vivo studies. There is a 
range of kidney cell lines currently available, which were originated from different 
nephron segments including proximal tubule (opossum kidney, OK; human renal 
proximal tubular epithelial cell, hRPTEC; human kidney 2, HK-2), distal tubule (mouse 
distal convoluted tubule, MDCT; murine distal convoluted tubule 4, mpkDCT4) and 
collecting duct (human collecting duct, HCD) (Bens and Vandewalle 2008). Some of 
these cell lines have been used for studies of mineral homeostasis. For instance, OK 
cells have been used to study the effects of hormones and drugs on phosphate 
reabsorption (Nashiki et al. 2005, Patzer et al. 2006). Also, MDCT (Gesek and White 
1997, Magyar et al. 2002) and mpkDCT4 (Diepens et al. 2004) cells have been used 
to study the physiological processes associated with calcium reabsorption. In addition 
to the established cell lines, human primary kidney cells have been described as a 
suitable model to study mineral ion homeostasis. Work carried out by Dr. Rebecca 
Wadey at Cardiff University has shown these cells express key proteins for mineral 
homeostasis including FGF receptors, TRPV5 and NaPi-IIa and retain responses to 
known physiological stimuli including FGF23 induced ERK phosphorylation and 
modulation of NaPi-IIa expression by phosphate. Nevertheless, the use of cell models 
for studies of mineral homeostasis has severe limitations. Established cell lines consist 
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of a specific cell type, thus not truly representing the nephron, which is composed by 
different segments, each containing different cell types. Also, most of the available 
kidney cell lines consist in cells that have de-differentiated to some extent, lacking the 
ability to polarize and the expression of kidney-specific proteins. Primary kidney cells 
may be a more representative model of the nephron since these show a lower level of 
de-differentiation than established cultures and can be composed of different cell 
types. Nevertheless primary cells encompass other limitations including more difficult 
culture protocols, higher variability and the loss of a kidney-like phenotype when the 
cells are cultured for >7d (Ekwall et al. 1990). In addition to primary cells and 
established cell lines, organotypic slice cultures have been used to study the kidney 
ex vivo. Precision microtomes (Krumdieck et al. 1980) allow the cutting of thin tissue 
slices that preserve key characteristics of in vivo tissue including tissue architecture, 
interactions between different cells and interactions between cells and matrix. 
Organotypic kidney slices were previously shown to retain kidney-specific 
characteristics after a few days in culture and to be suitable for toxicology studies 
(Vickers et al. 2004). In this chapter I aimed to establish an ex vivo kidney model that 
would allow the study of the mechanisms of mineralization induced by ERKi, MEKi or 
FGFRi. In order to accomplish this, kidney slices cultured for 1h, 1d and 3d were 
evaluated for cellular morphology, viability and expression of key proteins involved in 
mineral homeostasis. Also, these slices were evaluated for responses to known 
physiological stimuli including Pi changes and MEK inhibition. The results from this 
chapter suggest that this kidney slice model is suitable for studies of mineral 
homeostasis only up to 1d, deeming it an unsuitable model to study the effects of 
ERKi, MEKi and FGFRi in the process of soft-tissue mineralization.  
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4.2 Methods 
4.2.1 Tissue slice preparation and culture 
Animal kidney tissue was obtained from Han Wistar rats, supplied by Harlan (Hillcrest, 
UK) or Charles River (Harlow, UK). Han Wistar rats aged between 1 and 3 months 
were killed by CO2 inhalation and kidneys were collected. The kidney capsule and 
surrounding fat were removed and the kidneys were washed in PBS. Kidneys were 
cut in half along the transverse plane, mounted to the jig of an Integraslice 7550 PSDS 
(Campden Instruments, Loughborough, UK) and embedded in 1.8% low melting point 
agarose (Life Technologies, Carlsbad, USA) in PBS. The jig was screwed into the 
Integraslice chamber, which was then filled with PBS at 4ºC. Slices were cut at a 200 
µm thickness with 0.25 mm/s speed and 1.5 mm slicing amplitude. Slices were stored 
in a dish filled with sterile PBS at 4°C for up to 2h until all slices had been cut. Slices 
were transferred to individual wells of a 12-well-plate containing Dulbecco's modified 
Eagle medium (DMEM) / nutrient mixture F-12 (DMEM/F12) medium (Life 
Technologies, Carlsbad, USA), supplemented with 10% fetal bovine serum (GE 
Healthcare, Little Chalfont, UK) and 2% penicillin/streptomycin (Life Technologies, 
Carlsbad, USA). The plate was incubated at 37°C in a 5% CO2 / 95% air atmosphere 
and culture media was changed once daily. At the end of the incubation time, slices 
were either snap frozen in liquid nitrogen or fixed in neutrally buffered formalin for 1h 
and embedded in paraffin. 
4.2.2 Western blotting 
Rat kidney slices were homogenized in modified RIPA buffer (25 mM Tris HCl pH 7.6, 
150 mM NaCl, 1% NP40, 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, 1 
mM n-ethylmaleimide, 1 mM phenylmethanesulfonylfluoride) containing Halt protease 
and phosphatase inhibitors (Pierce, Rockford, USA). Cell lysis was carried out using 
a Dounce homogenizer (Wheaton, Rochdale, UK). Following lysis, homogenates were 
centrifuged at 10,000 x g for 5 min to remove insoluble debris. Protein extracts were 
quantified using a BCA protein assay (Pierce, Rockford, USA). Twenty micrograms of 
each extract were electrophoresed on NuPage® 10% or BisTris polyacrylamide gels 
(Invitrogen, Paisley, UK). Gels were transferred to nitrocellulose membranes and 
stained with Ponceau S to confirm even protein loading of wells. Non-specific protein 
binding was blocked using 5% low-fat dried milk in Tris-buffered saline containing 
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0.1%Tween (TBST) for 1h at room temperature. Phospho-ERK (CST4376, Cell 
Signaling Technology, Danvers, USA) or total-ERK (CST4695, Cell Signaling 
Technology) primary antibodies were added at a concentration of 1:2000 in 5% 
milk/TBST overnight at 4ºC. An HRP-conjugated anti-mouse or anti-rabbit secondary 
antibody (Promega, Madison, USA) was added appropriately at a concentration of 
1:20,000 or 1:6,000 in 5% milk/TBST before detection of immunoreactivity with ECL 
prime and development on a ChemiDoc MP  (Biorad, Hercules, USA). 
4.2.3 Immunohistochemistry 
Kidneys were fixed for 24 to 48h in 10% neutral-buffered formalin, embedded in 
paraffin, and 4µm sections were cut. Sections were de-waxed using xylene and 
rehydrated using 100% and 95% ethanol. Heat-mediated antigen retrieval was 
performed by incubating the sections in 10 mM Citrate buffer, pH 6 at 100°C for 10 
min. Endogenous peroxidase activity was blocked with 3% (aq) hydrogen peroxide for 
10 min. Nonspecific binding of the antibody was prevented by incubating slides with 
blocking solution (phosphate buffered saline containing 0.5% Tween 20, 1% bovine 
serum albumin and 3% of Seablock blocking buffer (EastCoast Bio, North Berwick, 
USA) for 20 min. Slides were incubated with primary antibodies (Table 4.1) diluted at 
1:200 in blocking solution for 1h at room temperature. Goat anti-mouse or goat anti-
rabbit secondary antibody (DAKO, Glostrup, Denmark) diluted at 1:800 in blocking 
solution was applied to the slides, and peroxidase was visualized with diamino 
benzidine (DAKO, Glostrup, Denmark). Sections were counterstained using 
hematoxylin (Carazzi’s) for 1min before dehydrating in 95% and 100% ethanol, 
clearing in xylene, and mounting using Hystomount (TAAB Labs, Aldermaston, UK). 
Negative controls were performed using isotype controls or omission of the primary 
antibodies. 
Whole slide images were scanned in a Scanscope® scanner (Aperio Technologies 
Incorporated, Vista, USA). Positive Pixel Count Algorithm of the ImageScope software 
(Aperio Technologies Incorporated, Vista, USA), was used to quantify the positive 
signal in whole kidney. Detection thresholds were manually set in order to obtain the 
best signal/noise ratio for NaPi-IIa. The percentage of positive staining (relative 
stained area) was calculated as the sum of all stained pixels divided by the sum of all 
stained and unstained pixels. 
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Table 4.1: Antibodies used for immunohistochemistry  
Protein Supplier/Code Raised in 
CaSR Thermo / MA1-934 Mouse 
Klotho Alpha Diagnostic / KL11-A Rabbit 
NaPi-IIa Alpha Diagnostic / NPT27-A Rabbit 
PMCA Santa Cruz / sc-20028 Mouse 
TRPV5 Alomone / ACC-035 Rabbit 
VDR Santa Cruz / sc-13133 Mouse 
 
4.2.4 ATP assay 
Kidney slices were cultured for 1h, 1d or 3d, snap frozen in liquid nitrogen and stored 
at -80 C. On the day of the assay, slices were removed from the -80ºC, weighted and 
a previously described phenolic extraction method (Chida et al. 2012) was used to 
extract ATP. The phenolic extracts were quantified using a luminescent ATP 
determination kit (Life Technologies, Carlsbad, USA), according to the manufacturer’s 
instructions. 
4.2.5 Phosphate response assay 
After slicing, kidney slices were acclimatized at 37°C for 1h in DMEM/F12 medium 
(Life Technologies, Carlsbad, USA), supplemented with 10% fetal bovine serum (GE 
Healthcare, Little Chalfont, UK) and 2% penicillin/streptomycin (Life Technologies, 
Carlsbad, USA). After 1h, slices were transferred into DMEM medium containing no 
Pi (Life Technologies, Carlsbad, USA), supplemented with 10% fetal bovine serum 
(GE Healthcare, Little Chalfont, UK), 2% penicillin/streptomycin (Life Technologies, 
Carlsbad, USA) and either 0 or 2 mM sodium phosphate. After 4h slices were fixed in 
10% neutrally buffered formalin for 1h and embedded in paraffin. Response to 
phosphate was assessed by analysing NaPi-IIa expression by IHC as described 
above. 
4.2.6 ERK inhibition assay 
After slicing, kidney slices were acclimatized at 37°C for 1h in DMEM/F12 medium 
(Life Technologies, Carlsbad, USA), supplemented with 10% fetal bovine serum (GE 
Healthcare, Little Chalfont, UK) and 2% penicillin/streptomycin (Life Technologies, 
Carlsbad, USA). After 1h, slices were transferred into DMEM/F12 medium containing 
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no serum and were incubated for 1h in a thermal block at 37°C. After 1h, the MEK 
inhibitor U0126 (Sigma, St Louis, USA) was added at a concentration of 0 or 15 nM, 
along with 50 ng/mL of epidermal growth factor (Lonza, Basel, Switzerland), used to 
induce ERK activation. After 10 min slices were snap frozen with liquid nitrogen. ERK 
inhibition was then analysed by Western blotting as described above. 
4.2.7 Statistics 
All data shown represents mean ± standard error of the mean. Statistical analysis was 
carried out with Microsoft Office Excel (Microsoft, Redmond, USA) using the Real 
Statistics Resource Pack. A two-tailed, Mann Whitney U test was employed and p 
values lower that 0.05 were considered to be significant. 
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4.3 Results 
4.3.1 Morphology and viability of cultured kidney slices 
By H&E (Figure 4.1 A-D), no differences in morphology were observed in control 
kidney and in slices cultured for 1h. The morphology was mostly preserved in slices 
cultured for 1d, however there was some evidence of tissue damage including nuclear 
pleomorphism, vacuolation and loss of PT brush border. Tissue damage was 
increased in slices cultured for 3d, which showed evidences of tubular necrosis 
including homogeneous eosinophilic cytoplasm and absence of nuclei. 
The cellular ATP levels (Figure 4.2) measured in kidney slices cultured for 1h (50.36 
± 5.09 nmol ATP/mg wet weight) were comparable to the ATP levels previously 
reported for freshly cut kidney tissue (53.85 ± 3.34 nmol ATP/mg wet weight) 
(Jaramillo-Juárez et al. 2005). The ATP values remained unchanged in slices cultured 
for 1d and reduced by 98% in slices cultured for 3d. These data suggests that kidney 
slices are viable up to 1d in culture. 
 
Kidney slices cultured for 1h show a similar morphology as control kidney tissue. 
Conversely, tissue damage is evident in slices cultured for >1d.  
ATP contents were similar in slices cultured for 1h and 1d, but strongly reduced in 
slices cultured for 3d, suggesting that kidney slices are viable up to 1d in culture. 
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Figure 4.1: Morphology of rat kidney slices cultured for 1h, 1d and 3d. 
Photomicrographs of hematoxylin and eosin staining in sections from control rat kidney 
(A) and kidney slices cultured for 1h (B), 1d (C) and 3d (D). Data representative of N 
= 3 rats. Scale bar = 100 µm. 
 
 
Figure 4.2: Viability of rat kidney slices cultured for 1h, 1d and 3d. Viability 
analysed by assessing the ATP contents of kidney slices cultured for 1h, 1d and 3d 
(E). Negative control for viability performed by incubating the kidney slices for 1h with 
1% Triton X. Data representative of N = 3 rats + SEM. * p<0.05 vs slices incubated for 
1h (Mann-Whitney test). 
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4.3.2 Kidney slices cultured for up to 3 days express CaSR, Klotho, NaPi-IIa, 
TRPV5, calbindin-D28k and PMCA. 
A problem that may be associated with ex vivo models is the de-differentiation of 
cells and loss of expression of cell type specific proteins. In order to confirm that the 
expression of key proteins for mineral homeostasis is not lost in cultured kidney 
slices, the expression of CaSR (Figure 4.3 A,D,G,J), Klotho (Figure 4.3 B,E,H,K), 
NaPi-IIa (Figure 4.3 C,F,I,L), TRPV5 (Figure 4.4 A,D,G,J), calbindin-D28k (Figure 
4.4 B,E,H,K) and PMCA (Figure 4.4 C,F,I,L) was analysed by IHC in slices cultured 
for 1h, 1d and 3d and compared to the expression of these proteins in control kidney 
tissue. No changes in protein distribution were observed between control kidney and 
slices cultured for 1h and 1d for all proteins. Moreover, all the analysed proteins 
were still expressed in slices cultured for 3d, however it was difficult to assess if the 
protein distribution is similar due to the poor morphology observed at these time 
points. 
 
Expression of key proteins for mineral homeostasis is maintained in kidney slices 
cultured up to 3 days. 
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Figure 4.3: Expression of CaSR, Klotho and NaPi-IIa in rat kidney slices cultured 
for 1h, 1d and 3d.  High magnification photographs of CaSR (A,D,G,J), Klotho 
(B,E,H,K) and NaPi-IIa (C,F,I,L) in sections from control rat kidney (A-C) and kidney 
slices cultured for 1h (D-F), 1d (G-I) and 3d (J-L). Data representative of N = 3. Scale 
bar = 100 µm. 
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Figure 4.4: Expression of TRPV5, calbindin-D28k and PMCA in rat kidney slices 
cultured for 1h, 1d and 3d.  Photomicrographs of TRPV5 (A,D,G,J), calbindin-D28k 
(B,E,H,K) and PMCA (C,F,I,L) in sections from control rat kidney (A-C) and kidney 
slices cultured for 1h (D-F), 1d (G-I) and 3d (J-L). Data representative of N = 3 rats. 
Scale bar = 100 µm. 
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4.3.3 Kidney slices retain functional characteristics of the kidney tissue 
The functionality of the cultured kidney slices was analysed through the assessment 
of responses to known physiological stimuli. Namely, the expression of NaPi-IIa was 
assessed by IHC in kidney slices incubated for 4h in media containing 0 mM or 2 mM 
of Pi (Figure 49). A 24% increase in NaPi-IIa expression was observed in slices 
incubated with 0 mM Pi versus 2 mM Pi. Also, the phosphorylation and expression of 
ERK were analysed by Western blotting in kidney slices incubated for 20 min with 50 
ng/mL EGF and 0 nM or 15 nM of the MEK inhibitor U0126 (Figure 50). ERK 
phosphorylation was strongly decreased in slices treated with U0126, whilst total ERK 
expression remained unchanged. These results show that this kidney slice model 
retains functional responses to extracellular Pi changes and MEK inhibition. 
 
Expression of NaPi-IIa in cultured kidney slices was modulated by the levels of Pi in 
the medium. 
Inhibition of MEK resulted in a reduction of EGF-induced ERK phosphorylation, but 
not total ERK expression in cultured kidney slices. 
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Figure 4.5: Functional characterization of rat kidney slices – response to Pi. 
Photomicrographs of NaPi-IIa immunostaining in sections of rat kidney slices 
incubated for 4h in culture media containing 0 mM (A) or 2 mM (B) of Pi. Positive signal 
in immunohistochemistry corresponds to the brown staining. Histogram represent the 
quantification of NaPi-IIa expression (immunohistochemically stained area) in animals 
from the study S1 (C). Data representative of N = 4 rats + SEM. * p<0.05 (Mann-
Whitney test). Scale bar = 100 µm. 
 
 
Figure 4.6: Functional characterization of rat kidney slices – response to a MEK 
inhibitor.  Western blotting to assess the expression of phospho-ERK (p-ERK) and 
total ERK in rat kidney sections incubated for 20m with 50ng/mL of EGF in the 
presence or absence of 15 nM of the MEK inhibitor U0126. Data representative of N 
= 3 rats. 
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4.4 Discussion 
 
The results from Chapter 3 show that MEK/ERK or FGFR inhibition affect the renal 
expression of genes/proteins involved in processes that contribute to mineral ion 
homeostasis, such as production of 1,25D3 and Ca2+ reabsorption. Since these 
processes take place in different nephron segments, the ex vivo study of the effects 
of MEK/ERK or FGFR inhibition at the organ level requires the use of models that 
preserve the identity and function of the cells from each of the nephron segments. 
Kidney slices were previously shown to retain renal cell architecture and kidney-
specific characteristics after a few days in culture (Vickers et al. 2004). Hence, I 
decided to evaluate the suitability of using kidney slice cultures as a model to study 
processes associated with Ca2+ and Pi homeostasis. If deemed a suitable model, I 
aimed to use kidney slice cultures to assess the process of mineralization induced by 
MEKi and FGFRi. The initial experiments that I intended to carry out using the kidney 
slice cultures are described in Chapter 5.3 / Table 5.5. 
In this study, kidney slices cultured up to 1d were viable and showed similar features 
as control kidney tissue including cellular morphology and expression of six key 
proteins for mineral homeostasis (TRPV5, calbindin-D28k, PMCA, NaPi-IIa, CaSR 
and Klotho). Besides, the kidney slices retained functional aspects of the kidney 
including responses to extracellular Pi and to MEK inhibition. These findings suggest 
that the kidney slice cultures assessed in this study are a suitable model for short-term 
(<1d) studies of Ca2+ and Pi homeostasis. Consistent with this observation, a previous 
study has shown that uncultured kidney slices show a decrease in Pi reabsorption 
following a 30-min incubation with FGF23 and/or PTH (Weinman et al. 2011). Although 
kidney slice cultures have not been commonly used for studies of mineral 
homeostasis, these have been widely used to study other topics including drug 
efficacy (Poosti et al. 2015) and drug toxicity (Vickers et al. 2004). A limitation of the 
kidney slice culture model analysed in this study is the large decrease in viability and 
pronounced tissue damage observed in slices cultured for 3d, which deems the model 
unsuitable for studies longer than 1d. Considering that most of the renal effects of 
MEKi and FGFRi in vivo, including soft-tissue mineralization, were only observed 
following treatments longer that 1d, this model may not be suitable to study the 
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biological effects induced by the treatment with these inhibitors. The quality and 
survival of tissue slices is depends on three main factors: slice thickness (Parrish et 
al. 1995), which should be low in order to allow the exchange of nutrients and oxygen; 
culture media (Obatomi et al. 1998), which should contain a suitable chemical and 
nutrient composition; and culture conditions, which should provide an adequate 
exposure of the slices to culture media and to oxygen (Toutain et al. 1998). The 
thickness of the slices (200 μm) and the culture media (DMEM/F12) used in this study 
were previously reported to be suitable for kidney slice culture (Obatomi et al. 1998). 
Nevertheless, the culture conditions (static multi-well plate) used in this study may 
have not been the most suitable for the proper aeration of the kidney slices, which 
possibly contributed to a rapid loss of viability. Previous studies have shown that 
kidney slices can be cultured up to at least 5 days by using a dynamic culture method 
(Parrish et al. 1995). This method consists of loading the kidney slices into titanium 
inserts, which are placed inside vials containing a small volume of culture media. Then, 
the vials are incubated in a rotator in order to alternately expose the slices to oxygen 
and culture media. Further studies should address if the kidney slices cultured for 5d 
with the dynamic culture method are a suitable model for studies of Ca2+ and Pi 
homeostasis. During the assessment of the maximum tolerated dose that preceded 
the studies presented in Chapter 3, soft-tissue mineralization and increased plasma 
Pi were observed in rats treated with MEKi for 3d or FGFRi for 2d (data not shown). 
Hence, by increasing the viability of the slices to 5 days with the use of a culture 
method such as dynamic culture method, kidney slice cultures may become a suitable 
model to assess the mineralization induced by MEKi and FGFRi.  
  
153 
 
4.5 Conclusions 
In summary, kidney slices cultured up to 1d retain key features of kidney tissue 
including cellular morphology, expression of key proteins for mineral homeostasis and 
functionality. Conversely, slices incubated for longer than 1d show pronounced tissue 
damage and severely decreased viability. These results suggest that the kidney slices 
are usable for studies of mineral ion homeostasis only up to 1d. This limitation deems 
this model unsuitable to study the mechanisms of mineralization induced by treatment 
with ERKi, MEKi and FGFRi.  
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5 Key findings and future directions 
 
Over the course of this thesis I have assessed the renal mechanisms of soft-tissue 
mineralization induced by the inhibition of the MEK/ERK pathway or the inhibition of 
FGF receptors. Below, I describe the key findings of each chapter and suggest 
experiments that would clarify or further explore some of the aspects associated with 
these mechanisms. 
 
5.1 Intra-renal distribution and role of the CaSR in the mineralization 
induced by inhibition of MEK/ERK pathway and FGF receptors 
I set out to assess the role of the renal CaSR in the mineralization induced by 
MEK/ERK or FGFR inhibition, since this receptor has been previously described to 
regulate key processes for mineral ion homeostasis including 1,25D3 production 
(Bland et al. 2002) and Ca2+ (Loupy et al. 2012) and Pi (Ba et al. 2003) reabsorption. 
Since the intra-renal distribution of the CaSR is a controversial topic, I first analysed 
the renal expression of this receptor using ISH, IHC and PLA techniques. The CaSR 
was detected throughout the nephron including the glomerulus, PT, TAL, DCT, CNT 
and CD segments. This distribution supports previous roles reported for the CaSR in 
different processes associated with mineral homeostasis including 1,25D3 production  
and Pi reabsorption in the PT (Bland et al. 2002, Ba and Friedman 2004), calcium 
reabsorption  in the TAL (Loupy et al. 2012) and DCT (Topala et al. 2009) and acid 
secretion in the CD (Renkema et al. 2009). Moreover, the clarification of the renal 
CaSR expression pattern allows further physiological roles to be determined in the 
kidney. A straightforward way of studying such roles is the assessment of the 
phenotype of nephron segment specific CaSR knockout mice models. 
Having the CaSR intra-renal distribution clarified, I analysed the effects of the 
administration of a MEK 1/2 inhibitor (MEKi) or an FGFR 1-3 inhibitor (FGFRi) to rats 
on the occurrence of soft-tissue mineralization, plasma levels of Ca2+and Pi in the 
renal expression of the CaSR. Both inhibitors induced an increase in plasma Pi and 
the occurrence of soft-tissue mineralization of different organs including kidney, 
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stomach and heart. Conversely, none of the inhibitors had any effect in plasma levels 
of Ca2+ or in the expression or cellular distribution of the CaSR. Although these results 
may suggest that the renal CaSR is not a key protein for the soft-tissue mineralization 
induced by MEKi or FGFRi, this conclusion cannot be drawn without assessing the 
effect of these inhibitors in the activation and downstream signalling of the CaSR.  
 
5.2 Effects of the inhibition of the MEK/ERK pathway or the FGF 
receptors in mineral homeostasis and soft-tissue mineralization 
Further analysis carried out in rats treated with ERKi, MEKi and FGFRi have shown 
that acute (6h) and repeated (>3/8d) dosing with these compounds resulted in different 
biological effects. Acute dosing with the ERKi and FGFRi resulted in the following 
effects:  
- Decrease in plasma FGF23;  
- Upregulation of Cyp27b1 and a downregulation of Cyp24a1 in the kidney, which 
are consistent with an increase in the production of 1,25D3;  
- Shift in NaPi-IIa expression from cytoplasmic vesicles to the brush border 
membrane. 
Conversely, following repeated dosing, ERKi/MEKi and FGFRi induced the following 
effects:  
- Increase in plasma Pi 
- Increase in plasma FGF23; 
- Attenuation of the expression changes in Cyp27b1 and Cyp24a1; 
- Alteration of the NaPi-IIa expression pattern in the kidney: decreased NaPiIIa 
expression in the outer kidney cortex in animals treated with ERKi (3d) or FGFRi (8d); 
increased NaPiIIa expression in the  inner cortex in animals treated with MEKi (28d);  
- Increase in the renal expression of TRPV5, calbindin-D28k and PMCA, 
consistent with an increased reabsorption of Ca2+ in the DCT;  
- Increase in the renal expression of the mineralization inducer alkaline 
phosphatase;  
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- Increase in the renal expression of osteopontin and plasma expression of 
DKK1, osteoprotegerin and sclerostin, which are mineralization inhibitors normally 
expressed in mineralized tissue.  
Most of the effects observed following >3/8d treatment with the inhibitors are 
consistent with the toxicity of 1,25D3. Unfortunately, it was not possible to accurately 
quantify 1,25D3 in animals treated with ERKi, MEKi and FGFRi. This impediment is 
associated with the fact that the assays available for 1,25D3 attain a low sensitivity 
which would not allow an accurate quantification of this hormone in the samples from 
this study (N = 3-6 animals per group). The number of animals used in this study was 
selected by carrying out power analysis for different parameters including soft-tissue 
mineralization and serum levels of Pi and FGF23 but not serum levels of 1,25D3. A 
power analysis estimated that a much larger number of animals than what was used 
in this study (N > 22 per group) would be needed to obtain significance from the 1,25D3 
quantification. Also due to the low sensitivity of the assay and/or inadequate sample 
processing, it was not possible to accurately quantify PTH in animals from this study. 
PTH may be involved in the process of mineralization induced by ERKi, MEKi and 
FGFRi since it is a key hormone for mineral homeostasis, susceptible to regulation by 
FGF23 and 1,25D3. The plasma levels of 1,25D3 and PTH should be addressed in 
future studies by developing better assays to quantify these hormones or by carrying 
out in vivo studies using a larger number of animals.  
Other limitations of this study include problems with the licensing of MEKi, which 
precluded the performance of studies comprising the acute administration of this 
compound; and the impossibility of analysing urinary function and urinary Ca2+ and Pi 
levels, since the experimental design used in this study was not compatible with the 
collection of urine using metabolic cages due to the home office license regulations. 
The acute effects of MEK inhibition should be addressed in further studies using MEKi, 
in case the licensing problems with this compound are solved, or alternatively in 
studies using a commercially available MEK inhibitor. Also, future studies should 
comprise the collection of urine to assess urinary function and urinary Ca2+ and Pi 
levels. Table 5.1 summarizes the limitations of this study. 
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Table 5.1: Limitations of the in vivo studies with ERKi, MEKi and FGFRi. 
Parameter Comment 
Plasma 1,25D3 
Assay used attained low sensitivity. Only 
tested in animals treated with MEKi 
Plasma PTH 
Assay used attained low sensitivity. Only 
tested in animals treated with MEKi and 
FGFRi 
Urinary function  
Assay not carried out because urine could 
not be collected 
Urine Ca2+ 
Assay not carried out because urine could 
not be collected 
Urine Pi 
Assay not carried out because urine could 
not be collected 
FGFR pathway activation 
Different phospho-FGFR and phospho-FRS2 
assays were tested, however these did not 
allow a sensitive detection of their intended 
targets 
MEKi 
experiments 
6h treatment 
The licensing of MEKi did not allow to carry 
out the study 
Cyp27b1 / 
Cyp24a1 
No frozen tissue samples were available to 
carry out mRNA extractions 
Sclerostin 
No plasma samples were available to 
perform these assays 
Osteoprotegerin 
DKK1 
 
In order to assess which nephron segments could be directly affected by the treatment 
with ERKi, MEKi or FGFRi, the intra-renal distributions of their targets ERK, MEK and 
FGFRs 1-4 were assessed in control rat kidney. The expression of these proteins was 
detected throughout the nephron including the PT, DT and CD (not FGFR4) segments. 
These findings are consistent with ERKi, MEKi and FGFRi regulating renal processes 
such as 1,25D3 production and Pi reabsorption by analogous mechanisms involving 
the inhibition of FGF23 signalling at the MEK/ERK pathway or at the FGFRs level.  
The administration of ERKi and MEKi to rats resulted in the inhibition of ERK signalling 
in the kidney, thus confirming the intended inhibitory effects of both inhibitors. 
Conversely, ERK activation was unaffected in rats treated with FGFRi. Since the 
MEK/ERK pathway is activated by different receptors, it is possible that FGFRi is able 
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to inhibit the FGFR-induced ERK activation, whilst having little effect on the overall 
activation of this pathway. An RPPA assay was carried out to identify cell signalling 
pathways affected by the administration of ERKi and FGFRi that might contribute to 
the occurrence of soft-tissue mineralization. With the exception of phospho-ERK 
upregulation by ERKi, the proteins analysed by the RPPA assay only showed small 
expression changes (<40% expression) in animals treated with ERKi or FGFRi, which 
suggests that the key pathways leading to soft-tissue mineralization were not identified 
by this assay. Since the experiments carried out in this study did not show any strong 
evidence that FGFRi directly targets the kidney, I aimed to analyse the activation of 
FGFR pathway. As no methods to detect FGFR activation in rat kidney had been 
described, I assessed the suitability of carrying out IHC or Western blotting using two 
different phospho-FGFR and a phospho-FRS antibodies for this purpose. 
Unfortunately, none of these methods allowed a sensitive detection of the intended 
targets. This issue should be addressed in further studies. 
Table 5.2, Table 5.3 and Table 5.4 show key future studies that can be performed to 
further the understanding of the mechanisms of mineralization induced by ERKi, MEKi 
or FGFRi. These include the confirmation of the role of 1,25D3, Ca2+ reabsorption and 
alkaline phosphatase in the mechanism of soft-tissue mineralization; the identification 
of the origin of the increased plasma Pi; and the assessment of the roles of FGF23 
and bone hormonal production in the mechanisms of soft-tissue mineralization. 
Table 5.2: Future experiments using in vivo studies to further unravel the 
mechanisms of mineralization induced by ERKi, MEKi or FGFRi - 1 
Parameter Rationale / Assays 
Origin of 
increased 
Pi 
Rationale – The results obtained in this study show that Pi is increased in animals 
treated with ERKi, MEKi or FGFRi. Since NaPi-IIa was not markedly upregulated in 
animals treated with these inhibitors, the increase in Pi is likely induced by increased 
expression of other Pi transport proteins in kidney or intestine, by increased Pi 
resorption from bone or by a decrease in urinary function. 
Assay - Dose animals with ERKi, MEKi or FGFRi and analyse the following 
parameters: 
Bone resorption - Analyse serum markers of bone resorption (eg. carboxy-terminal 
collagen crosslinks, CTX (Rosen et al. 2000)) and analyse bone expression of 
proteins involved in the resorption process 
Intestinal absorption - Analyse the expression of the type IIb sodium-phosphate co-
transporter (NaPi-IIb) in the intestine and the Pi content in the faeces 
Renal reabsorption - Analyse the renal expression of NaPi-IIc and Pit2 and the levels 
of Pi in the urine 
Urinary function – Analyse creatinine clearance  
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Table 5.3: Future experiments using in vivo studies to further unravel the 
mechanisms of mineralization induced by ERKi, MEKi or FGFRi - 2 
Parameter Rationale / Assays 
Role of 
1,25D3 
Rationale – The results obtained in this study suggest that an increase in 1,25D3 is 
the factor that drives the mineral homeostasis perturbations and soft-tissue 
mineralization in animals treated with ERKi, MEKi and FGFRi. If this holds true, the 
inhibition of 1,25D3 production or the inhibition of its genomic actions of should 
prevent these effects 
Assay - Dose animals with ERKi, MEKi or FGFRi in combination with an inhibitor of 
Cyp27b1 such as SDZ88-357 (Lou et al. 2010) or an inhibitor of VDR such as 
PS121912 (Sidhu et al. 2014) and assess the following parameters: 
Mineralization - Assess mineralization by von Kossa assay 
Pi and Ca2+- Assess plasma levels of Pi and Ca2+ and assess the expression of 
proteins involved in the renal reabsorption of these ions 
FGF23 - Assess the plasma levels of FGF23 
Alkaline phosphatase - Assess protein expression of alkaline phosphatase in 
kidney. 
Role of renal 
Ca2+ 
reabsorption 
Rationale – The results obtained in this study suggest that renal Ca2+ reabsorption 
is increased in the DCT of rats treated with MEKi or FGFRi, which leads to a high 
local Ca2+xPi product that favours the occurrence of renal soft-tissue mineralization. 
If this holds true, soft-tissue mineralization should be prevented by the 
administration of an inhibitor of TRPV5 such as ruthenium red (Nilius et al. 2001). 
Assay - Dose animals with ERKi, MEKi or FGFRi in combination with an inhibitor of 
TRPV5 and assess the following parameters: 
Mineralization - Assess mineralization by von Kossa assay 
Pi and Ca2+- Assess plasma levels of Pi and Ca2+ and assess the expression of 
proteins involved in the renal reabsorption of these ions 
Role of 
alkaline 
phosphatase 
Rationale – The results obtained in this study suggest that alkaline phosphatase 
expression is increased in kidneys of rats treated with ERKi, MEKi or FGFRi, 
favouring the occurrence of renal soft-tissue mineralization. If this holds true, soft-
tissue mineralization should be prevented by the administration of an alkaline 
phosphatase inhibitor such as SBI-425 (Sheen et al. 2015).   
Assay - Dose animals with ERKi, MEKi or FGFRi in combination with an alkaline 
phosphatase inhibitor and assess the following parameters: 
Mineralization - Assess mineralization by von Kossa assay. 
Pi and Ca2+- Assess plasma levels of Pi and Ca2+ and assess the expression of 
proteins involved in the renal reabsorption of these ions 
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Table 5.4: Future experiments using in vivo studies to further unravel the 
mechanisms of mineralization induced by ERKi, MEKi or FGFRi - 3 
Parameter Rationale / Assays 
Role of 
FGF23 
Rationale – The results from this study suggest that the increased production of 
1,25D3, mineral homeostasis perturbations and soft-tissue mineralization observed in 
animals treated with ERKi, MEKi and FGFRi are consequences of the inhibition of 
FGF23 signalling. If this holds true, treatment with an FGF23-neutralizing antibody 
alone should result in similar biological effects. Besides, the results from this study 
indicate that the plasma levels of FGF23 increase following >4d treatment with 
MEKi/FGFRi. The administration of ERKi, MEKi or ERKi in combination with an 
FGF23 neutralizing antibody aims to assess if the increase in FGF23 plays any role in 
the occurrence of soft-tissue mineralization. 
Assay - Dose animals with an FGF23 neutralizing antibody alone in combination with 
ERKi, MEKi and FGFRi and analyse the following parameters: 
ERK activation – Assess the phosphorylation of ERK in the kidney 
Mineralization - Assess mineralization by von Kossa assay 
Pi and Ca2+- Assess plasma levels of Pi and Ca2+ and assess the expression of 
proteins involved in the renal reabsorption of these ions 
FGF23 - Assess the plasma levels of FGF23 
Alkaline phosphatase - Assess protein expression of alkaline phosphatase in kidney 
Bone 
effects 
Rationale – The results from this study suggest that treatment with ERKi for >8d 
increased the plasma levels of different bone proteins including FGF23, DKK1, 
sclerostin and osteoprotegerin. FGF23 is a key protein for mineral homeostasis, 
DKK1 and sclerostin are inhibitors of Wnt signalling pathway and osteoprotegerin is a 
key protein for bone resorption. In addition to bone, these four proteins were 
previously detected in soft-tissue calcified under pathological conditions (Ueland et al. 
2009, van Venrooij et al. 2014). Previous studies have reported a crosstalk between 
FGF23 and Wnt signalling (Farrow et al. 2010), and also roles for both pathways in 
the process of bone resorption (Sapir-Koren and Livshits 2014). This study aims to 
assess if the increased expression of the proteins involved in FGF23, Wnt and 
RANK/osteoprotegerin signalling is originated from bone or from calcifying soft-tissue. 
Also, it aims to assess if bone resorption contributes to the soft-tissue mineralization 
induced by ERKi, MEKi or FGFRi. 
Assay - Dose animals with ERKi, MEKi or FGFRi and analyse the following 
parameters: 
FGF23 - Assess plasma levels and expression in bone and calcifying tissue 
Sclerostin - Assess plasma levels and expression in bone and calcifying tissue 
DKK1 - Assess plasma levels and expression in bone and calcifying tissue 
RANKL - Assess plasma levels and expression in bone and calcifying tissue 
Osteoprotegerin -  Assess plasma levels and expression in bone and calcifying tissue 
Beta-catenin - Assess expression in bone and calcifying tissue 
Bone resorption markers- Analyse serum markers of bone resorption (as described 
above) 
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5.3 Evaluation of an ex vivo kidney tissue slice model 
I evaluated the suitability of using kidney slice cultures to study the soft-tissue 
mineralization induced by MEK/ERK or FGFR inhibition, since the kidney in vitro 
models described in the literature encompass limitations that preclude an accurate 
assessment of some of the key processes associated with mineral ion homeostasis. 
Kidney slices cultured for <1d retained key features of kidney tissue including cellular 
morphology, expression of key proteins for mineral homeostasis and functionality, 
whilst slices cultured for >1d showed pronounced tissue damage and severely 
decreased viability. These results suggest that the kidney slice cultures may be a 
suitable model for studies of mineral ion homeostasis lasting only up to 1d, which might 
not be sufficient to study some of the biological effects induced by ERKi, MEKi and 
FGFRi including soft-tissue mineralization. Previous studies have shown that by using 
a dynamic culture method, kidney slices remain viable up to at least 5d in culture 
(Parrish et al. 1995). Further studies should assess if kidney slices cultured with the 
dynamic culture method are a suitable model for longer term (5-7d) studies of mineral 
ion homeostasis. If deemed a suitable model, the kidney slices should be used to 
further investigate the mechanism of mineralization induced by ERKi, MEKi or FGFRi. 
The initial experiments planned using the kidney slices are described in Table 5.5. 
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Table 5.5: Future experiments using kidney slice cultures to further unravel the 
mechanisms of mineralization induced by ERKi, MEKi or FGFRi 
Parameter Experimental aims 
Model 
validation 
Assess if kidney slices cultured with the dynamic culture method 
retain high viability and characteristics of kidney cells (eg. 
expression of proteins involved in mineral ion homeostasis and 
functionality) for 5-7d. 
Target 
inhibition 
Assess if treatment with ERKi, MEKi or FGFRi results in the 
inhibition of the MEK/ERK pathway. 
Assess if treatment with FGFRi results in the inhibition of FGFR 
signalling. 
Mineralization 
Assess if treatment with ERKi, MEKi or FGFRi results in 
mineralization ex vivo. 
Ca2+ and Pi 
reabsorption 
Assess if the expression of the proteins involved in the 
reabsorption of Ca2+ and Pi is affected by the treatment with ERKi, 
MEKi or FGFRi. 
Assess if the inhibition of the uptake of Ca2+ with a drug such as 
ruthenium red (Nilius et al. 2001) or Pi with a drug such as 
phosphonoformic acid (Brooks et al. 1997) prevents the 
occurrence of soft-tissue mineralization induced by ERKi, MEKi or 
FGFRi. 
1,25D3 
production 
Assess if the production of 1,25D3 is affected treatment with ERKi, 
MEKi or FGFRi. 
Assess if it is possible to prevent the mineralization induced by 
ERKi, MEKi or FGFRi through the inhibition of Cyp27b1 with a 
drug such as SDZ88-357 (Lou et al. 2010) . 
Pro-calcifying 
proteins 
Assess if the expression of alkaline phosphatase and/or other pro-
calcifying proteins is affected by the treatment with ERKi, MEKi or 
FGFRi. 
Assess if it possible to prevent the mineralization induced by with 
ERKi, MEKi or FGFRi by inhibiting the activity of alkaline 
phosphatase with a drug such as such as SBI-425 (Sheen et al. 
2015). 
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7 Appendix 
The tables presented in this appendix contain the raw data for the experiments 
presented in this thesis. 
 
Table 7.1: Image analysis of CaSR IHC carried out in sections from rats treated 
with 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or the respective vehicles. 
Group Study Time point N IHC positivity (%) P 
Vehicle 4 28d 10 3.58 ± 0.29 - 
MEKi 4 28d 10 2.91 ± 0.22 0.15 
Vehicle 4 25d 7 3.72 ± 0.26 - 
FGFRi 4 25d 6 3.38 ± 0.08 0.20 
 
Table 7.2: Plasma drug concentrations during a 12h period following the 
administration of 150 mg/kg of ERKi, 1.4 mg/kg of MEKi or 10 mg/kg of FGFRi to 
rats by oral gavage. 
Group Study Time point N Drug concentration (μmol/L) 
ERKi 2 d1, 2h 6 155 ± 15 
ERKi 2 d1, 6h 6 111 ± 7 
ERKi 2 d1, 12h 6 53 ± 8 
MEKi 1 d1, 2h 6 1.17 ± 0.22 
MEKi 1 d1, 4h 6 0.39 ± 0.06 
MEKi 1 d1, 6h 6 0.19 ± 0.01 
MEKi 1 d1, 12h 6 0.11 ± 0.01 
MEKi 1 d7, 2h 6 1.77 ± 0.37 
MEKi 1 d7, 4h 6 0.72 ± 0.17 
MEKi 1 d7, 6h 6 0.41 ± 0.08 
MEKi 1 d7, 12h 6 0.11 ± 0.03 
FGFRi 1 d1, 2h 6 2.94 ± 0.27 
FGFRi 1 d1, 4h 6 1.80 ± 0.33 
FGFRi 1 d1, 6h 6 0.76 ± 0.07 
FGFRi 1 d1, 12h 6 0.07 ± 0.03 
FGFRi 1 d7, 2h 6 2.00 ± 0.38 
FGFRi 1 d7, 4h 6 1.69 ± 0.37 
FGFRi 1 d7, 6h 6 1.32 ± 0.39 
FGFRi 1 d7, 12h 6 0.39 ± 0.11 
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Table 7.3: Plasma concentrations of Ca2+ in animals treated with 150 mg/kg/day 
of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day FGFRi or the respective vehicles.   
Group Study Time point N 
Plasma Ca2+ 
(mmol/L) 
P 
Vehicle 1 d1, 2h 3 2.75 ± 0.04 - 
MEKi 1 d1, 2h 6 2.79 ± 0.03 0.438 
FGFRi 1 d1, 2h 6 2.79 ± 0.01 0.366 
Vehicle 1 d1, 6h 3 2.75 ± 0.03 - 
MEKi 1 d1, 6h 6 2.69 ± 0.02 0.197 
FGFRi 1 d1, 6h 6 2.73 ± 0.04 0.519 
Vehicle 1 d1, 12h 3 2.59 ± 0.04 - 
MEKi 1 d1, 12h 6 2.52 ± 0.04 0.366 
FGFRi 1 d1, 12h 6 2.68 ± 0.02 0.071 
Vehicle 1 d7, 2h 3 2.80 ± 0.05 - 
MEKi 1 d7, 2h 6 2.88 ± 0.04 0.439 
FGFRi 1 d7, 2h 4 2.91 ± 0.02 0.077 
Vehicle 2 d1, 2h 6 2.84 ± 0.04 - 
ERKi 2 d1, 2h 6 2.62 ± 0.03 0.004 
FGFRi 2 d1, 2h 6 2.75 ± 0.02 0.045 
Vehicle 2 d1, 6h 6 2.76 ± 0.10 - 
ERKi 2 d1, 6h 5 2.70 ± 0.03 0.144 
FGFRi 2 d1, 6h 5 2.74 ± 0.02 0.200 
Vehicle 2 d1, 24h 6 2.83 ± 0.04 - 
ERKi 2 d1, 24h 6 2.79 ± 0.05 0.601 
FGFRi 2 d1, 24h 6 2.97 ± 0.01 0.036 
Vehicle 2 d4, 2h 6 2.70 ± 0.03 - 
ERKi 2 d4, 2h 6 3.00 ± 0.08 0.008 
FGFRi 2 d4, 2h 6 2.84 ± 0.03 0.02 
Vehicle 2 d7, 2h 5 2.64 ± 0.06 - 
FGFRi 2 d7, 2h 5 2.74 ± 0.08 0.465 
Vehicle 3 d1, 2h 6 2.87 ± 0.05 - 
ERKi 3 d1, 2h 6 2.70 ± 0.04 0.025 
FGFRi 3 d1, 2h 6 2.85 ± 0.03 0.872 
Vehicle 3 d1, 6h 5 2.80 ± 0.03 - 
ERKi 3 d1, 6h 6 2.80 ± 0.06 0.584 
FGFRi 3 d1, 6h 5 2.86 ± 0.02 0.143 
Vehicle 3 d1, 24h 6 2.84 ± 0.05 - 
ERKi 3 d1, 24h 6 2.69 ± 0.04 0.037 
FGFRi 3 d1, 24h 4 2.76 ± 0.03 0.241 
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Table 7.4: Plasma concentrations of Pi in animals treated with 150 mg/kg/day of 
ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day FGFRi or the respective vehicles.   
Group Study Time point N 
Plasma Pi 
(mmol/L) 
P 
Vehicle 1 d1, 2h 3 1.86 ± 0.09 - 
MEKi 1 d1, 2h 6 1.71 ± 0.14 0.438 
FGFRi 1 d1, 2h 6 1.81 ± 0.09 0.606 
Vehicle 1 d1, 6h 3 2.51 ± 0.14 - 
MEKi 1 d1, 6h 6 2.23 ± 0.19 0.302 
FGFRi 1 d1, 6h 6 2.38 ± 0.12 0.698 
Vehicle 1 d1, 12h 3 2.11 ± 0.09 - 
MEKi 1 d1, 12h 6 2.55 ± 0.10 0.028 
FGFRi 1 d1, 12h 6 2.41 ± 0.03 0.020 
Vehicle 1 d4, 2h 3 2.00 ± 0.04 - 
MEKi 1 d4, 2h 6 3.11 ± 0.04 0.020 
FGFRi 1 d4, 2h 6 3.18 ± 0.18 0.020 
Vehicle 1 d7, 2h 3 1.75 ± 0.04 - 
MEKi 1 d7, 2h 6 2.85 ± 0.12 0.020 
FGFRi 1 d7, 2h 5 2.71 ± 0.09 0.025 
Vehicle 2 d1, 2h 6 1.84 ± 0.05 - 
ERKi 2 d1, 2h 6 1.26 ± 0.06 0.004 
FGFRi 2 d1, 2h 6 1.38 ± 0.10 0.004 
Vehicle 2 d1, 6h 6 2.45 ± 0.09 - 
ERKi 2 d1, 6h 6 2.02 ± 0.09 0.006 
FGFRi 2 d1, 6h 6 2.19 ± 0.08 0.065 
Vehicle 2 d1, 24h 6 1.80 ± 0.06 - 
ERKi 2 d1, 24h 6 2.68 ± 0.09 0.004 
FGFRi 2 d1, 24h 6 2.11 ± 0.06 0.008 
Vehicle 2 d4, 2h 6 1.68 ± 0.11 - 
ERKi 2 d4, 2h 5 3.41 ± 0.16 0.006 
FGFRi 2 d4, 2h 6 3.59 ± 0.11 0.005 
Vehicle 2 d7, 2h 6 1.78 ± 0.10 - 
FGFRi 2 d7, 2h 6 3.07 ± 0.17 0.004 
Vehicle 3 d1, 2h 6 1.68 ± 0.09 - 
ERKi 3 d1, 2h 6 1.49 ± 0.12 0.262 
FGFRi 3 d1, 2h 6 1.54 ± 0.09 0.173 
Vehicle 3 d1, 6h 5 1.65 ± 0.14 - 
ERKi 3 d1, 6h 6 1.64 ± 0.22 0.361 
FGFRi 3 d1, 6h 5 1.59 ± 0.07 0.346 
Vehicle 3 d1, 24h 6 2.04 ± 0.13 - 
ERKi 3 d1, 24h 6 1.97 ± 0.14 0.810 
FGFRi 3 d1, 24h 4 2.00 ± 0.08 1.00 
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Table 7.5: Plasma concentrations of Mg2+ in animals treated with 150 mg/kg/day 
of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day FGFRi or the respective vehicles.   
Group Study Time point N 
Plasma Mg2+ 
(mmol/L) 
P 
Vehicle 1 d1, 2h 3 0.80 ± 0.04 - 
MEKi 1 d1, 2h 6 0.76 ± 0.03 0.301 
FGFRi 1 d1, 2h 6 0.72 ± 0.02 0.093 
Vehicle 1 d1, 6h 3 0.73 ± 0.04 - 
MEKi 1 d1, 6h 6 0.74 ± 0.03 0.897 
FGFRi 1 d1, 6h 6 0.75 ± 0.03 0.698 
Vehicle 1 d1, 12h 3 0.71 ± 0.01 - 
MEKi 1 d1, 12h 6 0.78 ± 0.04 0.366 
FGFRi 1 d1, 12h 6 0.79 ± 0.01 0.020 
Vehicle 1 d7, 2h 3 0.70 ± 0.03 - 
MEKi 1 d7, 2h 6 0.71 ± 0.02 0.060 
FGFRi 1 d7, 2h 4 0.79 ± 0.02 0.077 
Vehicle 2 d1, 2h 6 0.77 ± 0.01 - 
ERKi 2 d1, 2h 6 0.75 ± 0.03 0.078 
FGFRi 2 d1, 2h 6 0.72 ± 0.01 0.025 
Vehicle 2 d1, 6h 5 0.79 ± 0.01 - 
ERKi 2 d1, 6h 5 0.74 ± 0.04 0.210 
FGFRi 2 d1, 6h 5 0.75 ± 0.02 0.117 
Vehicle 2 d1, 24h 6 0.80 ± 0.02 - 
ERKi 2 d1, 24h 5 0.83 ± 0.04 0.201 
FGFRi 2 d1, 24h 6 0.82 ± 0.01 0.149 
Vehicle 2 d4, 2h 6 0.76 ± 0.01 - 
FGFRi 2 d4, 2h 6 0.80 ± 0.02 0.078 
Vehicle 2 d7, 2h 6 0.82 ± 0.02 - 
FGFRi 2 d7, 2h 5 0.81 ± 0.01 0.855 
Vehicle 3 d1, 2h 6 0.78 ± 0.01 - 
ERKi 3 d1, 2h 6 0.74 ± 0.01 0.055 
FGFRi 3 d1, 2h 6 0.79 ± 0.02 0.872 
Vehicle 3 d1, 6h 5 0.74 ± 0.01 - 
ERKi 3 d1, 6h 6 0.84 ± 0.06 0.273 
FGFRi 3 d1, 6h 5 0.77 ± 0.02 0.347 
Vehicle 3 d1, 24h 6 0.76 ± 0.02 - 
ERKi 3 d1, 24h 6 0.77 ± 0.06 0.173 
FGFRi 3 d1, 24h 4 0.78 ± 0.02 0.522 
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Table 7.6: Plasma concentrations of 1,25D3 in animals treated with 1.4 mg/kg/day 
of MEKi.   
Group Study Time point N Plasma 1,25D3 (pmol/L) P 
Vehicle 4 d5 5 154 ± 13 - 
MEKi 4 d5 5 216 ± 34 0.076 
Vehicle 4 d14 5 137 ± 11 - 
MEKi 4 d14 5 199 ± 44 0.531 
Vehicle 4 d28 5 115 ± 27 - 
MEKi 4 d28 5 63 ± 10 0.174 
 
Table 7.7: Cyp27b1 mRNA quantification by qPCR in samples from rats treated 
with 150 mg/kg/day of ERKi, 20 mg/kg/day of FGFRi or vehicle. 
Group Study Time point N 
Cyp27b1  
(relative mRNA 
expression) 
P 
Vehicle 3 6h 6 1.00 ± 0.13 - 
ERKi 3 6h 6 25.76 ± 9.33 0.004 
FGFRi 3 6h 6 9.72 ± 1.51 0.004 
Vehicle 2 d8 6 1.00 ± 0.21 - 
ERKi 2 d8 6 103.03 ± 21.66 0.004 
FGFRi 2 d8 6 2.47 ± 0.72 0.109 
 
Table 7.8: Cyp24a1 mRNA quantification by qPCR in samples from rats treated 
with 150 mg/kg/day of ERKi, 20 mg/kg/day of FGFRi or vehicle. 
Group Study Time point N 
Cyp24a1 
(relative mRNA 
expression) 
P 
Vehicle 3 6h 6 1.00 ± 0.24 - 
ERKi 3 6h 6 0.03 ± 0.02 0.004 
FGFRi 3 6h 6 0.05 ± 0.00 0.004 
Vehicle 2 d8 6 1.00 ± 0.41 - 
ERKi 2 d8 6 0.04 ± 0.02 0.006 
FGFRi 2 d8 6 0.55 ± 0.12 0.631 
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Table 7.9: VDR mRNA quantification by qPCR in samples from rats treated with 
150 mg/kg/day of ERKi, 20 mg/kg/day of FGFRi or vehicle. 
Group Study Time point N 
VDR  
(relative mRNA 
expression) 
P 
Vehicle 3 6h 6 1.00 ± 0.09 - 
ERKi 3 6h 6 0.65 ± 0.08 0.025 
FGFRi 3 6h 6 0.59 ± 0.08 0.006 
Vehicle 2 d8 6 1.00 ± 0.06 - 
ERKi 2 d8 6 0.60 ± 0.06 0.004 
FGFRi 2 d8 6 0.81 ± 0.03 0.016 
 
Table 7.10: Image analysis of VDR IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N IHC positivity (%) P 
Vehicle 1 8d 3 0.332 ± 0.103 - 
MEKi 1 8d 4 0.439 ± 0.087 0.470 
FGFRi 1 8d 6 0.161 ± 0.032 0.121 
Vehicle 2 8d 6 0.091 ± 0.019  - 
ERKi 2 3d 4 0.030 ± 0.008 0.033 
FGFRi 2 8d 3 0.094 ± 0.030 1.00 
Vehicle 3 6h 6 0.076 ± 0.006 - 
ERKi 3 6h 6 0.039 ± 0.005 0.004 
FGFRi 3 6h 6 0.038 ± 0.007 0.010 
Vehicle 4 28d 10 1.53 ± 0.12 - 
MEKi 4 28d 10 3.92 ± 0.35 <0.001 
Vehicle 4 25d 10 3.64 ± 0.53 - 
FGFRi 4 25d 10 5.21 ± 0.51 0.016 
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Table 7.11: Plasma concentrations of FGF23 in animals treated with 150 
mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day FGFRi or the 
respective vehicles.   
Group Study 
Time 
point 
N 
Plasma FGF23 
(pg/mL) 
P 
Vehicle 1 d1, 2h 3 306 ± 23 - 
MEKi 1 d1, 2h 5 245 ± 36 0.297 
FGFRi 1 d1, 2h 6 312 ± 25 0.897 
Vehicle 1 d1, 6h 3 319 ± 13 - 
MEKi 1 d1, 6h 6 76 ± 17 0.020 
FGFRi 1 d1, 6h 6 100 ± 12 0.020 
Vehicle 1 d1, 12h 3 435 ± 24 - 
MEKi 1 d1, 12h 5 121 ± 33 0.025 
FGFRi 1 d1, 12h 5 182 ± 28 0.025 
Vehicle 1 d7, 2h 3 427 ± 149 - 
MEKi 1 d7, 2h 3 5307 ± 479 0.049 
FGFRi 1 d7, 2h 4 2802 ± 215 0.033 
Vehicle 2 d1, 2h 6 476 ± 63 - 
ERKi 2 d1, 2h 6 250 ± 21 0.025 
FGFRi 2 d1, 2h 6 226 ± 52 0.025 
Vehicle 2 d1, 6h 4 464 ± 89 - 
ERKi 2 d1, 6h 5 153 ± 13 0.014 
FGFRi 2 d1, 6h 6 107 ± 28 0.010 
Vehicle 2 d1, 24h 6 462 ± 52 - 
ERKi 2 d1, 24h 6 222 ± 68 0.055 
FGFRi 2 d1, 24h 6 518 ± 58 0.378 
Vehicle 2 d4, 2h 6 388 ± 82 - 
ERKi 2 d4, 2h 6 142 ± 94 0.037 
FGFRi 2 d4, 2h 6 1823 ± 63 0.004 
Vehicle 2 d7, 2h 6 292 ± 48 - 
FGFRi 2 d7, 2h 6 2225 ± 291 0.004 
Vehicle 3 d1, 2h 6 332 ± 28 - 
ERKi 3 d1, 2h 6 203 ± 42 0.055 
FGFRi 3 d1, 2h 6 164 ± 12 0.004 
Vehicle 3 d1, 4h 6 304 ± 25 - 
ERKi 3 d1, 4h 5 138 ± 32 0.006 
FGFRi 3 d1, 4h 5 93 ± 8 0.006 
Vehicle 3 d1, 6h 6 294 ± 23 - 
ERKi 3 d1, 6h 6 108 ± 23 0.004 
FGFRi 3 d1, 6h 5 65 ± 11 0.006 
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Table 7.12: Plasma concentrations of PTH in animals treated with 150 mg/kg/day 
of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day FGFRi or the respective vehicles.   
Group Study 
Time 
point 
N Plasma PTH (pg/mL) P 
Vehicle 1 d8 3 606 ± 172 - 
MEKi 1 d8 6 523 ± 235 0.197 
FGFRi 1 d8 5 544 ± 208 0.881 
 
Table 7.13: Image analysis of phospho-ERK IHC carried out in sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of 
FGFRi or the respective vehicles. 
Group Study Time point N IHC positivity (%) P 
Vehicle 1 8d 3 1.716 ± 0.460 - 
MEKi 1 8d 4 0.133 ± 0.010 0.034 
FGFRi 1 8d 6 1.397 ± 0.155 0.605 
Vehicle 2 8d 6 0.142 ± 0.049 - 
ERKi 2 3d 4 2.239 ± 0.541 0.010 
FGFRi 2 8d 4 0.093 ± 0.015 1.000 
Vehicle 3 6h 6 0.046 ± 0.009 - 
ERKi 3 6h 6 0.708 ± 0.104 0.004 
FGFRi 3 6h 6 0.035 ± 0.008 0.200 
Vehicle 4 28d 10 0.243 ± 0.025 - 
MEKi 4 28d 10 0.093 ± 0.016 <0.001 
Vehicle 4 25d 10 0.119 ± 0.020 - 
FGFRi 4 25d 10 0.140 ± 0.026 0.705 
 
Table 7.14: Image analysis of ERK IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N IHC positivity (%) P 
Vehicle 1 8d 3 0.390 ± 0.09 - 
MEKi 1 8d 4 0.406 ± 0.05 1.00 
FGFRi 1 8d 6 0.414 ± 0.03 1.00 
Vehicle 2 8d 4 1.97 ± 0.14 - 
ERKi 2 3d 4 0.25 ± 0.14 0.021 
FGFRi 2 8d 4 0.56 ± 0.17 0.021 
Vehicle 3 6h 6 0.83 ± 0.16 - 
ERKi 3 6h 6 0.87 ± 0.06 0.749 
FGFRi 3 6h 6 1.08 ± 0.10 0.262 
Vehicle 4 28d 10 4.21 ± 0.52 - 
MEKi 4 28d 10 4.90 ± 0.43 0.290 
Vehicle 4 25d 9 2.67 ± 0.32 - 
FGFRi 4 25d 9 2.42 ± 0.38 0.566 
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Table 7.15: Image analysis of phospho-RSK IHC carried out in sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of 
FGFRi or the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 2.184 ± 0.660 - 
MEKi 1 8d 4 1.155 ± 0.187 0.158 
FGFRi 1 8d 6 1.002 ± 0.192 0.121 
Vehicle 2 8d 6 0.370 ± 0.065 - 
ERKi 2 3d 4 0.279 ± 0.019 0.522 
FGFRi 2 8d 4 0.370 ± 0.019 0.831 
Vehicle 3 6h 6 0.232 ± 0.055 - 
ERKi 3 6h 6 0.131 ± 0.016 0.200 
FGFRi 3 6h 6 0.164 ± 0.021 0.631 
 
Table 7.16: Image analysis of RSK IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 15.85 ± 1.21 - 
MEKi 1 8d 4 11.64 ± 2.72 0.157 
FGFRi 1 8d 6 7.44 ± 2.09 0.039 
Vehicle 2 8d 5 9.94 ± 1.52 - 
ERKi 2 3d 4 4.24 ± 1.03 0.014 
FGFRi 2 8d 4 7.04 ± 1.15 0.327 
Vehicle 3 6h 6 5.80 ± 0.94 - 
ERKi 3 6h 6 4.06 ± 0.33 0.055 
FGFRi 3 6h 6 4.59 ± 0.86 0.423 
 
Table 7.17: Image analysis of EGR1 IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.93 ± 0.15 - 
MEKi 1 8d 4 0.30 ± 0.09 0.034 
FGFRi 1 8d 6 1.71 ± 0.51 0.197 
Vehicle 2 8d 6 0.88 ± 0.13 - 
ERKi 2 3d 4 0.23 ± 0.03 0.010 
FGFRi 2 8d 4 1.62 ± 0.24 0.033 
Vehicle 3 6h 6 1.14 ± 0.18 - 
ERKi 3 6h 6 0.19 ± 0.01 0.004 
FGFRi 3 6h 6 1.12 ± 0.11 0.873 
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Table 7.18: RPPA performed in total kidney homogenate samples from rats 
treated for 6h with 150 mg/kg of ERKi or 20 mg/kg FGFRi – 1. 
 
Akt p-Akt Bcl-x β-Catenin 
Expression P Expression P Expression P Expression P 
Vehicle 1.04 ± 0.04 - 0.72 ± 0.02 - 3.28 ± 0.11 - 5.54 ± 0.11 - 
ERKi 1.21 ± 0.05 0.016 0.71 ± 0.04 1.000 3.66 ± 0.16 0.025 5.86 ± 0.15 0.150 
FGFRi 1.18 ± 0.09 0.150 0.66 ± 0.02 0.078 4.10 ± 0.01 0.004 6.189 ± 0.13 0.006 
 p-β-Catenin Calpain2 CC3 p-Chk1 
 Expression P Expression P Expression P Expression P 
Vehicle 0.47 ± 0.01 - 1.67 ± 0.07 - 0.47 ± 0.02 - 0.61 ± 0.02 - 
ERKi 0.51 ± 0.01 0.025 1.72 ± 0.04 0.522 0.49 ± 0.02 0.522 0.62 ± 0.01 0.262 
FGFRi 0.60 ± 0.03 0.025 1.82 ± 0.08 0.200 0.47 ± 0.03 1.000 0.59 ± 0.02 0.423 
 c-Jun p-c-Jun CREB p-CREB 
 Expression P Expression P Expression P Expression P 
Vehicle 0.41 ± 0.02 - 0.36 ± 0.02 - 1.52 ± 0.13 - 1.69 ± 0.08 - 
ERKi 0.39 ± 0.02 0.749 0.37 ± 0.01 0.873 1.33 ± 0.09 0.262 1.49 ± 0.06 0.078 
FGFRi 0.45 ± 0.02 0.631 0.38 ± 0.02 0.631 1.06 ± 0.08 0.010 1.44 ± 0.04 0.037 
 p-EGFR EGFR GSK-3-β p-GSK-3-β 
 Expression P Expression P Expression P Expression P 
Vehicle 2.12 ± 0.10 - 0.70 ± 0.03 - 1.74 ± 0.06 - 0.52 ± 0.02 - 
ERKi 2.14 ± 0.09 0.873 0.67 ± 0.02 0.631 1.79 ± 0.05 0.423 0.58 ± 0.02 0.037 
FGFRi 2.16 ± 0.05 1.000 0.62 ± 0.02 0.037 1.87 ± 0.05 0.200 0.58 ± 0.03 0.078 
 p-IGF-1R β p-IKK α/β IRS-1 p-IRS-1 
 Expression P Expression P Expression P Expression P 
Vehicle 4.23 ± 0.18 - 0.70 ± 0.03 - 0.31 ± 0.02 - 0.49 ± 0.02 - 
ERKi 4.47 ± 0.20 0.423 0.79 ± 0.02 0.078 0.31 ± 0.01 0.749 0.49 ± 0.03 1.00 
FGFRi 4.83 ± 0.25 0.109 0.74 ± 0.02 0.522 0.32 ± 0.02 0.522 0.48 ± 0.03 0.749 
 JAK1 MAPKAPK-2 p-MAPKAPK-2 MEK1/2 
 Expression P Expression P Expression P Expression P 
Vehicle 0.54 ± 0.02 - 5.96 ± 0.27 - 0.66 ± 0.02 - 1.10 ± 0.06 - 
ERKi 0.56 ± 0.02 0.631 5.49 ± 0.11 0.109 0.63 ± 0.03 0.522 1.00 ± 0.03 0.423 
FGFRi 0.64 ± 0.03 0.010 5.89 ± 0.18 0.631 0.59 ± 0.02 0.037 1.00 ± 0.05 0.262 
 p-MEK1/2 p-MNK1 p-MSK1 mTOR 
 Expression P Expression P Expression P Expression P 
Vehicle 1.12 ± 0.06 - 1.07 ± 0.03 - 0.40 ± 0.02 - 2.07 ± 0.08 - 
ERKi 1.17 ± 0.04 0.423 0.98 ± 0.02 0.055 0.36 ± 0.01 0.109 2.05 ± 0.06 0.522 
FGFRi 1.02 ± 0.04 0.200 0.97 ± 0.04 0.037 0.33 ± 0.01 0.055 2.08 ± 0.05 0.873 
 p-NFkB p-p21 p38 p-p38 
 Expression P Expression P Expression P Expression P 
Vehicle 0.37 ± 0.01 - 4.51 ± 0.26 - 15.24 ± 0.33 - 2.47 ± 0.27 - 
ERKi 0.37 ± 0.02 0.749 5.07 ± 0.29 0.200 15.17 ± 0.59 0.873 2.44 ± 0.20 0.631 
FGFRi 0.36 ± 0.02 0.109 5.37 ± 0.25 0.055 15.99 ± 0.46 0.337 2.00 ± 0.19 0.262 
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Table 7.19: RPPA performed in total kidney homogenate samples from rats 
treated for 6h with 150 mg/kg of ERKi or 20 mg/kg FGFRi – 2. 
 ERK1/2 p-ERK1/2 PARP p-PDGFR 
 Expression P Expression P Expression P Expression P 
Vehicle 10.99 ± 0.43 - 4.637 ± 0.38 - 1.13 ± 0.03 - 4.57 ± 0.11 - 
ERKi 9.91 ± 0.26 0.055 19.96 ± 2.03 0.004 1.28 ± 0.08 0.109 4.48 ± 0.17 0.522 
FGFRi 10.54 ± 0.20 0.337 4.18 ± 0.28 0.522 1.389 ± 0.04 0.004 4.71 ± 0.12 0.423 
 p-PDK-1 PI3K α PKA p-PKC 
 Expression P Expression P Expression P Expression P 
Vehicle 2.08 ± 0.08 - 0.90 ± 0.02 - 2.88 ± 0.16 - 3.19 ± 0.13 - 
ERKi 2.04 ± 0.06 0.873 0.89 ± 0.03 0.522 2.78 ± 0.09 0.522 2.89 ± 0.10 0.109 
FGFRi 2.20 ± 0.08 0.423 0.87 ± 0.03 0.423 2.53 ± 0.08 0.078 2.84 ± 0.05 0.037 
 p-VEGFR PLC-γ p-PLC-γ PTEN 
 Expression P Expression P Expression P Expression P 
Vehicle 0.45 ± 0.01 - 0.48 ± 0.02 - 0.43 ± 0.01 - 1.83 ± 0.04 - 
ERKi 0.44 ± 0.02 0.749 0.45 ± 0.01 0.262 0.40 ± 0.01 0.055 1.81 ± 0.06 0.873 
FGFRi 0.43 ± 0.01 0.150 0.45 ± 0.01 0.337 0.35 ± 0.01 0.004 1.82 ± 0.03 0.631 
 p-Raf (259) p-Raf (338) Raf1 Rap1 
 Expression P Expression P Expression P Expression P 
Vehicle 0.72 ± 0.03 - 1.67 ± 0.05 - 1.84 ± 0.06 - 0.41 ± 0.02 - 
ERKi 0.66 ± 0.03 0.262 1.88 ± 0.05 0.010 1.93 ± 0.07 0.337 0.41 ± 0.02 0.873 
FGFRi 0.62 ± 0.02 0.025 1.84 ± 0.05 0.055 2.14 ± 0.05 0.006 0.39 ± 0.02 0.631 
 p-S6 Rib JNK p-JNK p-Smad1/5 
 Expression P Expression P Expression P Expression P 
Vehicle 1.04 ± 0.21 - 1.15 ± 0.05 - 0.57 ± 0.03 - 0.79 ± 0.04 - 
ERKi 0.69 ± 0.04 0.522 1.18 ± 0.04 0.522 0.60 ± 0.02 0.522 0.80 ± 0.04 0.873 
FGFRi 0.64 ± 0.06 0.150 1.30 ± 0.04 0.078 0.61 ± 0.07 0.873 0.71 ± 0.02 0.109 
 Src p-Src p-Tyk2 Ubiquitin 
 Expression P Expression P Expression P Expression P 
Vehicle 47.46 ± 2.25 - 0.70 ± 0.033 - 1.00 ± 0.04 - 13.79 ± 0.73 - 
ERKi 44.63 ± 1.68 0.337 0.66 ± 0.036 0.423 0.93 ± 0.02 0.337 12.81 ± 0.58 0.337 
FGFRi 45.04 ± 1.46 0.337 0.59 ± 0.023 0.025 0.98 ± 0.03 0.631 13.13 ± 0.51 0.631 
 PKC-α       
 Expression P       
Vehicle 1.08 ± 0.06 -       
ERKi 1.08 ± 0.05 0.749       
FGFRi 1.01 ± 0.05 0.200       
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Table 7.20: Image analysis of β-catenin IHC carried out in sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of 
FGFRi or the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 2.00 ± 0.26 - 
MEKi 1 8d 4 1.59 ± 0.28 0.480 
FGFRi 1 8d 6 1.75 ± 0.22 0.302 
Vehicle 2 8d 6 1.68 ± 0.25 - 
ERKi 2 3d 4 1.66 ± 0.27 1.009 
FGFRi 2 8d 4 2.10 ± 0.30 0.522 
Vehicle 3 6h 6 1.28 ± 0.21 - 
ERKi 3 6h 6 1.91 ± 0.26 0.078 
FGFRi 3 6h 6 1.60 ± 0.29 0.337 
Vehicle 4 28d 10 2.27 ± 0.33 - 
MEKi 4 28d 10 2.37 ± 0.24 0.701 
 
Table 7.21: Image analysis of NaPi-IIa IHC carried out in sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of 
FGFRi or the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.911 ± 0.204 - 
MEKi 1 8d 4 1.020 ± 0.249 0.724 
FGFRi 1 8d 6 1.041 ± 0.242 0.439 
Vehicle 2 8d 6 1.176 ± 0.284 - 
ERKi 2 3d 4 0.290 ± 0.134 0.033 
FGFRi 2 8d 4 0.318 ± 0.082 0.033 
Vehicle 3 6h 6 0.741 ± 0.197 - 
ERKi 3 6h 6 0.996 ± 0.187 0.149 
FGFRi 3 6h 6 1.832 ± 0.312 0.016 
Vehicle 4 28d 10 3.856 ± 0.406 - 
MEKi 4 28d 10 5.573 ± 0.564 0.023 
Vehicle 4 25d 10 2.479 ± 0.361 - 
FGFRi 4 25d 10 1.241 ± 0.136 0.010 
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Table 7.22: Image analysis of TRPV5 IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.039 ± 0.021 - 
MEKi 1 8d 4 0.418 ± 0.083 0.034 
FGFRi 1 8d 6 0.170 ± 0.047 0.034 
Vehicle 2 8d 6 0.075 ± 0.010 - 
ERKi 2 3d 4 0.026 ± 0.004 0.019 
FGFRi 2 8d 4 0.235 ± 0.034 0.011 
Vehicle 3 6h 6 0.036 ± 0.008 - 
ERKi 3 6h 6 0.017 ± 0.004 0.046 
FGFRi 3 6h 6 0.009 ± 0.002 0.016 
Vehicle 4 28d 10 1.537 ± 0.163 - 
MEKi 4 28d 10 2.189 ± 0.166 0.016 
Vehicle 4 25d 10 0.560 ± 0.110 - 
FGFRi 4 25d 10 0.955 ± 0.111 0.023 
 
Table 7.23: Image analysis of calbindin-D28k IHC carried out in sections from 
rats treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day 
of FGFRi or the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 1.34 ± 0.50 - 
MEKi 1 8d 4 3.78 ± 0.53 0.034 
FGFRi 1 8d 6 2.54 ± 0.34 0.071 
Vehicle 2 8d 6 0.18 ± 0.03 - 
ERKi 2 3d 4 0.28 ± 0.10 0.394 
FGFRi 2 8d 4 0.50 ± 0.09 0.011 
Vehicle 3 6h 6 0.18 ± 0.04 - 
ERKi 3 6h 6 0.15 ± 0.05 0.631 
FGFRi 3 6h 6 0.21 ± 0.04 0.631 
Vehicle 4 28d 10 0.73 ± 0.07 - 
MEKi 4 28d 10 1.37 ± 0.09 <0.001 
Vehicle 4 25d 10 1.11 ± 0.16 - 
FGFRi 4 25d 10 1.74 ± 0.18 0.034 
 
  
204 
 
 
Table 7.24: Image analysis of PMCA IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.094 ± 0.037 - 
MEKi 1 8d 4 0.724 ± 0.074 0.034 
FGFRi 1 8d 6 0.335 ± 0.042 0.020 
Vehicle 2 8d 5 0.924 ± 0.165 - 
ERKi 2 3d 4 0.636 ± 0.069 0.327 
FGFRi 2 8d 4 1.252 ± 0.181 0.086 
Vehicle 3 6h 6 0.331 ± 0.054 - 
ERKi 3 6h 6 0.375 ± 0.053 0.749 
FGFRi 3 6h 6 0.517 ± 0.064 0.078 
Vehicle 4 28d 10 2.331 ± 0.130 - 
MEKi 4 28d 8 3.905 ± 0.361 <0.001 
Vehicle 4 25d 10 0.712 ± 0.090 - 
FGFRi 4 25d 10 0.944 ± 0.142 0.174 
 
Table 7.25: Image analysis of Klotho IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.498 ± 0.156 - 
MEKi 1 8d 4 0.547 ± 0.097 0.724 
FGFRi 1 8d 6 0.710 ± 0.079 0.121 
Vehicle 2 8d 6 0.932 ± 0.319 - 
ERKi 2 3d 4 0.955 ± 0.645 0.522 
FGFRi 2 8d 4 0.957 ± 0.207 0.831 
Vehicle 3 6h 6 2.022 ± 1.077 - 
ERKi 3 6h 6 0.860 ± 0.294 0.262 
FGFRi 3 6h 6 1.634 ± 0.499 0.872 
Vehicle 4 28d 9 1.635 ± 0.341 - 
MEKi 4 28d 10 2.002 ± 0.466 0.568 
Vehicle 4 25d 10 1.497 ± 0.161 - 
FGFRi 4 25d 10 1.115 ± 0.137 0.096 
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Table 7.26: Plasma concentrations of Klotho in animals treated with 1.4 
mg/kg/day of MEKi, 20 mg/kg/day FGFRi or vehicle.   
Group Study Time point N 
Plasma Klotho 
(ng/mL) 
P 
Vehicle 1 d8 3 11.17 ± 0.09 - 
MEKi 1 d8 6 12.57 ± 0.51 0.028 
FGFRi 1 d8 5 8.52 ± 0.29 0.025 
 
Table 7.27: Image analysis of alkaline phosphatase IHC carried out in sections 
from rats treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 
mg/kg/day of FGFRi or the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.003 ± 0.001 - 
MEKi 1 8d 4 0.007 ± 001 0.077 
FGFRi 1 8d 6 0.007 ± 0.002 0.071 
Vehicle 2 8d 6 0.252 ± 0.059 - 
ERKi 2 3d 4 0.531 ± 0.055 0.019 
FGFRi 2 8d 4 0.501 ± 0.121 0.033 
Vehicle 3 6h 6 0.441 ± 0.087 - 
ERKi 3 6h 6 0.592 ± 0.168 0.749 
FGFRi 3 6h 6 0.497 ± 0.096 0.631 
 
Table 7.28: Image analysis of Pit-1 IHC carried out in sections from rats treated 
with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of FGFRi or 
the respective vehicles. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 1 8d 3 0.920 ± 0.334 - 
MEKi 1 8d 4 0.704 ± 0.278 0.724 
FGFRi 1 8d 6 1.163 ± 0.155 0.439 
Vehicle 2 8d 6 1.422 ± 0.122 - 
ERKi 2 3d 3 1.186 ± 0.108 0.180 
FGFRi 2 8d 4 1.395 ± 0.283 1.000 
Vehicle 3 6h 6 1.136 ± 0.128 - 
ERKi 3 6h 6 1.014 ± 0.761 0.423 
FGFRi 3 6h 6 0.861 ± 0.118 0.150 
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Table 7.29: Image analysis of osteopontin IHC carried out in sections from rats 
treated with 150 mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day of 
FGFRi or vehicle. 
Group Study Time point N 
IHC positivity 
(%) 
P 
Vehicle 2 8d 6 0.049 ± 0.011 - 
ERKi 2 3d 4 0.064 ± 0.012 0.286 
FGFRi 2 8d 4 0.494 ± 0.258 0.011 
Vehicle 3 6h 6 0.050 ± 0.007 - 
ERKi 3 6h 6 0.064 ± 0.013 0.522 
FGFRi 3 6h 6 0.056 ± 0.010 0.749 
 
Table 7.30: Plasma concentrations of osteoprotegerin in animals treated with 
150 mg/kg/day of ERKi, 20 mg/kg/day FGFRi or the vehicle.   
Group Study Time point N 
Plasma osteoprotegerin 
(pg/mL) 
P 
Vehicle 2 d8 6 360 ± 25 - 
ERKi 2 d3 6 570 ± 64 0.010 
FGFRi 2 d8 6 500 ± 24 0.004 
Vehicle 3 6h 6 442 ± 63 - 
ERKi 3 6h 6 458 ± 56 0.423 
FGFRi 3 6h 6 572 ± 132 0.749 
 
Table 7.31: Plasma concentrations of sclerostin in animals treated with 150 
mg/kg/day of ERKi, 20 mg/kg/day FGFRi or vehicle.   
Group Study Time point N Plasma sclerostin (pg/mL) P 
Vehicle 2 d8 6 214 ± 10 - 
ERKi 2 d3 6 201 ± 15 0.631 
FGFRi 2 d8 6 657 ± 81 0.004 
Vehicle 3 6h 6 279 ± 35 - 
ERKi 3 6h 6 252 ± 32 0.522 
FGFRi 3 6h 6 250 ± 32 0.631 
 
Table 7.32: Plasma concentrations of DKK1 in animals treated with 150 
mg/kg/day of ERKi, 20 mg/kg/day FGFRi or vehicle.   
Group Study Time point N Plasma DKK1 (pg/mL) P 
Vehicle 2 d8 6 881 ± 40 - 
ERKi 2 d3 6 1481 ± 162 0.004 
FGFRi 2 d8 6 1414 ± 111 0.004 
Vehicle 3 6h 6 1073 ± 110 - 
ERKi 3 6h 6 822 ± 107 0.109 
FGFRi 3 6h 6 888 ± 165 0.423 
 
207 
 
Table 7.33: Plasma concentrations of creatinine in animals treated with 150 
mg/kg/day of ERKi, 1.4 mg/kg/day of MEKi, 20 mg/kg/day FGFRi or vehicle.   
Group Study Time point N Plasma creatinine (μmol/L) P 
Vehicle 1 d8 3 25.67 ± 1.76 - 
MEKi 1 d8 6 30.00 ± 0.86 0.071 
FGFRi 1 d8 5 31.60 ± 1.50 0.053 
Vehicle 2 d8 6 31.17 ± 1.01 - 
ERKi 2 d3 6 60.50 ± 11.50 0.005 
FGFRi 2 d8 5 38.00 ± 2.21 0.028 
Vehicle 3 6h 6 3.17 ± 0.95 - 
ERKi 3 6h 6 28.83 ± 1.64 0.230 
FGFRi 3 6h 6 27.33 ± 0.95 0.045 
Vehicle 4 d28 10 60.50 ± 1.30 - 
MEKi 4 d28 10 61.50 ± 1.15 0.496 
Vehicle 4 d25 10 22.30 ± 0.50 - 
FGFRi 4 d25 10 28.9 ± 1.05 0.001 
 
Table 7.34: ATP contents of rat kidney slices cultured for 1h, 1d, 2d and 3d 
Time point N nmol ATP / mg wet weight P 
1h 3 50.36 ± 4.23 - 
1h (Trit X1) 3 3.78 ± 1.80 0.049 
24h 3 32.03 ± 6.94 0.126 
48h 3 12.90 ± 5.11 0.049 
72h 3 0.98 ± 0.80 0.049 
1 – 1% Triton X 
 
Table 7.35: Image analysis of NaPi-IIa IHC carried out in sections of rat kidney 
slices incubated for 4h in culture media containing 0 mM or 2 mM of Pi 
Group N IHC positivity (%) P 
0 mM Pi 4 3.29 ± 0.16 
0.021 
2 mM Pi 4 2.64 ± 0.11 
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